
<html lang="en"     class="pb-page"  data-request-id="cf063599-e304-483e-aa13-9981bd3ace7b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-13;article:article:10.1021/acs.jmedchem.7b00472;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells" /></meta><meta name="dc.Creator" content="Jose Antonio  Ortega" /></meta><meta name="dc.Creator" content="Jose M.  Arencibia" /></meta><meta name="dc.Creator" content="Giuseppina  La Sala" /></meta><meta name="dc.Creator" content="Marco  Borgogno" /></meta><meta name="dc.Creator" content="Inga  Bauer" /></meta><meta name="dc.Creator" content="Luca  Bono" /></meta><meta name="dc.Creator" content="Clarissa  Braccia" /></meta><meta name="dc.Creator" content="Andrea  Armirotti" /></meta><meta name="dc.Creator" content="Stefania  Girotto" /></meta><meta name="dc.Creator" content="Anand  Ganesan" /></meta><meta name="dc.Creator" content="Marco  De Vivo" /></meta><meta name="dc.Description" content="Acid ceramidase (AC) hydrolyzes ceramides, which are central lipid messengers for metabolism and signaling of sphingolipids. A growing body of evidence links deregulation of sphingolipids to severa..." /></meta><meta name="Description" content="Acid ceramidase (AC) hydrolyzes ceramides, which are central lipid messengers for metabolism and signaling of sphingolipids. A growing body of evidence links deregulation of sphingolipids to severa..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 27, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00472" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2017 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00472" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00472" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00472" /></link>
        
    
    

<title>Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00472" /></meta><meta property="og:title" content="Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0017.jpeg" /></meta><meta property="og:description" content="Acid ceramidase (AC) hydrolyzes ceramides, which are central lipid messengers for metabolism and signaling of sphingolipids. A growing body of evidence links deregulation of sphingolipids to several diseases, including cancer. Indeed, AC expression is abnormally high in melanoma cells. AC inhibition may thus be key to treating malignant melanoma. Here, we have used a systematic scaffold exploration to design a general pharmacophore for AC inhibition. This pharmacophore comprises a 6 + 5 fused ring heterocycle linked to an aliphatic substituent via a urea moiety. We have thus identified the novel benzimidazole derivatives 10, 21, 27, and 30, which are highly potent AC inhibitors. Their chemical and metabolic stabilities are comparable or superior to those of previously reported AC inhibitors. Moreover, they are potent against endogenous AC in intact melanoma cells. These novel inhibitors merit further characterization and can serve as a promising starting point for the discovery of new antimelanoma therapeutics." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00472"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00472">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00472&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00472&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00472&amp;href=/doi/10.1021/acs.jmedchem.7b00472" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 5800-5815</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00490" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00514" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jose+Antonio++Ortega">Jose Antonio Ortega</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jose+M.++Arencibia">Jose M. Arencibia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Giuseppina++La+Sala">Giuseppina La Sala</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marco++Borgogno">Marco Borgogno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Inga++Bauer">Inga Bauer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luca++Bono">Luca Bono</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Clarissa++Braccia">Clarissa Braccia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Armirotti">Andrea Armirotti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefania++Girotto">Stefania Girotto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anand++Ganesan">Anand Ganesan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marco++De+Vivo">Marco De Vivo</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-4022-5661" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Laboratory of Molecular Modeling & Drug Discovery, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">IAS-5/INM-9 Computational Biomedicine Forschungszentrum JÃ¼lich, Wilhelm-Johnen-StraÃe, 52428 JÃ¼lich, Germany</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">Â§</span> <span class="aff-text">D3-PharmaChemistry, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">â¥</span> <span class="aff-text">CompuNet, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">â¥</span> <span class="aff-text">Department of Dermatology and Biological Chemistry, University of California, 202 Sprague Hall, 92697-2400 Irvine, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +39 01071781577. E-mail: <a href="/cdn-cgi/l/email-protection#a7eac6d5c4c889c3c2d1ced1c8e7ceced389ced3"><span class="__cf_email__" data-cfemail="662b07140509480203100f1009260f0f12480f12">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00472&amp;href=/doi/10.1021%2Facs.jmedchem.7b00472" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 5800â5815</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 12, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 March 2017</li><li><span class="item_label"><b>Published</b> online</span>27 June 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 July 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00472" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00472</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00472"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2763</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00472" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jose&quot;,&quot;last_name&quot;:&quot;Antonio Ortega&quot;},{&quot;first_name&quot;:&quot;Jose&quot;,&quot;last_name&quot;:&quot;M. Arencibia&quot;},{&quot;first_name&quot;:&quot;Giuseppina&quot;,&quot;last_name&quot;:&quot;La Sala&quot;},{&quot;first_name&quot;:&quot;Marco&quot;,&quot;last_name&quot;:&quot;Borgogno&quot;},{&quot;first_name&quot;:&quot;Inga&quot;,&quot;last_name&quot;:&quot;Bauer&quot;},{&quot;first_name&quot;:&quot;Luca&quot;,&quot;last_name&quot;:&quot;Bono&quot;},{&quot;first_name&quot;:&quot;Clarissa&quot;,&quot;last_name&quot;:&quot;Braccia&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Armirotti&quot;},{&quot;first_name&quot;:&quot;Stefania&quot;,&quot;last_name&quot;:&quot;Girotto&quot;},{&quot;first_name&quot;:&quot;Anand&quot;,&quot;last_name&quot;:&quot;Ganesan&quot;},{&quot;first_name&quot;:&quot;Marco&quot;,&quot;last_name&quot;:&quot;De Vivo&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;5800-5815&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00472&quot;},&quot;abstract&quot;:&quot;Acid ceramidase (AC) hydrolyzes ceramides, which are central lipid messengers for metabolism and signaling of sphingolipids. A growing body of evidence links deregulation of sphingolipids to several diseases, including cancer. Indeed, AC expression is abnormally high in melanoma cells. AC inhibition may thus be key to treating malignant melanoma. Here, we have used a systematic scaffold exploration to design a general pharmacophore for AC inhibition. This pharmacophore comprises a 6 + 5 fused ring heterocycle linked to an aliphatic substituent via a urea moiety. We have thus identified the novel benzimidazole derivatives 10, 21, 27, and 30, which are highly potent AC inhibitors. Their chemical and metabolic stabilities are comparable or superior to those of previously reported AC inhibitors. Moreover, they are potent against endogenous AC in intact melanoma cells. These novel inhibitors merit further characterization and can serve as a promising starting point for the discovery of new antimelanoma therapeutic&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00472&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00472" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00472&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00472" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00472&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00472" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00472&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00472&amp;href=/doi/10.1021/acs.jmedchem.7b00472" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00472" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00472" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00472%26sid%3Dliteratum%253Aachs%26pmid%3D28603987%26genre%3Darticle%26aulast%3DOrtega%26date%3D2017%26atitle%3DPharmacophore%2BIdentification%2Band%2BScaffold%2BExploration%2Bto%2BDiscover%2BNovel%252C%2BPotent%252C%2Band%2BChemically%2BStable%2BInhibitors%2Bof%2BAcid%2BCeramidase%2Bin%2BMelanoma%2BCells%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D13%26spage%3D5800%26epage%3D5815%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292271" title="Urea">Urea</a>,</li><li><a href="/action/doSearch?ConceptID=290921" title="Heterocyclic compounds">Heterocyclic compounds</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/jmcmar.2017.60.issue-13/20170713/jmcmar.2017.60.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Acid ceramidase (AC) hydrolyzes ceramides, which are central lipid messengers for metabolism and signaling of sphingolipids. A growing body of evidence links deregulation of sphingolipids to several diseases, including cancer. Indeed, AC expression is abnormally high in melanoma cells. AC inhibition may thus be key to treating malignant melanoma. Here, we have used a systematic scaffold exploration to design a general pharmacophore for AC inhibition. This pharmacophore comprises a 6 + 5 fused ring heterocycle linked to an aliphatic substituent via a urea moiety. We have thus identified the novel benzimidazole derivatives <b>10</b>, <b>21</b>, <b>27</b>, and <b>30</b>, which are highly potent AC inhibitors. Their chemical and metabolic stabilities are comparable or superior to those of previously reported AC inhibitors. Moreover, they are potent against endogenous AC in intact melanoma cells. These novel inhibitors merit further characterization and can serve as a promising starting point for the discovery of new antimelanoma therapeutics.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60513" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60513" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The incidence of cutaneous melanoma continues to rise.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> At the same time, treating unresectable or metastatic melanoma with conventional cytotoxic agents (such as dacarbazine) has failed to produce the expected survival benefit.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The survival of patients with advanced melanoma has been increased by using BRAF and MEK inhibitors and by using antibodies that block immune-checkpoint molecules (such as ipilimumab, which targets the cytotoxic T lymphocyte antigen 4 (CTLA-4)).<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a> Nevertheless, progression of melanoma due to intrinsic and/or acquired resistance to these novel treatments remains a major issue.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In addition, clinicians are concerned about the toxicity, tolerability, and effectiveness of these new agents.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Combination therapy is an alternative and promising approach, where novel targeted agents and traditional anticancer modalities (radiation, chemotherapy, or surgery) are used together to enhance treatment efficacy and reduce side-effects.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Combination therapy, however, has not yet demonstrated a significant decrease in the mortality of melanoma patients. For all these reasons, treatment of advanced melanoma is still an unmet medical need,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and novel therapeutic strategies are urgently required.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">Recent findings have shown that the acid ceramidase (AC) enzyme may be a novel target for treating several types of cancer, including melanoma.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> AC is a cysteine amidase that hydrolyzes the proapoptotic lipid-derived messenger ceramide, a central molecule in sphingolipid metabolism and signaling.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13-15)</a> The expression of AC is abnormally high in several tumors, suggesting that the dysregulation of ceramide metabolism could be linked to cancer development and progression.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16-18)</a> Indeed, AC overexpression has been detected in various types of human cancer (e.g., melanoma, head and neck, prostate, and colon cancer). Moreover, autoantibodies against AC have been found in the serum of melanoma patients, suggesting that AC might also be used as a biomarker for disease prognosis.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> There is also evidence that overexpression of AC may be related to higher resistance to pharmacological induction of apoptosis,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> while AC inhibition sensitizes cancer cells to the action of anticancer therapeutics.<a onclick="showRef(event, 'ref20 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref22">(20, 22)</a> Taken together, there is a growing body of evidence that indicates AC inhibition as an effective and innovative therapeutic approach to treat melanoma, as well as other cancers.<a onclick="showRef(event, 'ref10 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref10 ref23 ref24 ref25">(10, 23-25)</a></div><div class="NLM_p">In the last two decades, a few potent AC inhibitors have been discovered.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> Initially, inhibitors such as NOE<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and D-e-MAPP<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> were designed for their similarity to ceramide, the endogenous AC ligand (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). However, these inhibitors have low potency and selectivity, being also active against Cz-ceramide-activated phosphatase (CAPP) and protein kinase C (PKC). Optimization of these first-generation inhibitors led to slightly better activity in vitro and in vivo (ceranib 1 and 2, see <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref23 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref26">(23, 26)</a> Recently, however, more potent ceramide-unrelated inhibitors of AC have been identified by synthesizing new derivatives of 5-fluorouracil (5-FU) and by screening commercial chemical libraries, which returned promising AC blockers such as the benzoxazolone carboxamide compounds.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30-32)</a> These inhibitors are fairly potent, being active in the nanomolar range (see benzoxazolone 1, 2, and 3 in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). This class of inhibitors blocks AC by forming a covalent adduct with the catalytic Cys-143. This covalent ligandâtarget interaction is due to the presence of a urea group in the benzoxazolone carboxamide derivatives. The urea is cleaved to generate the covalent ACâinhibitor complex.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Although promising, these benzoxazolone carboxamides derivatives suffer from limited stability, which may hinder their development as clinically viable therapeutic agents.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Ceramide and known acid ceramidase (AC) inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Here, we report on an extensive exploration of different scaffolds that act by covalently inhibiting AC, just like their template benzoxazolone carboxamide derivatives. Our goal was to understand which chemical features are necessary for potent AC inhibition while improving chemical stability. Thus, we present a general pharmacophore for AC inhibition that combines 6 + 5 fused ring heterocycles with different aliphatic chains, linked via a urea functional group (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). We obtained a set of 30 new compounds, with seven different chemical cores. The four most potent and stable AC inhibitors <b>10</b>, <b>21</b>, <b>27</b>, and <b>30</b> also inhibited AC in intact cells. This information will be useful for further optimizing these promising compounds.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed pharmacophore for AC covalent inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46604" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46604" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Strategy for Pharmacophore Exploration</h3><div class="NLM_p">Previous studies described a set of potent but only fairly stable benzoxazolone inhibitors of the AC enzyme (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). These were all characterized by the presence of the urea functional group, which was demonstrated to be crucial for activity against AC. These potent compounds are active in the low nanomolar range, acting by forming an adduct with the nucleophilic Cys-143 residue of AC.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Notably, all these covalent inhibitors are characterized by an aliphatic substituent, which mimics the alkylic tail of the AC natural substrate, and which is linked through the urea functional group to the benzoxazolone heterocyclic core.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p">In an effort to elucidate and improve the pharmacological shortcomings of the existing covalent inhibitors of AC, we explored the chemistry of a general pharmacophore for AC inhibition. This was designed by combining 6 + 5 fused ring heterocycles and different aliphatic tails (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Seven different 6 + 5 fused ring heterocycles (benzothiazole, benzoxazole, benzimidazole, indazole, benzotriazole, 4-azabenzotriazole, and phathalimide) were combined via a urea functional group to different aliphatic tails. In this way, these seven different cores were linked to both hexyl- and 4-phenylbutyl fragment tails, which were selected from previous inhibition studies<a onclick="showRef(event, 'ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34">(31-34)</a> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), obtaining an initial set of 18 compounds. In addition, we synthesized a set of four 2-benzimidazole derivatives to study the effect of these modifications on potency and stability. We also considered a benzyl-containing tail, generating eight additional compounds, for a total of 30 new derivatives that block the targeted AC enzyme (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Synthesized Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0008.gif" alt="" id="fx1" /></img><div></div></div><div class="NLM_p last">First, we investigated how the presence of either an exocyclic or endocyclic urea linked to each different compound core affects their inhibitory activity against AC. We used either 2-aminobenzothiazole or 2-aminobenzoxazole to synthesize an initial set of four derivatives containing the exocyclic urea (<b>1</b>â<b>4</b> in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Notably, these compounds only have an exocyclic amino group accessible for chemical synthesis. Then, four additional derivatives were synthesized from 2-aminobenzimidazole, where both endocyclic and exocyclic amino groups could be derivatized (<b>5</b>â<b>8</b> in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In a second step, after identifying endocyclic ureas as the most active ones, we synthesized a group of 10 compounds bearing different heterocycles and both hexyl- and 4-phenylbutyl tails (<b>9</b>â<b>18</b> in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In addition, we synthesized a third set of four compounds containing the 4-phenylbutyl fragment tail, which produced the best inhibitory results against AC, and different 2-substituted benzimidazoles. Finally, we synthesized a group of eight compounds containing a benzyl group with a single methyl substituent at different positions along the aliphatic fragment, as an alternative tail. Encouraged by the results obtained with compounds bearing the 4-phenylbutyl tail, which resulted in more potent inhibitors, we investigated additional tails formed by combining an aromatic group with an alkyl fragment.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">The synthesis of all the differently substituted ureas was efficiently accomplished by a general strategy, which involved reacting different heterocycle cores (Het, see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) with an appropriate isocyanate in the presence of a catalytic amount of 4-(dimethylamino)pyridine (DMAP) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Pathway for Urea Synthesis<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) DMAP (0.1 equiv), pyridine, N<sub>2</sub>, room temperature, 5 h.</p></p></figure><div class="NLM_p">All heterocycles were commercially available, with the exception of 2-methoxy-1<i>H</i>-benzimidazole, which was synthesized following an adapted procedure from a previously described protocol (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 2-Methoxy-1<i>H</i>-benzimidazole<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) tetramethylortho carbonate (1.4 equiv), Ar, 90 Â°C, 24 h.</p></p></figure><div class="NLM_p">Compounds <b>1</b>â<b>4</b> and <b>7</b>â<b>30</b> were obtained in moderate to good yields as indicated in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_001.pdf" class="ext-link">Supporting Information</a>. The reaction with heterocycles 2-aminobenzimidazole (<b>7</b>,<b>8</b>) and with 1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridine (<b>15</b>,<b>16</b>) was regioselective, as previously described.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> Compounds <b>19</b> and <b>20</b> were obtained by adding one or two equivalents of the corresponding isocyanate, respectively.</div><div class="NLM_p">Compounds <b>5</b> and <b>6</b> bear a urea in the exocyclic amino group attached to the 2-aminobenzimidazole. They were obtained via an alternative strategy (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The heterocycle was first selectively protected on N1 with a <i>tert-</i>butyl carbamoyl group, adapting a known procedure.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Then, intermediate <b>31</b> permitted regioselective urea formation on the 2-amino group with both hexyl and 4-phenylbutyl isocyanates, in the presence of catalytic DMAP at 80 Â°C. Finally, elimination of the protecting group in pyridine was achieved by heating at 80 Â°C, yielding the 2-amino derivatives <b>5</b> and <b>6</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 2-Aminobenzimidazole Exocyclic Ureas <b>5</b> and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Boc<sub>2</sub>O (1 equiv), Et<sub>3</sub>N (3 equiv), THF (dry), room temperature, 5 h, yield 95%. (ii) R-NCO (1 equiv), DMAP (0.1 equiv), pyridine, N<sub>2</sub>, 80 Â°C, 3 h. For R = hexyl yield 11%. For R = 4-phenylbutyl yield 12%. (iii) Pyridine, 80 Â°C, 16 h. For R = hexyl yield 70%. For R = 4-phenylbutyl yield 70%.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> StructureâActivity Relationships</h3><div class="NLM_p">For the first set of compounds, those bearing endocyclic ureas are more active than exocyclic ones (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Compounds <b>1</b>â<b>6</b>, which all have the urea fragment linked to the exocyclic 2-amino group, were inactive (at the highest concentration tested), whereas compounds <b>7</b> and <b>8</b>, which present the same type of substitution in the endocyclic N1, displayed potent AC inhibition (IC<sub>50</sub> 2.4 nM and 0.9 nM, respectively).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exocyclic Amine Ureas versus Endocyclic Amine Ureas</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0009.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0010.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are reported as mean Â± SD values of three determinations.</p></div></div><div></div></div><div class="NLM_p">On the basis of this evidence, we focused on those heterocycles bearing endocyclic ureas. Four more 6 + 5 fused ring heterocycles with an endocyclic amino group were used to synthesize new derivatives with either a hexyl or a 4-phenylbutyl group (compounds <b>9</b>â<b>18</b>, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Exploration of 5 + 6 Fused Ring Heterocycles</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0011.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0012.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">IC50 values are reported as mean Â± SD values of three determinations.</p></div></div><div></div></div><div class="NLM_p last">Interestingly, all of the considered heterocycles generated potent AC inhibitors. All of the compounds bearing the same aliphatic tail can be considered equipotent, suggesting that a 6 + 5 fused ring heterocycle anchored by an endocyclic amino group is sufficient for AC inhibition. Larger differences were observed when comparing both aliphatic tails. In all cases, compounds bearing the 4-phenylbutyl tail returned an IC<sub>50</sub> value that was on average twice as potent as those bearing the hexyl tail. Notably, the presence of a phenyl group in the aliphatic tail of the molecules provided an advantage in terms of AC inhibition. This slight improvement in potency may be due to the preference that the enzyme has for substrates containing more double bonds.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Potency, Chemical, and Metabolic Stability</h3><div class="NLM_p">The previously reported covalent inhibitors of AC have limited stability.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> In this respect, we selected our most active compounds <b>9</b>â<b>18</b> to further characterize their stability (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). We tested their chemical stability in neutral buffered solution in PBS at pH 7.4 and acetate at pH 4.5, and used mouse plasma to test their metabolic stability. Notably, depending on the heterocycle, the half-life of each compound ranged from a few minutes (<b>13</b>â<b>18</b>) to 1 or 2 h (<b>9</b>â<b>12</b>) in neutral buffered solution. This difference in stability was even more pronounced in plasma where, remarkably, <b>9</b>â<b>12</b> had a half-life of over 2 h.</div><div class="NLM_p">To further investigate whether additional modifications of the heterocycle core could improve the potency and stability of our best AC inhibitors, we focused on the benzimidazole heterocycle core of <b>9</b> and <b>10</b>, which presented the best compromise between potency and stability (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Since a phenyl group is preferred in the aliphatic tail, we studied a new set of compounds with modifications at the benzimidazole 2 position, while maintaining the 4-phenylbutyl tail linked to the urea (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The presence of an amino group at postion 2 (<b>8</b>) returned an IC<sub>50</sub> = 0.9 nM, twice as potent as the nonsubstituted benzimidazole (<b>10</b>). Interestingly, the presence of a methyl group at the same position (<b>22</b>) also produce a compound that was twice as potent as the unsubstituted benzimidazole <b>10</b>. In contrast, introducing a methoxide substituent (<b>21</b>) resulted in a 4-fold decrease in potency, with an IC<sub>50</sub> = 13.9 nM. Finally, we considered the 3-dihydrobenzimidazol-2-one heterocycle, which has two nitrogen atoms that can be derivatized. Thus, we obtained <b>19</b> with just one urea, which was surprisingly inactive, while <b>20</b> with two substituents was almost 10-fold less potent than the unsubstituted benzimidazole <b>10</b>. The activity with two substituents as in <b>20</b>, compared to the inactive derivative <b>19</b>, is also confirmed by analogues <b>35</b> and <b>36</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_001.pdf" class="ext-link">Supporting Information</a>) and remains a puzzling result that merits further investigation. In terms of stability, substituents introduced at the benzimidazole 2-position, as in <b>8</b> and <b>22</b>, resulted in less chemically stable compounds (<i>t</i><sub>1/2</sub> 14 and 7 min, respectively). This suggests that modifications introduced to make the urea group more sensitive to the Cys-143 nucleophilic attack may potentially render these compounds more easily hydrolyzable in solution.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Additional 2-Benzimidazole Derivative Exploration</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0013.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are reported as mean Â± SD values of three determinations.</p></div></div><div></div></div><div class="NLM_p">Encouraged by the fact that a phenyl group in the aliphatic tail consistently increased the potency of our inhibitors, we further explored the presence of a benzyl group in this part of the molecule. All of the resulting compounds had a benzyl group directly attached to the urea. We expected this to affect the electrophilic properties of the carbonyl group. For these compounds, we used benzimidazole and 2-aminobenzimidazole cores, which offer the best balance between potency and stability. This generated eight new derivatives (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, <b>23</b>â<b>26</b> and <b>27</b>â<b>30</b>, i.e., four new derivatives per core).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Exploration of Benzyl Ureas</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0014.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0015.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are reported as mean Â± SD values of three determinations.</p></div></div><div></div></div><div class="NLM_p">Substituting the 4-phenylbutyl tail for a benzyl tail in the 2-aminobenzimidazole and benzimidazole heterocycles produced <b>23</b> and <b>27</b>, which both had diminished potency (35-fold and 7-fold decrease, respectively). Moreover, the position of a methyl group in the benzyl tail affected AC activity in different ways. For example, ortho-substitution in <b>24</b> and <b>28</b> resulted in an â¼2-fold decrease in potency compared with that of the nonsubstituted benzyl derivatives <b>23</b> and <b>27</b>. This is likely due to the bigger steric hindrance of the ortho-substituted compounds, which occlude the urea electrophilic center. In fact, meta- and para-substitutions, <b>25</b>,<b>26</b> and <b>29</b>,<b>30</b>, have a better inhibitory potency, even compared to that of the benzyl derivatives <b>23</b> and <b>27</b>. Again, this is probably due to an increased lipophilicity of these meta- and para-substituted compounds, compared to that of nonsubstituted benzyl urea. This is in accordance with the hydrophobic nature of the natural AC substrate.</div><div class="NLM_p last">Related to the stability of these benzyl derivatives, a significant effect was again observed depending on the heterocycles. In agreement with <b>8</b> containing 4-phenylbutyl urea (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>), derivatives based on the 2-aminobenzimidazole heterocycle were less stable (chemically and metabolically) than those based on the benzimidazole heterocycle, resulting in half-life values of less than 30 min. However, for benzimidazole derivatives, both benzyl and 4-methylbenzyl substituents returned more stable compounds, reaching >120 min as half-time, with potency in the low nanomolar range (see <b>27</b> and <b>30</b> in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). These results support this para-substituted benzyl fragment as a valid alternative to our pharmacophore aliphatic tails.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Study of the Mechanism of Inhibition</h3><div class="NLM_p">A covalent mechanism of action has been proved for previously reported benzoxazolone AC inhibitors.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> Specifically, it was confirmed that Cys-143 attacks the urea carbonyl group of the benzoxazolone, with the 4-phenylbutyl remaining attached to the enzyme AC (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). As for the benzoxazolone carboxamides,<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> here we used liquid chromatographyâmass spectrometry (LC-MS) to characterize the mode of action of compounds <b>10</b> and <b>21</b>. As expected, results demonstrate that these compounds act through the same mechanism of action observed for benzoxazolone AC inhibitors (adduct A, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). Incubation with purified recombinant human AC, followed by trypsin digestion and peptide analysis by LC-MS, showed the formation of an adduct with the N-terminal peptide of AC (CTSIVAEDK, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B, red trace) for both inhibitors. In contrast, only native unmodified peptide was observed after control incubation of AC with DMSO. For both compounds <b>10</b> and <b>21</b>, tandem MS analysis showed the formation of the same adduct (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C). That is, a peak of the 4-phenylbutyl carboxamide fragment (adduct A) was observed (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> No evidence supporting an alternative mode of action and no adducts with other AC tryptic peptides were observed, which indicate that our new compounds covalently bind to Cys-143.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Adduct formed by covalent modification of catalytic Cys-143 by a reported benzoxazolone AC inhibitor<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> and possible adducts formed upon nucleophilic attack of the catalytic Cys-143 on compounds <b>10</b> and <b>21</b>. (B) Chromatograms of peptide analysis after trypsin digestion of AC incubated with compound <b>10</b> or <b>21</b> (red trace) and DMSO (blue trace). (C) Tandem mass spectrum confirming the CTSIVAEDK peptide sequence and mass increased of covalently modified Cys-143 (+ 175.10 Da), in concordance with adduct A formation (+ C<sub>11</sub>H<sub>13</sub>NO). See also <a href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Computational Analysis</h3><div class="NLM_p">On the most potent and promising AC inhibitors (compounds <b>8</b>, <b>10</b>, and <b>19</b>â<b>22</b>), we performed a coordinate scan analysis as a function of the dihedral angle Ï centered along the N1âC1â² axis of the C2âN1âC1â²âO1â² atoms of the urea moiety.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> In this way, we could identify the most probable (i.e., lowest energy) conformations, which are likely adopted by urea during nucleophilic attack by the Cys-143 residue in AC, generating the covalent enzyme-ligand adduct.<a onclick="showRef(event, 'ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44 ref45">(42-45)</a></div><div class="NLM_p">As expected, in all of the compounds we detected two energetic minima for Ï. One was located at Ï = 180Â°, where the oxygen atom of the urea group at position 1 is oriented toward the âouterâ side of the molecule (hereafter referred to as the exo conformation, <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). One was located at Ï = 360Â°, where the oxygen atom points toward the âinnerâ side of the molecule (hereafter referred to as the endo conformation, <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Interestingly, the most active compounds <b>8</b>, <b>10</b>, and <b>22</b> (IC<sub>50</sub> of 0.9 Â± 0.2 nM, 2.5 Â± 0.1 nM, and 1.0 Â± 0.4 nM, respectively) prefer the exo conformation, while the others prefer endo conformations. Compound <b>8</b> is highly stabilized in exo thanks to the formation of an intramolecular H-bond between the amino group in position 2 and the oxygen atom of the urea. However, exo conformations are also preferred in <b>10</b> and <b>22</b> in the absence of this H-bond, indicating that this conformation is stabilized by the nature of the central core. In fact, the less active compounds <b>19</b>â<b>21</b>, (IC<sub>50</sub> of >10000 nM, 21.0 Â± 6.9 nM, and 13.9 Â± 3.9 nM, respectively) prefer the endo conformation in which they form an intramolecular H-bond (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). These results suggest that the nucleophilic attack performed by Cys-143 is favored when urea assumes the exo conformation, which therefore identifies more potent compounds. In other words, based on our computational analysis, we hypothesize that the AC active site is more selective toward the exo conformation of the amide group of the inhibitor. Then, when bound, the amide bond might undergo a slight distortion, which has been suggested to facilitate the nucleophilic attack for amide hydrolysis.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a></div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Coordinate scan of the urea torsional angles of compounds <b>8</b>, <b>10</b>, and <b>19</b>â<b>22</b>. The pink sphere represents the global minimum conformation, which is shown as a 2D structure. The <i>exo</i> conformation is preferred for <b>8</b>, <b>10</b>, and <b>22</b> and the <i>endo</i> conformation for <b>19</b>â<b>21</b>. The dark gray spheres in position 1 represent the phenylbutyl moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In conclusion, the minimal energy conformation assumed by Ï and, in particular, the stabilization of the exo conformation seems to be an important prerequisite for the rational design of a potent compound against AC.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Targeting AC in Melanoma Cells</h3><div class="NLM_p">On the basis of in vitro activity results on AC inhibition, as well as on the stability studies, benzimidazole derivatives <b>10</b>, <b>21</b>, <b>27</b>, and <b>30</b> were also tested for their ability to inhibit endogenous AC in intact cells. The assay is based on the intracellular enzymo-chemical transformation of the AC substrate Rbm-14â12 into fluorescent umbelliferone.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> To this end, we used two different melanoma cell lines, A375 and G-361, which are representative of the invasive and proliferative phenotype of the disease, respectively.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> After 2 h of treatment, all four compounds inhibited endogenous AC activity with variable potencies in both cell lines (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). The A375 cell line was more sensitive to AC inhibition than G-361. This difference is likely due to the higher levels of expression of catalytically competent AC in proliferative G-361 melanoma cells than in invasive A375 cells.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The inhibitory activity of these compounds against AC in intact cells correlated well with that obtained in vitro, with <b>10</b> being the most potent and promising compound. In addition, the benzimidazole derivatives had improved stability and comparable potency to carmofur, which has been used to generate similarly active derivatives to block AC.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The effect observed for these compounds in melanoma cells can be attributed to their ability to block AC activity. In fact, under these experimental conditions, we did not observe any cytotoxic effect of the compounds, alone. Moreover, cytotoxicity assays treating the cells for 72 h demonstrated the lack of cytotoxicity (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Effect of AC Inhibitors in Melanoma Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0016.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are reported as mean Â± SD values of at least two determinations</p></div></div><div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the present work, we have identified a pharmacophore model that captures essential features for covalent inhibition of the AC enzyme. Our results show that a chemical structure formed by a 6 + 5 fused ring heterocycles, functionalized at the endocyclic amino group, is critical for AC inhibition. Although all of the fused ring heterocycles considered were quite potent, each returned different results in terms of chemical stability. In this regard, benzimidazole derivatives showed the best balance between potency and stability. Exploration of 2-benzimidazole substituents yielded slightly more potent compounds when an electrodonating group was inserted, as in <b>8</b> and <b>22</b>. However, electron withdrawing substituents helped both chemical and metabolic stabilities, with a compound half-life of more than 2 h. Our findings also show that compounds with an aliphatic chain that contains an aromatic group are more potent in blocking AC. We have demonstrated this for tails based on a 4-phenylbutyl fragment as in <b>10</b>, <b>12</b>, <b>14</b>, <b>16</b>, and <b>18</b>, compared to those with the hexyl group as in <b>9</b>, <b>11</b>, <b>13</b>, <b>15</b>, and <b>17</b>. Along these lines, a benzyl fragment in the tail showed different effects depending on methyl substituent position. While a naked benzyl fragment resulted in less potent compounds, as in <b>23</b> and <b>27</b>, the presence of a methyl group showed different effects depending on its position. Ortho-substitution, as in <b>24</b> and <b>28</b>, had diminished potency, probably due to a larger steric hindrance. We also observed a slight decrease in potency for meta-derivatives, as in <b>25</b> and <b>29</b>, and para-derivatives, as in <b>26</b> and <b>30</b>, especially for benzimidazole heterocycle. Benzyl substituents also affected chemical and metabolic stabilities. For example, 2-aminobenzimidazole derivatives are unstable compounds. However, when the benzimidazole core is linked to either a benzyl or a <i>para</i>-methylbenzyl group, compounds become more stable, reaching an optimal half-time that exceeds 2 h, as for <b>27</b> and <b>30</b>.</div><div class="NLM_p last">In summary, our scaffold exploration and derivatization suggest a general pharmacophore for AC inhibition formed by a 6 + 5 fused ring heterocycle bearing a urea at an endocyclic nitrogen group. This nitrogen should be derivatized with an alkyl chain presenting a phenyl substituent. In our study, this general scaffold resulted in benzimidazole derivatives <b>10</b>, <b>21</b>, <b>27</b>, and <b>30</b>, which are potent and fairly stable AC inhibitors, with promising activity against AC in different melanoma cell lines. These novel AC inhibitors merit further characterization and can serve as a promising starting point for the discovery of new therapeutics for melanoma.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21127" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21127" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Chemistry</h3><div class="NLM_p last">All of the commercially available reagents and solvents were used as purchased from vendors without further purification. Dry solvent pyridine was purchased from Sigma-Aldrich. Automated column chromatography purifications were done using a Teledyne ISCO apparatus (Combi<i>Flash R</i><sub>f</sub>) with prepacked silica gel columns of different sizes (from 4 g up to 24 g) and mixtures of increasing polarity of cyclohexane and ethyl acetate (EtOAc) or cyclohexane and <i>tert</i>-butyl methyl ether (TBME). NMR experiments were run on a Bruker Avance III 400 system (400.13 MHz for <sup>1</sup>H and 100.62 MHz for <sup>13</sup>C), equipped with a BBI probe and Z-gradients. Spectra were acquired at 300 K, using deuterated dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>) or deuterated chloroform (CDCl<sub>3</sub>) as solvents. UPLC/MS analyses were run on a Waters Acquity UPLC/MS system consisting of an SQD (single quadrupole detector) mass spectrometer equipped with an electrospray ionization interface and a photodiode array detector. The PDA range was 210â400 nm. Analyses were performed on an Acquity UPLC BEH C<sub>18</sub> column (100 Ã 2.1 mm ID, particle size 1.7 Î¼m) with a VanGuard BEH C<sub>18</sub> precolumn (5 Ã 2.1 mm ID, particle size 1.7 Î¼m). Mobile phase was 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O at pH 5 adjusted with CH<sub>3</sub>COOH (A) and 10 mM NH<sub>4</sub>OAc in CH<sub>3</sub>CNâH<sub>2</sub>O (95:5) at pH 5.0 (B). Depending on the analysis method used, a different gradient increasing the proportion of mobile phase B was applied. For analysis method 1, the mobile-phase B proportion increased from 5% to 95% in 3 min. For analysis method 2, the mobile-phase B proportion increased from 50% to 100% in 3 min. Electrospray ionization in positive and negative modes was applied. All tested compounds showed â¥95% purity by NMR and UPLC/MS analysis.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Procedure for Urea Synthesis</h3><div class="NLM_p">Under N<sub>2</sub> atmosphere, to a room temperature solution of corresponding heterocycle (1.0 mmol) and 4-(Dimethylamino)pyridine (0.1 mmol) in dry pyridine (2.7 mL) was dropwise added corresponding isocyanate (1.0 mmol). Then, the reaction crude was stirred at room temperature for 5 h, portioned between EtOAc (20 mL) and NaHCO<sub>3</sub> saturated solution (20 mL), and the organic layer extracted with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to dryness at low pressure. The pure compounds were afforded by purification by typical silica gel flash chromatography, using mixtures of increasing polarity of cyclohexane and EtOAc or <i>tert</i>-butyl methyl ether (TBME), followed by trituration in diethyl ether.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Synthesis of 1-(1,3-Benzothiazol-2-yl)-3-hexyl-urea (<b>1</b>) in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a></h4><div class="NLM_p last">Compound <b>1</b> was synthesized following the general procedure previously described using 2-aminobenzothiazole (100 mg, 0.65 mmol) and hexyl isocyanate (0.10 mL, 0.65 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 95:5 to 70:30) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>1</b> (111 mg, 64%) as a white solid. Rt = 2.70 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 278.1 [M â H]<sup>+</sup>, calculated 278.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.58 (s, 1H), 7.85 (d, <i>J</i> = 7.1 Hz, 1H), 7.59 (d, <i>J</i> = 7.9 Hz, 1H), 7.40â7.27 (m, 1H), 7.19 (m, 1H), 6.74 (t, <i>J</i> = 5.6 Hz, 1H), 3.12â3.16 (m, 2H), 1.44 (q, <i>J</i> = 7.0 Hz, 2H), 1.35â1.23 (m, 6H), 0.92â0.79 (m, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 125.71 (CH), 122.54 (CH), 121.28 (CH), 119.82 (CH), 39.08 (CH<sub>2</sub>), 30.93 (CH<sub>2</sub>), 29.36 (CH<sub>2</sub>), 25.96 (CH<sub>2</sub>), 22.06 (CH<sub>2</sub>), 13.91 (CH<sub>3</sub>). qNMR: 97.3%.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Synthesis of 1-(1,3-Benzothiazol-2-yl)-3-(4-phenylbutyl)urea (<b>2</b>)</h4><div class="NLM_p last">Compound <b>2</b> was synthesized following the general procedure previously described using 2-aminobenzothiazole (50 mg, 0.32 mmol) and 4-phenylbutyl isocyanate (0.06 mL, 0.32 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 95:5 to 60:40) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>2</b> (89 mg, 85%) as a white solid. Rt = 2.73 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 326.1 [M â H]<sup>+</sup>, calculated 326.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.59 (s, 1H), 7.86 (d, <i>J</i> = 7.8 Hz, 1H), 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.35 (td, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.27 (t, <i>J</i> = 7.5 Hz, 2H), 7.23â7.19 (m, 3H), 7.21â7.12 (m, 1H), 6.77 (t, 1H), 3.19 (q, <i>J</i> = 6.6 Hz, 2H), 2.60 (t, <i>J</i> = 7.5 Hz, 2H), 1.68â1.54 (m, 2H), 1.54â1.41 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 142.09 (CH), 128.29 (CH), 128.24 (CH), 125.72 (CH), 125.67 (CH), 122.56 (CH), 121.29 (CH), 38.98 (CH<sub>2</sub>), 34.76 (CH<sub>2</sub>), 29.09 (CH<sub>2</sub>), 28.33 (CH<sub>2</sub>). qNMR: 97.5%.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Synthesis of 1-(1,3-Benzoxazol-2-yl)-3-hexyl-urea (<b>3</b>)</h4><div class="NLM_p last">Compound <b>3</b> was synthesized following the general procedure previously described using 2-aminobenzoxazole (100 mg, 0.72 mmol) and hexyl isocyanate (0.11 mL, 0.72 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 95:5 to 70:30) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>3</b> (48 mg, 64%) as a white solid. Rt = 2.81 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 262.1 [M â H]<sup>+</sup>, calculated 262.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.03 (s, 1H), 8.39 (t, <i>J</i> = 5.7 Hz, 1H), 7.55 (d, <i>J</i> = 7.5 Hz, 1H), 7.50 (d, <i>J</i> = 7.5 Hz, 1H), 7.28 (td, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.21 (td, <i>J</i> = 7.7, 1.2 Hz, 1H), 3.30â3.20 (m, 2H), 1.52 (q, <i>J</i> = 7.3 Hz, 2H), 1.37 (m, 6H), 0.98â0.77 (m, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 157.18 (CO), 151.95 (C), 146.95 (C), 140.31(C), 124.53 (CH), 122.89 (CH), 117.14 (CH), 109.77 (CH), 39.37 (CH<sub>2</sub>), 30.89 (CH<sub>2</sub>), 29.29 (CH<sub>2</sub>), 25.98 (CH<sub>2</sub>), 22.04 (CH<sub>2</sub>), 13.88 (CH<sub>3</sub>). qNMR: 97.1%.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Synthesis of 1-(1,3-Benzoxazol-2-yl)-3-(4-phenylbutyl)urea (<b>4</b>)</h4><div class="NLM_p last">Compound <b>4</b> was synthesized following the general procedure previously described using 2-aminobenzoxazole (50 mg, 0.36 mmol) and 4-phenylbutyl isocyanate (0.06 mL, 0.36 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 100:0 to 80:20) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>4</b> (65 mg, 57%) as a white solid. Rt = 2.80 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 310.1 [M â H]<sup>+</sup>, calculated 310.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.03 (s, 1H), 8.39 (t, <i>J</i> = 5.7 Hz, 1H), 7.55 (d, <i>J</i> = 7.7 Hz, 1H), 7.49 (d, <i>J</i> = 7.7 Hz, 1H), 7.32â7.23 (m, 3H), 7.23â7.11 (m, 4H), 3.28 (q, <i>J</i> = 6.6 Hz, 2H), 2.62 (t, <i>J</i> = 7.5 Hz, 2H), 1.67â1.61 (m, 2H), 1.59â1.49 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 157.17 (CO), 151.99 (C), 146.97 (C), 142.09 (C), 140.31 (C), 128.29 (CH), 128.24 (CH), 125.67 (CH), 124.54 (CH), 122.91 (CH), 117.15 (CH), 109.78 (CH), 38.76 (CH<sub>2</sub>), 34.73 (CH<sub>2</sub>), 29.02 (CH<sub>2</sub>), 28.34 (CH<sub>2</sub>). qNMR: 97.4%.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Synthesis of 1-(1<i>H</i>-Benzimidazol-2-yl)-3-hexyl-urea (<b>5</b>)</h4><div id="sec4_2_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Step 1. Synthesis of <i>tert</i>-Butyl 2-aminobenzimidazole-1-carboxylate (<b>31</b>)</h5><div class="NLM_p last">A room temperature solution of 2-aminobenzimidazole (200.0 mg, 1.46 mmol), di-<i>tert</i>-butyl dicarbonate (327.8 mg, 1.46 mmol), and triethylamine (0.6 mL, 4.37 mmol) in dry THF (2.4 mL) was stirred at room temperature for 5 h. Then, the reaction crude was portioned between AcOEt (20 mL) and NaHCO<sub>3</sub> saturated solution (20 mL), and the organic layer extracted with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to dryness at low pressure. Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 75:25 to 65:45) afforded <b>31</b> (323 mg, 95%) as a white solid. Rt = 2.03 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 234.2 [M â H]<sup>+</sup>, calculated 234.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.61 (d, <i>J</i> = 8.0 Hz, 1H), 7.34 (d, <i>J</i> = 7.5 Hz, 1H), 7.20 (td, <i>J</i> = 7.5, 1.2 Hz, 1H), 7.06 (td, <i>J</i> = 8.0, 1.2 Hz, 1H), 6.20 (s, 2H), 1.72 (s, 9H).</div></div><div id="sec4_2_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> Step 2. <i>tert</i>-Butyl 2-(hexylcarbamoylamino)benzimidazole-1-carboxylate (<b>32</b>)</h5><div class="NLM_p last">To a room temperature solution of <b>31</b> (160 mg, 0.68 mmol) and 4-(dimethylamino)pyridine (8.4 mg, 0.07 mmol) in dry pyridine (1.8 mL) was dropwise added hexyl isocyanate (0.10 mL, 0.68 mmol). Then, the reaction crude was stirred at 80 Â°C for 3 h, portioned between AcOEt (20 mL) and NaHCO<sub>3</sub> saturated solution (20 mL), and the organic layer extracted with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to dryness at low pressure. Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 100:0 to 75:25) afforded <b>32</b> (27 mg, 11%) as a white solid. Rt = 2.45 min (analysis method 2). MS (ESI) <i>m</i>/<i>z</i>: 361.2 [M â H]<sup>+</sup>, calculated 361.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.44 (s, 1H), 9.75 (s, 1H), 7.44â7.25 (m, 2H), 7.04â6.97 (m, 2H), 3.18 (td, <i>J</i> = 6.9, 5.7 Hz, 2H), 1.56â1.38 (m, 2H), 1.52 (s, 9H), 1.37â1.22 (m, 6H), 0.98â0.77 (m, 3H).</div></div><div id="sec4_2_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> Step 3. Synthesis of 1-(1<i>H</i>-Benzimidazol-2-yl)-3-hexyl-urea (<b>5</b>)</h5><div class="NLM_p last">A solution of <b>32</b> (26 mg, 0.07 mmol) in dry pyridine (0.2 mL) was stirred at 80 Â°C for 16 h, then the reaction crude was concentrated to dryness at low pressure and purified by typical silica gel flash chromatography (cyclohexane/AcOEt from 80:20 to 50:50) and final trituration in diethyl ether twice (2 Ã 1 mL) affording <b>5</b> (13 mg, 70%) as a white solid. Rt = 0.95 min (analysis method 2). MS (ESI) <i>m</i>/<i>z</i>: 261.2 [M â H]<sup>+</sup>, calculated 261.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.40 (s, 1H), 9.73 (s, 1H), 7.34 (dd, <i>J</i> = 7.1, 3.5 Hz, 2H), 7.01 (dd, <i>J</i> = 7.1, 3.5 Hz, 2H), 3.26â3.07 (m, 2H), 1.48 (dt, <i>J</i> = 14.5, 7.2 Hz, 2H), 1.37â1.18 (m, 6H), 0.98â0.75 (m, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 154.27 (CO), 148.40 (C), 120.54 (CH), 38.70 (CH<sub>2</sub>), 30.97 (CH<sub>2</sub>), 29.51 (CH<sub>2</sub>), 26.03 (CH<sub>2</sub>), 22.10 (CH<sub>2</sub>), 13.93 (CH<sub>3</sub>). qNMR: 96.3%.</div></div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Synthesis of 1-(1<i>H</i>-Benzimidazol-2-yl)-3-(4-phenylbutyl)urea (<b>6</b>)</h4><div id="sec4_2_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> Step 1. <i>tert</i>-Butyl 2-(4-phenylbutylcarbamoylamino)benzimidazole-1-carboxylate (<b>33</b>)</h5><div class="NLM_p last">To a room temperature solution of <b>31</b> (160 mg, 0.68 mmol) and 4-(dimethylamino)pyridine (8.4 mg, 0.07 mmol) in dry pyridine (1.8 mL) was dropwise added 4-phenylbutil isocyanate (0.12 mL, 0.68 mmol). Then, the reaction crude was stirred at 80 Â°C for 3 h, portioned between AcOEt (20 mL) and NaHCO<sub>3</sub> saturated solution (20 mL), and the organic layer extracted with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to dryness at low pressure. Purification by typical silica gel flash chromatography (cyclohexane/TBME from 95:5 to 10:90) afforded <b>33</b> (34 mg, 12%) as a white solid. Rt = 2.36 min (analysis method 2). MS (ESI) <i>m</i>/<i>z</i>: 409.1 [M â H]<sup>+</sup>, calculated 409.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.50 (s, 1H), 9.20 (t, <i>J</i> = 5.5 Hz, 1H), 7.70 (d, <i>J</i> = 8.4 Hz, 1H), 7.46 (d, <i>J</i> = 7.8 Hz, 1H), 7.37â7.23 (m, 4H), 7.24â7.07 (m, 3H), 3.58â3.30 (m, 2H), 2.69 (t, <i>J</i> = 7.3 Hz, 2H), 1.89â1.64 (m, 2H), 1.73 (s, 9H), 1.26 (t, <i>J</i> = 7.1 Hz, 2H).</div></div><div id="sec4_2_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> Step 2. 1-(1<i>H</i>-Benzimidazol-2-yl)-3-(4-phenylbutyl)urea (<b>6</b>)</h5><div class="NLM_p last">A solution of <b>33</b> (34 mg, 0.08 mmol) in dry pyridine (0.2 mL) was stirred at 80 Â°C for 16 h, then the reaction crude was concentrated to dryness at low pressure and purified by typical silica gel flash chromatography (cyclohexane/AcOEt from 80:20 to 50:50), and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>6</b> (18 mg, 70%) as a white solid. Rt = 0.95 min (analysis method 2). MS (ESI) <i>m</i>/<i>z</i>: 309.2 [M â H]<sup>+</sup>, calculated 309.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.42 (s, 1H), 7.40 (s, 1H), 7.34 (m, 2H), 7.27 (m, 2H), 7.23â7.12 (m, 4H), 7.01 (m, 2H), 3.22 (q, <i>J</i> = 6.5 Hz, 2H), 2.61 (t, <i>J</i> = 7.5 Hz, 2H), 1.74â1.56 (m, 2H), 1.56â1.42 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 154.29 (CO), 148.40 (C), 142.13 (C), 128.31(CH), 128.27 (CH), 125.69 (CH), 120.53 (CH), 99.54 (CH), 38.60 (CH<sub>2</sub>), 34.81 (CH<sub>2</sub>), 29.23 (CH<sub>2</sub>), 28.40 (CH<sub>2</sub>). qNMR: 96.1%.</div></div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Synthesis of 2-Amino-<i>N</i>-hexyl-benzimidazole-1-carboxamide (<b>7</b>)</h4><div class="NLM_p last">Compound <b>7</b> was synthesized following the general procedure previously described using 2-aminobenzimidazole (211.5 mg, 1.54 mmol) and hexyl isocyanate (0.114 mL, 0.68 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 50:50 to 20:80) followed by trituration in Et<sub>2</sub>O (5 mL) afforded <b>7</b> (128 mg, 64%) as a white solid. Rt = 2.17 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 261.2 [M â H]<sup>+</sup>, calculated 261.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.40 (d, <i>J</i> = 7.8 Hz, 1H), 7.29 (d, <i>J</i> = 7.8 Hz, 2H), 7.22 (td, <i>J</i> = 7.8, 1.2 Hz, 2H), 7.09 (td, <i>J</i> = 7.8, 1.2 Hz, 2H), 3.48 (td, <i>J</i> = 7.2, 5.6 Hz, 2H), 1.87â1.61 (m, 2H), 1.47â1.39 (m, 2H), 1.38â1.32 (m, 4H), 0.96â0.87 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 154.26 (C), 152.36 (CO), 143.05 (C), 130.01 (C), 124.31 (CH), 120.70 (CH), 117.52 (CH), 110.10 (CH), 41.15 (CH<sub>2</sub>), 31.54 (CH<sub>2</sub>), 29.61 (CH<sub>2</sub>), 26.74 (CH<sub>2</sub>), 22.67 (CH<sub>2</sub>), 14.13 (CH<sub>3</sub>). qNMR: 96.2%.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Synthesis of 2-Amino-<i>N</i>-(4-phenylbutyl)benzimidazole-1-carboxamide (<b>8</b>)</h4><div class="NLM_p last">Compound <b>8</b> was synthesized following the general procedure previously described using 2-aminobenzimidazole (152.0 mg, 1.11 mmol) and 4-phenylbutyl isocyanate (0.098 mL, 0.55 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 60:40 to 30:70) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>8</b> (109 mg, 64%) as a white solid. Rt = 2.47 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 309.2 [M â H]<sup>+</sup>, calculated 309.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.40 (d, <i>J</i> = 7.7 Hz, 1H), 7.33â7.27 (m, 2H), 7.25â7.15 (m, 5H), 7.07 (td, <i>J</i> = 7.7, 1.1 Hz, 1H), 6.11 (s, 2H), 5.86 (s, 1H), 3.50 (q, <i>J</i> = 6.6 Hz, 2H), 2.70 (t, <i>J</i> = 7.0 Hz, 2H), 1.91â1.58 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 154.23 (C), 152.39 (CO), 141.84 (C), 129.95 (C), 128.61(CH), 128.54 (CH), 126.16 (CH), 124.33 (CH), 120.71 (CH), 117.52 (CH), 110.12 (CH), 40.94 (CH<sub>2</sub>), 35.53 (CH<sub>2</sub>), 29.19 (CH<sub>2</sub>), 28.77 (CH<sub>2</sub>). qNMR: 96.3%.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Synthesis of <i>N</i>-Hexylbenzimidazole-1-carboxamide (<b>9</b>)</h4><div class="NLM_p last">Compound <b>9</b> was synthesized following the general procedure previously described using benzimidazole (100 mg, 0.84 mmol) and hexyl isocyanate (0.13 mL, 0.84 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 60:40 to 30:70) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>9</b> (41 mg, 20%) as a white solid. Rt = 2.53 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 246.2 [M â H]<sup>+</sup>, calculated 246.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.43 (s, 1H), 7.89â7.82 (m, 1H), 7.80â7.77 (m, 1H), 7.43â7.32 (m, 2H), 6.27 (s, 1H), 3.50 (td, <i>J</i> = 7.3, 5.7 Hz, 2H), 1.78â1.59 (m, 2H), 1.47â1.36 (m, 2H), 1.33 (m, 4H), 1.01â0.80 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 149.72 (CO), 143.27 (C), 141.20 (CH), 131.92 (C), 124.36 (CH), 123.38 (CH), 119.78 (CH), 114.37 (CH), 40.19 (CH<sub>2</sub>), 30.97 (CH<sub>2</sub>), 28.88 (CH<sub>2</sub>), 26.02 (CH<sub>2</sub>), 22.05 (CH<sub>2</sub>), 13.91 (CH<sub>3</sub>). qNMR: 96.1%.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Synthesis of <i>N</i>-(4-Phenylbutyl)benzimidazole-1-carboxamide (<b>10</b>)</h4><div class="NLM_p last">Compound <b>10</b> was synthesized following the general procedure previously described using benzimidazole (100.0 mg, 0.84 mmol) and 4-phenylbutyl isocyanate (0.15 mL, 0.84 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 90:10 to 60:40) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>10</b> (106 mg, 43%) as a white solid. Rt = 2.57 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 294.2 [M â H]<sup>+</sup>, calculated 294.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.70 (s, 1H), 8.53 (t, <i>J</i> = 5.5 Hz, 1H), 8.11â7.99 (m, 1H), 7.76â7.66 (m, 1H), 7.36 (td, <i>J</i> = 7.7, 1.5 Hz, 1H), 7.32 (dd, <i>J</i> = 7.7, 1.5 Hz, 1H), 7.30â7.24 (m, 2H), 7.23â7.13 (m, 3H), 3.34 (m, 2H), 2.63 (t, <i>J</i> = 7.2 Hz, 2H), 1.72â1.57 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 149.73 (CO), 143.25 (C), 142.02 (C), 141.20 (CH), 131.90 (C), 128.30 (CH), 128.23 (CH), 125.67 (CH), 124.36 (CH), 123.37 (CH), 119.77 (CH), 114.35 (CH), 40.00 (CH<sub>2</sub>), 34.77 (CH<sub>2</sub>), 28.56 (CH<sub>2</sub>), 28.28 (CH<sub>2</sub>). qNMR: 97.2%.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Synthesis of <i>N</i>-Hexylindazole-1-carboxamide (<b>11</b>)</h4><div class="NLM_p last">Compound <b>11</b> was synthesized following the general procedure previously described using indazole (100 mg, 0.84 mmol) and hexyl isocyanate (0.13 mL, 0.84 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 100:0 to 80:20) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>11</b> (144 mg, 70%) as a white solid. Rt = 1.82 min (analysis method 2). MS (ESI) <i>m</i>/<i>z</i>: 246.2 [M â H]<sup>+</sup>, calculated 246.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.02 (t, <i>J</i> = 6.0 Hz, 1H), 8.90 (d, <i>J</i> = 1.1 Hz, 1H), 7.77 (dt, <i>J</i> = 8.6, 1.1 Hz, 1H), 7.66 (dq, <i>J</i> = 8.6, 1.0 Hz, 1H), 7.37 (ddd, <i>J</i> = 8.6, 6.5, 1.1 Hz, 1H), 7.12 (ddd, <i>J</i> = 8.6, 6.5, 1.1 Hz, 1H), 3.33â3.28 (m, 2H), 1.58 (q, <i>J</i> = 7.2 Hz, 2H), 1.38â1.21 (m, 6H), 0.91â0.80 (m, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 149.72 (CO), 148.86 (C), 128.54 (CH), 122.89 (CH), 122.82 (CH), 121.99 (C), 121.47 (CH), 117.72 (CH), 39.94 (CH<sub>2</sub>), 30.92 (CH<sub>2</sub>), 28.86 (CH<sub>2</sub>), 25.91(CH<sub>2</sub>), 22.02 (CH<sub>2</sub>), 13.89 (CH<sub>3</sub>). qNMR: 98.5%.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Synthesis of <i>N</i>-(4-Phenylbutyl)indazole-1-carboxamide (<b>12</b>)</h4><div class="NLM_p last">Compound <b>12</b> was synthesized following the general procedure previously described using indazole (100.0 mg, 0.84 mmol) and 4-phenylbutyl isocyanate (0.15 mL, 0.84 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 100:0 to 80:20) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>12</b> (150 mg, 61%) as a white solid. Rt = 1.80 min (analysis method 2). MS (ESI) <i>m</i>/<i>z</i>: 294.2 [M â H]<sup>+</sup>, calculated 294.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.07 (t, <i>J</i> = 6.0 Hz, 1H), 8.90 (s, 1H), 7.77 (d, <i>J</i> = 8.6 Hz, 1H), 7.65 (d, <i>J</i> = 8.9 Hz, 1H), 7.37 (dd, <i>J</i> = 8.9, 6.6 Hz, 1H), 7.26 (t, <i>J</i> = 7.5 Hz, 2H), 7.21â7.09 (m, 4H), 3.37 (m, 2H), 2.66â2.56 (m, 2H), 1.62 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 149.76 (CO), 148.86 (C), 142.07 (C), 128.54 (CH), 128.29 (CH), 128.20 (CH), 125.63 (CH), 122.89 (CH), 122.83 (C), 121.98 (CH), 121.46 (CH), 117.71 (CH), 39.75 (CH<sub>2</sub>), 34.75 (CH<sub>2</sub>), 28.59 (CH<sub>2</sub>), 28.29 (CH<sub>2</sub>). qNMR: 97.3%.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Synthesis of <i>N</i>-Hexylbenzotriazole-1-carboxamide (<b>13</b>)</h4><div class="NLM_p last">Compound <b>13</b> was synthesized following the general procedure previously described using benzotriazole (50 mg, 0.42 mmol) and hexyl isocyanate (0.06 mL, 0.42 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 100:0 to 70:30) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>13</b> (65 mg, 64%) as a white solid. Rt = 2.92 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 247.1 [M â H]<sup>+</sup>, calculated 247.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.29 (d, <i>J</i> = 8.3 Hz, 1H), 8.09 (d, <i>J</i> = 8.3 Hz, 1H), 7.62 (ddd, <i>J</i> = 8.3, 7.1, 1.0 Hz, 1H), 7.46 (ddd, <i>J</i> = 8.3, 7.1, 1.0 Hz, 1H), 7.30 (s, 1H), 3.55 (td, <i>J</i> = 7.2, 5.9 Hz, 2H), 1.97â1.61 (m, 2H), 1.41â1.47 (m, 2H), 1.39â1.32 (m, 4H), 1.03â0.77 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 149.39 (CO), 146.46 (C), 131.82 (C), 130.02 (CH), 125.51 (CH), 120.12 (CH), 114.14 (CH), 40.74 (CH<sub>2</sub>), 31.57 (CH<sub>2</sub>), 29.70 (CH<sub>2</sub>), 26.64 (CH<sub>2</sub>), 22.68 (CH<sub>2</sub>), 14.15 (CH<sub>3</sub>). qNMR: 96.3%.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Synthesis of <i>N</i>-(4-Phenylbutyl)benzotriazole-1-carboxamide (<b>14</b>)</h4><div class="NLM_p last">Compound <b>14</b> was synthesized following the general procedure previously described using benzotriazole (50 mg, 0.42 mmol) and 4-phenylbutyl isocyanate (0.08 mL, 0.42 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 100:0 to 70:30) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>14</b> (78 mg, 64%) as a white solid. Rt = 2.91 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 295.1 [M â H]<sup>+</sup>, calculated 295.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.28 (dt, <i>J</i> = 8.3, 1.0 Hz, 1H), 8.09 (dt, <i>J</i> = 8.3, 1.0 Hz, 1H), 7.63 (ddd, <i>J</i> = 8.3, 7.0, 1.0 Hz, 1H), 7.46 (ddd, <i>J</i> = 8.3, 7.0, 1.0 Hz, 1H), 7.33â7.26 (m, 3H), 7.22â7.15 (m, 2H), 3.57 (q, <i>J</i> = 6.5 Hz, 2H), 2.70 (t, <i>J</i> = 7.0 Hz, 2H), 1.81â1.73 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 149.39 (CO), 146.45 (C), 141.93 (C), 131.80 (C), 130.05 (CH), 128.55 (CH), 126.08 (CH), 125.53 (CH), 120.13 (CH), 114.12 (CH), 40.54 (CH<sub>2</sub>), 35.59 (CH<sub>2</sub>), 29.33 (CH<sub>2</sub>), 28.69 (CH<sub>2</sub>). qNMR: 95.7%.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Synthesis of <i>N</i>-Hexyltriazolo[4,5-<i>b</i>]pyridine-1-carboxamide (<b>15</b>)</h4><div class="NLM_p last">Compound <b>15</b> was synthesized following the general procedure previously described using 1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridine (50 mg, 0.41 mmol) and hexyl isocyanate (0.06 mL, 0.42 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 90:10 to 60:40) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>15</b> (62 mg, 61%) as a white solid. Rt = 2.50 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 248.1 [M â H]<sup>+</sup>, calculated 248.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.82 (dd, <i>J</i> = 4.4, 1.6 Hz, 1H), 8.63 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 7.58 (dd, <i>J</i> = 8.3, 4.4 Hz, 1H), 7.32 (s, 1H), 3.64â3.48 (m, 2H), 1.80â1.63 (m, 2H), 1.50â1.40 (m, 2H), 1.42â1.27 (m, 1H), 1.01â0.79 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 157.86 (CO), 149.51 (CH), 148.71 (C), 124.71 (C), 124.50 (CH), 123.11 (CH), 40.86 (CH<sub>2</sub>), 31.53 (CH<sub>2</sub>), 29.61 (CH<sub>2</sub>), 26.60 (CH<sub>2</sub>), 22.67 (CH<sub>2</sub>), 14.13 (CH<sub>3</sub>). qNMR: 97.2%.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Synthesis of <i>N</i>-(4-Phenylbutyl)triazolo[4,5-<i>b</i>]pyridine-1-carboxamide (<b>16</b>)</h4><div class="NLM_p last">Compound <b>16</b> was synthesized following the general procedure previously described using 1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridine (50 mg, 0.41 mmol) and 4-phenylbutyl isocyanate (0.07 mL, 0.41 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 100:0 to 70:30) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>16</b> (75 mg, 62%) as a white solid. Rt = 2.53 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 296.1 [M â H]<sup>+</sup>, calculated 296.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.82 (dd, <i>J</i> = 4.4, 1.6 Hz, 1H), 8.62 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 7.58 (dd, <i>J</i> = 8.3, 4.4 Hz, 1H), 7.35â7.26 (m, 3H), 7.23â7.15 (m, 2H), 3.58 (q, <i>J</i> = 6.5 Hz, 2H), 2.70 (t, <i>J</i> = 6.9 Hz, 2H), 1.84â1.71 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 157.85 (C), 149.52 (CH), 148.72 (C), 141.82 (CO), 128.57 (CH), 128.53 (CH), 126.12 (CH), 124.69 (C), 124.52 (CH), 123.09 (CH), 40.67 (CH<sub>2</sub>), 35.56 (CH<sub>2</sub>), 29.24 (CH<sub>2</sub>), 28.65 (CH<sub>2</sub>). qNMR: 96.1%.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-Hexyl-1,3-dioxo-isoindoline-2-carboxamide (<b>17</b>)</h4><div class="NLM_p last">Compound <b>17</b> was synthesized following the general procedure previously described using isoindoline-1,3-dione (300 mg, 2.0 mmol) and hexyl isocyanate (0.15 mL, 0.5 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 100:0 to 60:40) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>17</b> (105 mg, 38%) as a white solid. Rt = 2.53 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 275.2 [M â H]<sup>+</sup>, calculated 275.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.42 (t, <i>J</i> = 5.7 Hz, 1H), 8.04â7.82 (m, 4H), 3.26â3.17 (m, 2H), 1.60â1.43 (m, 2H), 1.42â1.18 (m, 6H), 0.96â0.82 (m, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 165.40 (CO), 147.45 (CO), 135.24 (CH), 131.06 (C), 123.81 (CH), 40.08 (CH<sub>2</sub>), 30.86 (CH<sub>2</sub>), 28.56 (CH<sub>2</sub>), 25.73 (CH<sub>2</sub>), 22.04 (CH<sub>2</sub>), 13.90 (CH<sub>3</sub>). qNMR: 96.3%.</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Synthesis of 1,3-Dioxo-<i>N</i>-(4-phenylbutyl)isoindoline-2-carboxamide (<b>18</b>)</h4><div class="NLM_p last">Compound <b>18</b> was synthesized following the general procedure previously described using isoindoline-1,3-dione (300 mg, 2.0 mmol) and 4-phenylbutyl isocyanate (0.18 mL, 1.0 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 100:0 to 70:30) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>18</b> (39 mg, 12%) as a white solid. Rt = 2.59 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 323.2 [M â H]<sup>+</sup>, calculated 323.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.45 (t, <i>J</i> = 5.8 Hz, 1H), 8.05â7.87 (m, 4H), 7.32â7.25 (m, 2H), 7.24â7.19 (m, 2H), 7.20â7.14 (m, 1H), 3.26 (q, <i>J</i> = 6.5 Hz, 2H), 2.61 (t, <i>J</i> = 7.6 Hz, 2H), 1.76â1.56 (m, 2H), 1.59â1.44 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 165.39 (CO), 162.72 (CO), 147.47 (C), 142.02 (C), 135.25 (CH), 131.05 (CH), 128.28 (C), 128.24 (CH), 125.67 (CH), 123.82 (CH), 39.87 (CH<sub>2</sub>), 34.68 (CH<sub>2</sub>), 28.27 (CH<sub>2</sub>), 27.99 (CH<sub>2</sub>). qNMR: 96.5%.</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-3<i>H</i>-benzimidazole-1-carboxamide (<b>19</b>)</h4><div class="NLM_p last">Compound <b>19</b> was synthesized following the general procedure previously described using 1,3-dihydrobenzimidazol-2-one (52 mg, 0.39 mmol) and 4-phenylbutyl isocyanate (0.03 mL, 0.19 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 100:0 to 85:15) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>19</b> (14 mg, 23%) as a white solid. Rt = 1.28 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 310.2 [M â H]<sup>+</sup>, calculated 310.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.65 (s, 2H), 8.21 (dd, <i>J</i> = 6.0, 3.3 Hz, 1H), 7.29 (d, <i>J</i> = 7.7 Hz, 1H), 7.22â7.14 (m, 6H), 7.08â7.02 (m, 1H), 3.46 (q, <i>J</i> = 6.6 Hz, 2H), 2.68 (t, <i>J</i> = 7.2 Hz, 2H), 1.80â1.63 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 154.50 (CO), 151.80 (CO), 142.20 (C), 128.54 (CH), 128.48 (C), 127.88 (C), 126.84 (CH), 125.96 (CH), 123.99 (CH), 123.10 (CH), 115.74 (CH), 109.39 (CH), 39.96 (CH<sub>2</sub>), 35.66 (CH<sub>2</sub>), 29.37 (CH<sub>2</sub>), 28.84 (CH<sub>2</sub>). qNMR: 97.1%.</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Synthesis of 2-Oxo-<i>N</i>1,<i>N</i>3-bis(4-phenylbutyl)benzimidazole-1,3-dicarboxamide (<b>20</b>)</h4><div class="NLM_p last">Compound <b>20</b> was synthesized following the general procedure previously described using 1,3-dihydrobenzimidazol-2-one (30 mg, 0.22 mmol) and 4-phenylbutyl isocyanate (0.08 mL, 0.45 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 100:0 to 80:20) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>20</b> (61 mg, 56%) as a white solid. Rt = 2.77 min (analysis method 2). MS (ESI) <i>m</i>/<i>z</i>: 485.2 [M â H]<sup>+</sup>, calculated: 485.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.43 (t, <i>J</i> = 5.4 Hz, 2H), 8.30 (dd, <i>J</i> = 6.1, 3.4 Hz, 2H), 7.34â7.26 (m, 6H), 7.20 (d, <i>J</i> = 7.1 Hz, 2H), 3.49 (q, <i>J</i> = 6.6 Hz, 2H), 2.71 (t, <i>J</i> = 7.2 Hz, 1H), 1.81â1.65 (m, 8H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 153.03 (CO), 150.56 (CO), 141.78 (C), 128.24 (C), 128.19 (CH), 126.06 (CH), 125.70 (CH), 124.58 (CH), 114.85 (CH), 39.87 (CH<sub>2</sub>), 35.31 (CH<sub>2</sub>), 28.91 (CH<sub>2</sub>), 28.45 (CH<sub>2</sub>). qNMR: 97.1%.</div></div><div id="sec4_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Synthesis of 2-Methoxy-<i>N</i>-(4-phenylbutyl)benzimidazole-1-carboxamide (<b>21</b>)</h4><div id="sec4_2_21_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> Step 1. Synthesis of 2-Methoxy-1<i>H</i>-benzimidazole (<b>34</b>)</h5><div class="NLM_p last">Under Ar atmosphere, a mixture of <i>o</i>-phenylenediamine (500 mg, 4.53 mmol) and tetramethylorthocarbonate (0.89 mL, 6.34 mmol) was stirred at 90 Â°C for 24 h. Afterward, the reaction crude was concentrated to dryness at low pressure and purification by typical silica gel flash chromatography (cyclohexane/TBME from 95:5 to 70:30) afforded <b>34</b> (400 mg, 60%) as a white solid. Rt = 1.27 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 149.1 [M â H]<sup>+</sup>, calculated 149.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.80 (s, 1H), 7.42â7.28 (m, 1H), 7.26â7.12 (m, 1H), 7.11â6.94 (m, 2H), 4.04 (s, 3H).</div></div><div id="sec4_2_21_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> Step 2. 2-Methoxy-<i>N</i>-(4-phenylbutyl)benzimidazole-1-carboxamide (<b>21</b>)</h5><div class="NLM_p last">Compound <b>21</b> was synthesized following the general procedure previously described using <b>34</b> (100 mg, 0.65 mmol) and 4-phenylbutyl isocyanate (0.12 mL, 0.65 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 95:5 to 75:25) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>21</b> (95 mg, 45%) as a white solid. Rt = 2.49 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 324.1 [M â H]<sup>+</sup>, calculated 324.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.11â8.04 (m, 1H), 7.45â7.37 (m, 1H), 7.24â7.13 (m, 4H), 7.13â7.07 (m, 3H), 6.84 (t, <i>J</i> = 6.2 Hz, 1H), 4.21 (s, 3H), 3.37 (q, <i>J</i> = 6.6 Hz, 2H), 2.60 (t, <i>J</i> = 7.1 Hz, 2H), 1.70â1.57 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 154.78 (CO), 150.19 (CO), 142.07 (C), 138.89 (C), 132.77 (C), 128.50 (CH), 126.01 (CH), 123.85 (CH), 123.23 (CH), 117.79 (CH), 115.32 (CH), 58.60 (OCH<sub>3</sub>), 40.48 (CH<sub>2</sub>), 35.56 (CH<sub>2</sub>), 29.28 (CH<sub>2</sub>), 28.78 (CH<sub>2</sub>). qNMR: 97.2%.</div></div></div><div id="sec4_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Synthesis of 2-Methyl-<i>N</i>-(4-phenylbutyl)benzimidazole-1-carboxamide (<b>22</b>)</h4><div class="NLM_p last">Compound <b>22</b> was synthesized following the general procedure previously described using 2-mehthylbenzimidazole (100 mg, 0.75 mmol) and 4-phenylbutyl isocyanate (0.13 mL, 0.75 mmol). Purification by typical silica gel flash chromatography (cyclohexane/TBME from 50:50 to 30:70) and final trituration in diethyl ether twice (2 Ã 1 mL) afforded <b>22</b> (131 mg, 57%) as a white solid. Rt = 2.27 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 308.2 [M â H]<sup>+</sup>, calculated 308.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.70â7.62 (m, 1H), 7.51â7.44 (m, 1H), 7.33â7.27 (m, 4H), 7.24â7.15 (m, 3H), 6.01 (s, 1H), 3.54 (q, <i>J</i> = 6.4 Hz, 2H), 2.77 (s, 3H), 2.72 (t, <i>J</i> = 6.9 Hz, 2H), 1.89â1.68 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 152.58 (CO), 150.75 (C), 142.73 (C), 141.83 (C), 132.57 (C), 128.60 (CH), 128.53 (CH), 128.50 (CH), 126.16 (CH), 123.84 (CH), 120.03 (CH), 111.02 (CH), 41.22 (CH<sub>2</sub>), 35.53 (CH<sub>2</sub>), 29.24 (CH<sub>2</sub>), 28.81 (CH<sub>2</sub>), 16.60 (CH<sub>3</sub>). qNMR: 96.1%.</div></div><div id="sec4_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Synthesis of 2-Amino-<i>N</i>-benzyl-benzimidazole-1-carboxamide (<b>23</b>)</h4><div class="NLM_p last">Compound <b>23</b> was synthesized following the general procedure previously described using 2-aminobenzimidazole (100 mg, 0.74 mmol) and benzyl isocyanate (0.11 mL, 0.84 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 80:20 to 40:60) followed by trituration in Et<sub>2</sub>O (5 mL) afforded <b>23</b> (125 mg, 64%) as a white solid. Rt = 1.83 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 267.1 [M â H]<sup>+</sup>, calculated 267.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.46â7.31 (m, 5H), 7.29â7.25 (m, 2H), 7.21 (td, <i>J</i> = 7.7, 1.0 Hz, 1H), 7.05 (td, <i>J</i> = 7.7, 1.0 Hz, 1H), 6.24 (bs, 1H), 4.68 (d, <i>J</i> = 4.8 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 128.64 (CH), 128.61 (CH), 125.43 (CH), 121.42 (CH), 117.86 (CH), 110.75 (CH), 45.39 (CH<sub>2</sub>). qNMR: 95.8%.</div></div><div id="sec4_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Synthesis of 2-Amino-<i>N</i>-(<i>o</i>-tolylmethyl)benzimidazole-1-carboxamide (<b>24</b>)</h4><div class="NLM_p last">Compound <b>24</b> was synthesized following the general procedure previously described using 2-aminobenzimidazole (100 mg, 0.74 mmol) and 2-methylbenzyl isocyanate (0.11 mL, 0.74 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 70:30 to 50:50) followed by trituration in Et<sub>2</sub>O (5 mL) afforded <b>24</b> (120 mg, 64%) as a white solid. Rt = 1.97 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 281.1 [M â H]<sup>+</sup>, calculated 281.4. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.39 (d, <i>J</i> = 8.1 Hz, 1H), 7.34 (d, <i>J</i> = 7.1 Hz, 1H), 7.30â7.24 (m, <i>J</i> = 6.1 Hz, 3H), 7.24â7.14 (m, 2H), 7.02 (t, <i>J</i> = 7.7 Hz, 1H), 6.04 (s, 1H), 4.67 (d, <i>J</i> = 4.3 Hz, 2H), 2.43 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 154.21 (CNH<sub>2</sub>), 152.22 (CO), 136.49 (C), 134.57 (C), 131.09 (CH), 129.86 (C), 128.73 (CH), 128.60 (CH), 126.75 (CH), 124.42 (CH), 120.81 (CH), 117.53 (CH), 110.09 (CH), 43.21 (CH<sub>2</sub>), 19.28 (CH<sub>3</sub>). qNMR: 95.2%.</div></div><div id="sec4_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Synthesis of 2-Amino-<i>N</i>-(<i>m</i>-tolylmethyl)benzimidazole-1-carboxamide (<b>25</b>)</h4><div class="NLM_p last">Compound <b>25</b> was synthesized following the general procedure previously described using 2-aminobenzimidazole (100 mg, 0.74 mmol) and 3-methylbenzyl isocyanate (0.10 mL, 0.74 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 85:15 to 65:35) followed by trituration in Et<sub>2</sub>O (5 mL) afforded <b>25</b> (65 mg, 35%) as a white solid. Rt = 0.97 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 281.1 [M â H]<sup>+</sup>, calculated 281.4. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.39 (d, <i>J</i> = 7.8 Hz, 1H), 7.34â7.22 (m, 2H), 7.23â7.14 (m, 4H), 7.03 (t, <i>J</i> = 7.7 Hz, 1H), 6.19 (s, 1H), 4.63 (d, <i>J</i> = 4.2 Hz, 2H), 2.38 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 154.25 (CNH<sub>2</sub>), 152.37 (CO), 142.99 (C), 139.04 (C), 136.87 (C), 129.88 (C), 129.14 (CH), 129.07 (CH), 128.72 (CH), 124.96 (CH), 124.41 (CH), 120.77 (CH), 117.49 (CH), 110.27 (CH), 45.12 (CH<sub>2</sub>), 21.55 (CH<sub>3</sub>). qNMR: 95.8%.</div></div><div id="sec4_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Synthesis of 2-Amino-<i>N</i>-(<i>p</i>-tolylmethyl)benzimidazole-1-carboxamide (<b>26</b>)</h4><div class="NLM_p last">Compound <b>26</b> was synthesized following the general procedure previously described using 2-aminobenzimidazole (100 mg, 0.74 mmol) and 4-methylbenzyl isocyanate (0.11 mL, 0.74 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 60:40 to 30:70) followed by trituration in Et<sub>2</sub>O (5 mL) afforded <b>26</b> (110 mg, 60%) as a white solid. Rt = 1.99 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 281.1 [M â H]<sup>+</sup>, calculated 281.4. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.39 (d, <i>J</i> = 7.9 Hz, 1H), 7.28 (t, <i>J</i> = 7.2 Hz, 2H), 7.24â7.18 (m, 4H), 7.08â7.01 (m, 1H), 6.19 (s, 1H), 4.63 (d, <i>J</i> = 4.7 Hz, 2H), 2.37 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ (CH), 130.06 (CH), 128.10 (CH), 124.46 (CH), 121.27 (CH), 117.60 (CH), 110.54 (CH), 45.08 (CH<sub>2</sub>), 21.65 (CH<sub>3</sub>). qNMR: 95.7%.</div></div><div id="sec4_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Synthesis of <i>N</i>-Benzylbenzimidazole-1-carboxamide (<b>27</b>)</h4><div class="NLM_p last">Compound <b>27</b> was synthesized following the general procedure previously described using benzimidazole (100 mg, 0.84 mmol) and benzyl isocyanate (0.11 mL, 0.84 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 70:30 to 50:50) followed by trituration in Et<sub>2</sub>O (5 mL) afforded <b>27</b> (118 mg, 56%) as a white solid. Rt = 1.95 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 252.2 [M â H]<sup>+</sup>, calculated 252.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.47 (s, 1H), 7.85 (dd, <i>J</i> = 7.2, 1.6 Hz, 1H), 7.80 (dd, <i>J</i> = 7.2, 1.6 Hz, 1H), 7.46â7.30 (m, 7H), 6.36 (t, <i>J</i> = 5.6 Hz, 1H), 4.70 (d, <i>J</i> = 5.6 Hz, 2H). <sup>13</sup>C NMR (101 MHz CDCl<sub>3</sub>) Î´ 150.09 (CO), 144.17 (C), 140.93 (CH), 137.13 (C), 131.33 (C), 129.18 (CH), 128.31 (CH), 128.12 (CH), 125.33 (CH), 124.33 (CH), 121.01 (CH), 113.13 (CH), 45.27 (CH<sub>2</sub>). qNMR: 96.2%.</div></div><div id="sec4_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Synthesis of <i>N</i>-(<i>o</i>-Tolylmethyl)benzimidazole-1-carboxamide (<b>28</b>)</h4><div class="NLM_p last">Compound <b>28</b> was synthesized following the general procedure previously described using benzimidazole (100 mg, 0.84 mmol) and 2-methylbenzyl isocyanate (0.12 mL, 0.84 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 85:15 to 65:35) followed by trituration in Et<sub>2</sub>O (5 mL) afforded <b>28</b> (147 mg, 66%) as a white solid. Rt = 2.07 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 266.1 [M â H]<sup>+</sup>, calculated 266.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.37 (s, 1H), 7.83 (dd, <i>J</i> = 7.2, 1.8 Hz, 1H), 7.76 (dd, <i>J</i> = 7.2, 1.8 Hz, 1H), 7.43â7.30 (m, 4H), 7.28â7.17 (m, 2H), 6.27 (t, <i>J</i> = 5.2 Hz, 1H), 4.69 (d, <i>J</i> = 5.2 Hz, 2H), 2.41 (s, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 149.89 (CO), 144.15 (C), 140.87 (CH), 136.67 (C), 134.71 (C), 131.34 (C), 131.03 (CH), 128.93 (CH), 128.58 (CH), 126.67 (CH), 125.33 (CH), 124.32 (CH), 121.01 (CH), 113.08 (CH), 43.37 (CH<sub>2</sub>), 19.27 (CH<sub>3</sub>). qNMR: 95.7%.</div></div><div id="sec4_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Synthesis of <i>N</i>-(<i>m</i>-Tolylmethyl)benzimidazole-1-carboxamide (<b>29</b>)</h4><div class="NLM_p last">Compound <b>29</b> was synthesized following the general procedure previously described using benzimidazole (100 mg, 0.84 mmol) and 3-methylbenzyl isocyanate (0.12 mL, 0.84 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 85:15 to 65:35) followed by trituration in Et<sub>2</sub>O (5 mL) afforded <b>29</b> (152 mg, 68%) as a white solid. Rt = 2.09 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 266.1 [M â H]<sup>+</sup>, calculated 266.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.44 (s, 1H), 7.86 (dd, <i>J</i> = 7.5, 1.7 Hz, 1H), 7.78 (dd, <i>J</i> = 7.5, 1.7 Hz, 1H), 7.41â7.33 (m, 2H), 7.32â7.24 (m, 2 H), 7.20 (d, <i>J</i> = 7.9 Hz, 1H), 7.14 (d, <i>J</i> = 7.6 Hz, 1H), 6.34 (t, <i>J</i> = 5.6 Hz, 1H), 4.65 (d, <i>J</i> = 5.6 Hz, 2H), 2.36 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 150.03 (CO), 144.21 (C), 140.95 (CH), 139.00 (C), 137.02 (C), 131.32 (C), 129.09 (CH), 129.06 (CH), 128.88 (CH), 125.31 (CH), 125.13 (CH), 124.32 (CH), 121.05 (CH), 113.09 (CH), 45.27 (CH<sub>2</sub>), 21.53 (CH<sub>3</sub>). qNMR: 97.3%.</div></div><div id="sec4_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Synthesis of <i>N</i>-(<i>p</i>-Tolylmethyl)benzimidazole-1-carboxamide (<b>30</b>)</h4><div class="NLM_p last">Compound <b>30</b> was synthesized following the general procedure previously described using benzimidazole (100 mg, 0.84 mmol) and 4-methylbenzyl isocyanate (0.12 mL, 0.84 mmol). Purification by typical silica gel flash chromatography (cyclohexane/AcOEt from 85:15 to 65:35) followed by trituration in Et<sub>2</sub>O (5 mL) afforded <b>30</b> (147 mg, 66%) as a white solid. Rt = 2.07 min (analysis method 1). MS (ESI) <i>m</i>/<i>z</i>: 266.1 [M â H]<sup>+</sup>, calculated 266.1 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.41 (s, 1H), 7.84 (dd, <i>J</i> = 6.5, 1.6 Hz, 1H), 7.75 (dd, <i>J</i> = 6.5, 1.6 Hz, 1H), 7.41â7.31 (m, 2H), 7.28 (d, <i>J</i> = 7.9 Hz, 2H), 7.18 (d, <i>J</i> = 7.9 Hz, 2H), 6.45 (t, <i>J</i> = 5.5 Hz, 1H), 4.63 (d, <i>J</i> = 5.5 Hz, 2H), 2.35 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 150.09 (CO), 143.87 (C), 140.86 (CH), 138.00 (C), 134.14 (C), 131.43 (C), 129.72 (CH), 128.05 (CH), 125.25 (CH), 124.23 (CH), 120.67 (CH), 113.41 (CH), 44.95 (CH<sub>2</sub>), 21.24 (CH<sub>3</sub>). qNMR: 96.1%.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Coordinate Scan</h3><div class="NLM_p last">We performed a force-field-based coordinate scan of the dihedral angle formed by C2âN1âC1â²âO1â² atoms of the most promising compounds <b>8</b>, <b>10</b>, and <b>19</b>â<b>22</b>. To do this, we used the coordinate scan tool implemented in Maestro software, version 10.4. First, the scaffold of the six compounds was manually designed, excluding the alkyl chains. Then, the 360Â° coordinate scan was performed using the OPLS 2005 force field in water, incrementing the dihedral angle of 10Â°.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Generation of Stably Overexpressing AC HEK293 Cells</h3><div class="NLM_p last">The plasmid hACpCDNA3.1 containing the human AC variant 1 coding sequence (NM_177924), a N-ter Kozak sequence, and a C-ter His tag<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> was modified to remove the C-ter His-tag. It was then used to transfect HEK293 cells using Lipofectamine 2000 (Invitrogen), following the manufacturerâs instructions. A stable cell line was generated by selection with G418 (1 mg/mL), and cell clones were obtained by limited dilution plating.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> AC Activity in Vitro</h3><div class="NLM_p last">Clonal HEK293 cells stably expressing AC were used to prepare lysosomal lysates enriched with AC as described,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and AC activity was measured using a fluorogenic assay.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Briefly, 2 Î¼g of protein from lysosomal extracts was preincubated with the inhibitors for 30 min in 25 mM sodium acetate buffer at pH 4.5 at 37 Â°C. The reaction was started by the addition of the fluorogenic substrate Rbm-14-12 (final concentration in the assay 10 Î¼M), incubated for 1 h at 37 Â°C, and stopped by the addition of methanol and 2.5 mg/mL of NaIO<sub>4</sub> freshly prepared in 100 mM glycine/NaOH buffer at pH 10.6. After an additional incubation for 2 h at 37 Â°C in the dark, fluorescence intensity was measured using an Infinite 200 (Tecan) plate reader (Î»<sub>ex</sub> 355 nm/Î»<sub>em</sub> 460). Experiments were performed in triplicate, and IC<sub>50</sub> values of AC inhibition responses were calculated by fitting a four-parameter nonlinear regression model, using GraphPad Prism software V5.03 (GraphPad Software, Inc., USA). Values reported are the mean Â± SD of three independent measurements.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> AC Activity in Intact Cells</h3><div class="NLM_p last">Melanoma cell lines A375 (ECACC 88113005) and G-361 (ECACC 88030401) were obtained from SIGMA and cultured in Dulbeccoâs modified Eagleâs medium containing 10% fetal bovine serum and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine in a humidified atmosphere of 5% CO<sub>2</sub> at 37 Â°C. AC activity was measured using a fluorogenic assay<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> as described by Morad and collaborators<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> with minor modifications. Briefly, A375 and G-361 cells (5 Ã 10<sup>4</sup> and 2.5 Ã 10<sup>4</sup>, respectively) were seeded in 96-well plates and 24 h later treated with compounds or DMSO as control for 2 h at 37 Â°C. The fluorogenic substrate dissolved in DMSO was then added to a final concentration of 20 Î¼M, and the plates incubated for an additional 3 h. Reaction was stopped by the addition of methanol and NaIO<sub>4</sub>, and fluorescence intensity was measured as described above. Experiments were performed in triplicate, and IC<sub>50</sub> values of AC inhibition responses were calculated by fitting a four-parameter nonlinear regression model, using GraphPad Prism software V5.03 (GraphPad Software, Inc., USA). Values reported are the mean Â± SD of two independent measurements.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Chemical and Mouse Plasma Stability</h3><div class="NLM_p">All compounds were tested for their chemical stability in both neutral buffered solution in PBS at pH 7.4 and acetate at pH 4.5. They also were tested for their metabolic stability using mouse plasma. In all cases was monitored the disappearance of compounds by UPLC/MS analysis. Compound stability was evaluated on the basis of the corresponding peak areas plotted versus time. A solution of the same compounds in ACN was also prepared and analyzed in the same conditions and used as reference. The compoundsâ half-lives were calculated using a one-phase fitting decay of the peak area vs time profiles.</div><div class="NLM_p">The following approach and methods were used. Stability in PBS (pH 7.4) and acetate (pH 4.5) buffers: compounds from 10 mM stock solutions in DMSO were diluted at 10 Î¼M concentration in selected buffer then incubated at 37 Â°C, and PBS buffer was preheated at 37 Â°C. Compounds were sampled at different time points (50 Î¼L diluted in 150 Î¼L of ACN). Solutions were kept at 37 Â°C under shaking. The stability of the compounds was analyzed on a UPLC chromatographic system equipped with BEH C18 reverse phase column (2.1 Ã 50 mm). The compounds were eluted with a linear gradient of ACN in water from 30 to 100% in 4 min. Eluted compounds were analyzed in positive ion mode by high-resolution mass spectrometry on a Synapt G2 qTOF mass spectrometer (UPLC, column and qTOF instrument were purchased from Waters, Milford MA, USA).</div><div class="NLM_p last">In vitro mouse plasma stability: compounds were diluted in mouse plasma added with 5% DMSO to help solubilization. Plasma was already preheated at 37 Â°C (15 min). The final compound concentration was 2.0 Î¼M. At time points (immediately after dilution, 5, 15, 30, 60, and 120 min), a 30 Î¼L aliquot of the incubation solution was diluted in 200 Î¼L of cold ACN spiked with Warfarin 200 nM, as internal standard. After vortexing for 30 s, the solution was centrifuged at 3500<i>g</i> for 15 min at 4 Â°C and the supernatant transferred for LC-MS analysis on a Waters Acquity UPLC/MS TQD system.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> LC-MS Analysis of Protein Modification</h3><div class="NLM_p last">Ten micrograms of recombinant purified human AC were incubated in 20 mM acetate buffer + 3 mM DTT for 1 h at 37 Â°C at pH 4.5 (AC enzymatic assay buffer). Analyzed compounds were added in 10:1 molar ratio with the protein and incubated for 1 h at 37 Â°C. The reaction was stopped with the addition of cold acetone (4 Â°C) to the samples (10Ã in volume). After centrifugation for 10 min at 15000<i>g</i> at 4 Â°C, the supernatant was discarded, and the pellet was dried under a nitrogen stream. 50 Î¼L of 50 mM (NH<sub>4</sub>)<sub>2</sub>CO<sub>3</sub> in water (pH 8) was added to dissolve the pellet. Trypsin (Sigma-Aldrich, Italy) was then added to a final 1:50 trypsin to protein (w/w) ratio. After an overnight incubation at 37 Â°C, the resulting peptides were dried and then redissolved in 25 Î¼L of 3% ACN in water added with 0.1% formic acid. The peptides were analyzed on a UPLC chromatographic system equipped with a BEH C18 reverse phase column (1 Ã 100 mm). The peptides were eluted with a linear gradient of ACN in water (both added with 0.1% formic acid) from 3 to 50% in 10 min. Eluted peptides were analyzed in positive ion mode by high resolution tandem mass spectrometry on a Synapt G2 qTOF mass spectrometer (UPLC, column and qTOF instrument were purchased from Waters, Milford MA, USA).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-4"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00472">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00472" class="ext-link">10.1021/acs.jmedchem.7b00472</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">General procedures and spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and additional experimental data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_001.pdf">jm7b00472_si_001.pdf (2.21 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_002.csv">jm7b00472_si_002.csv (23.49 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00472" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marco De Vivo</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Molecular Modeling & Drug Discovery, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span>;Â 
    <span class="hlFld-Affiliation affiliation">IAS-5/INM-9
Computational Biomedicine Forschungszentrum JÃ¼lich, Wilhelm-Johnen-StraÃe, 52428 JÃ¼lich, Germany</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4022-5661" title="Orcid link">http://orcid.org/0000-0003-4022-5661</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#baf7dbc8d9d594dedfccd3ccd5fad3d3ce94d3ce"><span class="__cf_email__" data-cfemail="ade0ccdfcec283c9c8dbc4dbc2edc4c4d983c4d9">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jose Antonio Ortega</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Molecular Modeling & Drug Discovery, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jose M. Arencibia</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Molecular Modeling & Drug Discovery, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giuseppina La Sala</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Molecular Modeling & Drug Discovery, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marco Borgogno</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Molecular Modeling & Drug Discovery, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Inga Bauer</span> - <span class="hlFld-Affiliation affiliation">CompuNet, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luca Bono</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto
Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clarissa Braccia</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto
Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Armirotti</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto
Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefania Girotto</span> - <span class="hlFld-Affiliation affiliation">CompuNet, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anand Ganesan</span> - <span class="hlFld-Affiliation affiliation">Department
of Dermatology and Biological Chemistry, University of California, 202 Sprague Hall, 92697-2400 Irvine, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>J.A.O. and J.M.A. are equal contributors to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): One patent application protecting the class of compounds disclosed in this article has been filed by the following authors: Marco De Vivo, Jose Antonio Ortega and Jose M. Arencibia.<br /></br></div></li></ul></div><div class="ack" id="ACK-d46e3838-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">M.D.V. thanks the Italian Association for Cancer Research (AIRC) [âMFAG n. 14140â and âIG n. 18883â] for financial support. We thank Grace Fox for copyediting and proofreading the manuscript.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23873" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23873" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Maverakis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, F. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzmaurice, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrall, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kloxin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sultani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, F.</span><span> </span><span class="NLM_article-title">Metastatic melanoma - a review of current and future treatment options</span> <span class="citation_source-journal">Acta Derm. Venereol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">â</span> <span class="NLM_lpage">524</span><span class="refDoi">Â DOI: 10.2340/00015555-2035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.2340%2F00015555-2035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=25520039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCqsL%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=516-524&author=E.+Maverakisauthor=L.+A.+Corneliusauthor=G.+M.+Bowenauthor=T.+Phanauthor=F.+B.+Patelauthor=S.+Fitzmauriceauthor=Y.+Heauthor=B.+Burrallauthor=C.+Duongauthor=A.+M.+Kloxinauthor=H.+Sultaniauthor=R.+Wilkenauthor=S.+R.+Martinezauthor=F.+Patel&title=Metastatic+melanoma+-+a+review+of+current+and+future+treatment+options&doi=10.2340%2F00015555-2035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Metastatic melanoma - a review of current and future treatment options</span></div><div class="casAuthors">Maverakis, Emanual; Cornelius, Lynn A.; Bowen, Glen M.; Phan, Tiffany; Patel, Falin B.; Fitzmaurice, Sarah; He, Young; Burrall, Barbara; Duong, Christopher; Kloxin, April M.; Sultani, Hawa; Wilken, Reason; Martinez, Steve R.; Patel, Forum</div><div class="citationInfo"><span class="NLM_cas:title">Acta Dermato-Venereologica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">516-524</span>CODEN:
                <span class="NLM_cas:coden">ADVEA4</span>;
        ISSN:<span class="NLM_cas:issn">1651-2057</span>.
    
            (<span class="NLM_cas:orgname">Acta Dermato-Venereologica</span>)
        </div><div class="casAbstract">Despite advances in treatment and surveillance, melanoma continues to claim approx. 9,000 lives in the US annually (SEER 2013).  The National Comprehensive Cancer Network currently recommends ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma.  Little data exists to guide management of cutaneous and s.c. metastases despite the fact that they are relatively common.  Existing options include intralesional Bacillus Calmette-GuÂ´erin, isolated limb perfusion/infusion, interferon-Î±, topical imiquimod, cryotherapy, radiation therapy, interferon therapy, and intratumoral interleukin-2 injections.  Newly emerging treatments include the anti-programmed cell death 1 receptor agents (nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec).  Available treatments for select sites include adoptive T-cell therapies and dendritic cell vaccines.  In addn. to reviewing the above agents and their mechanisms of action, this review will also focus on combination therapy as these strategies have shown promising results in clin. trials for metastatic melanoma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAa0FXSOBmpbVg90H21EOLACvtfcHk0ljWoLZkY4HYgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCqsL%252FN&md5=35e168f336e024eabcf0900894e4d268</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2340%2F00015555-2035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2340%252F00015555-2035%26sid%3Dliteratum%253Aachs%26aulast%3DMaverakis%26aufirst%3DE.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DBowen%26aufirst%3DG.%2BM.%26aulast%3DPhan%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DF.%2BB.%26aulast%3DFitzmaurice%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBurrall%26aufirst%3DB.%26aulast%3DDuong%26aufirst%3DC.%26aulast%3DKloxin%26aufirst%3DA.%2BM.%26aulast%3DSultani%26aufirst%3DH.%26aulast%3DWilken%26aufirst%3DR.%26aulast%3DMartinez%26aufirst%3DS.%2BR.%26aulast%3DPatel%26aufirst%3DF.%26atitle%3DMetastatic%2520melanoma%2520-%2520a%2520review%2520of%2520current%2520and%2520future%2520treatment%2520options%26jtitle%3DActa%2520Derm.%2520Venereol.%26date%3D2015%26volume%3D95%26spage%3D516%26epage%3D524%26doi%3D10.2340%2F00015555-2035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Lens, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawes, M.</span><span> </span><span class="NLM_article-title">Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">â</span> <span class="NLM_lpage">185</span><span class="refDoi">Â DOI: 10.1111/j.1365-2133.2004.05708.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1111%2Fj.1365-2133.2004.05708.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=14996086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A280%3ADC%252BD2c7gsFarsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2004&pages=179-185&author=M.+B.+Lensauthor=M.+Dawes&title=Global+perspectives+of+contemporary+epidemiological+trends+of+cutaneous+malignant+melanoma&doi=10.1111%2Fj.1365-2133.2004.05708.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma</span></div><div class="casAuthors">Lens M B; Dawes M</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of dermatology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-85</span>
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    </div><div class="casAbstract">During the past several decades, there has been a substantial increase in the incidence of cutaneous melanoma among all caucasian populations.  The number of deaths due to cutaneous malignant melanoma has also increased in most fair-skinned populations throughout the world in the past few decades.  Trends in melanoma incidence worldwide are examined.  The most recent data on the mortality from cutaneous melanoma are reported.  The role of different environmental, genetic and host factors in the aetiology of melanoma is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQT-_PG-lkWcZZoeNcnHOQ9fW6udTcc2eYEq0KaWV22XLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7gsFarsg%253D%253D&md5=3fc0be1a3dc58c7e9dfbeddbc573b56d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2004.05708.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2004.05708.x%26sid%3Dliteratum%253Aachs%26aulast%3DLens%26aufirst%3DM.%2BB.%26aulast%3DDawes%26aufirst%3DM.%26atitle%3DGlobal%2520perspectives%2520of%2520contemporary%2520epidemiological%2520trends%2520of%2520cutaneous%2520malignant%2520melanoma%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2004%26volume%3D150%26spage%3D179%26epage%3D185%26doi%3D10.1111%2Fj.1365-2133.2004.05708.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Eigentler, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caroli, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radny, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span> </span><span class="NLM_article-title">Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">748</span><span class="NLM_x">â</span> <span class="NLM_lpage">759</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(03)01280-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2FS1470-2045%2803%2901280-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=14662431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1OgsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=748-759&author=T.+K.+Eigentlerauthor=U.+M.+Caroliauthor=P.+Radnyauthor=C.+Garbe&title=Palliative+therapy+of+disseminated+malignant+melanoma%3A+a+systematic+review+of+41+randomised+clinical+trials&doi=10.1016%2FS1470-2045%2803%2901280-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials</span></div><div class="casAuthors">Eigentler, Thomas K.; Caroli, Ulrich M.; Radny, Peter; Garbe, Claus</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">748-759</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">A review.  We undertook a systematic review of 41 randomized studies in disseminated melanoma, identified by a comprehensive search.  We aimed to investigate rates of response to various treatment modalities and the outcome for the patients.  We analyzed seven studies that compared polychemotherapy with single-agent dacarbazine, six that compared different chemotherapeutic schedules with each other, five on the addn. of tamoxifen to a ref. therapy, and six that included non-specific immunostimulators.  In 17 studies, the addn. of interferon alfa, interleukin 2, or both, to a ref. therapy was investigated, including trials with biochemotherapy.  Many trials had small sample sizes and did not report a power anal.; not all were analyzed by intention to treat.  Although some treatment regimens, esp. polychemotherapeutic schedules, seem to increase response rates, none of the treatment schedules was proven to prolong overall survival.  Patients with disseminated melanoma should be treated with well-tolerated drug regimens, such as single-agent treatments or in combination with interferon alfa.  Systemic treatments should preferably be investigated in randomized trials so that the potential benefits of new treatment concepts can be thoroughly examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ7b4WSQa3LLVg90H21EOLACvtfcHk0lhXB_dLgq_6Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1OgsLo%253D&md5=d8c835b5e696b2b47d8ff848c3462018</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2803%2901280-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252803%252901280-4%26sid%3Dliteratum%253Aachs%26aulast%3DEigentler%26aufirst%3DT.%2BK.%26aulast%3DCaroli%26aufirst%3DU.%2BM.%26aulast%3DRadny%26aufirst%3DP.%26aulast%3DGarbe%26aufirst%3DC.%26atitle%3DPalliative%2520therapy%2520of%2520disseminated%2520malignant%2520melanoma%253A%2520a%2520systematic%2520review%2520of%252041%2520randomised%2520clinical%2520trials%26jtitle%3DLancet%2520Oncol.%26date%3D2003%26volume%3D4%26spage%3D748%26epage%3D759%26doi%3D10.1016%2FS1470-2045%2803%2901280-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cebon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudchadkar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchook, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Algazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Little, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J.</span><span> </span><span class="NLM_article-title">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">1694</span><span class="NLM_x">â</span> <span class="NLM_lpage">1703</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1210093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1056%2FNEJMoa1210093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=23020132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1694-1703&author=K.+T.+Flahertyauthor=J.+R.+Infanteauthor=A.+Daudauthor=R.+Gonzalezauthor=R.+F.+Keffordauthor=J.+Sosmanauthor=O.+Hamidauthor=L.+Schuchterauthor=J.+Cebonauthor=N.+Ibrahimauthor=R.+Kudchadkarauthor=H.+A.+Burrisauthor=G.+Falchookauthor=A.+Algaziauthor=K.+Lewisauthor=G.+V.+Longauthor=I.+Puzanovauthor=P.+Lebowitzauthor=A.+Singhauthor=S.+Littleauthor=P.+Sunauthor=A.+Allredauthor=D.+Ouelletauthor=K.+B.+Kimauthor=K.+Patelauthor=J.+Weber&title=Combined+BRAF+and+MEK+inhibition+in+melanoma+with+BRAF+V600+mutations&doi=10.1056%2FNEJMoa1210093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span></div><div class="casAuthors">Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Richard F.; Sosman, Jeffrey; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; Kudchadkar, Ragini; Burris, Howard A., III; Falchook, Gerald; Algazi, Alain; Lewis, Karl; Long, Georgina V.; Puzanov, Igor; Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Kim, Kevin B.; Patel, Kiran; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Resistance to therapy with BRAF kinase inhibitors is assocd. with reactivation of the mitogen-activated protein kinase (MAPK) pathway.  To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.  METHODS In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy.  The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response.  Secondary end points were overall survival and pharmacokinetic activity.  RESULTS Dose-limiting toxic effects were infrequently obsd. in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2).  Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%).  Median progression-free survival in the combination 150/2 group was 9.4 mo, as compared with 5.8 mo in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001).  The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03).  CONCLUSIONS Dabrafenib and trametinib were safely combined at full monotherapy doses.  The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced.  Progression-free survival was significantly improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk7I8zrGTVbVg90H21EOLACvtfcHk0lhXB_dLgq_6Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ&md5=199ae281d44c3b41309b934d88674cd3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1210093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1210093%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLittle%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DAllred%26aufirst%3DA.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520inhibition%2520in%2520melanoma%2520with%2520BRAF%2520V600%2520mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1694%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1210093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Hodi, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâDay, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Eertwegh, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutzky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaubel, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linette, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottensmeier, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peschel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quirt, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolchok, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yellin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichol, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urba, W. J.</span><span> </span><span class="NLM_article-title">Improved survival with ipilimumab in patients with metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">â</span> <span class="NLM_lpage">723</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1003466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1056%2FNEJMoa1003466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=20525992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCrtrbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=711-723&author=F.+S.+Hodiauthor=S.+J.+O%E2%80%99Dayauthor=D.+F.+McDermottauthor=R.+W.+Weberauthor=J.+A.+Sosmanauthor=J.+B.+Haanenauthor=R.+Gonzalezauthor=C.+Robertauthor=D.+Schadendorfauthor=J.+C.+Hasselauthor=W.+Akerleyauthor=A.+J.+van+den+Eertweghauthor=J.+Lutzkyauthor=P.+Loriganauthor=J.+M.+Vaubelauthor=G.+P.+Linetteauthor=D.+Hoggauthor=C.+H.+Ottensmeierauthor=C.+Lebbeauthor=C.+Peschelauthor=I.+Quirtauthor=J.+I.+Clarkauthor=J.+D.+Wolchokauthor=J.+S.+Weberauthor=J.+Tianauthor=M.+J.+Yellinauthor=G.+M.+Nicholauthor=A.+Hoosauthor=W.+J.+Urba&title=Improved+survival+with+ipilimumab+in+patients+with+metastatic+melanoma&doi=10.1056%2FNEJMoa1003466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with ipilimumab in patients with metastatic melanoma</span></div><div class="casAuthors">Hodi, F. Stephen; O'day, Steven J.; McDermott, David F.; Weber, Robert W.; Sosman, Jeffrey A.; Haanen, John B.; Gonzalez, Rene; Robert, Caroline; Schadendorf, Dirk; Hassel, Jessica C.; Akerley, Wallace; van den Eertwegh, Alfons J. M.; Lutzky, Jose; Lorigan, Paul; Vaubel, Julia M.; Linette, Gerald P.; Hogg, David; Ottensmeier, Christian H.; Lebbe, Celeste; Peschel, Christian; Quirt, Ian; Clark, Joseph I.; Wolchok, Jedd D.; Weber, Jeffrey S.; Tian, Jason; Yellin, Michael J.; Nichol, Geoffrey M.; Hoos, Axel; Urba, Walter J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-723</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal.  In this phase 3 study, ipilimumab - which blocks cytotoxic T-lymphocyte-assocd. antigen 4 to potentiate an antitumor T-cell response - administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma.  Methods: A total of 676 HLA-A*0201-pos. patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136).  Ipilimumab, at a dose of 3 mg per kg of body wt., was administered with or without gp100 every 3 wk for up to four treatments (induction).  Eligible patients could receive reinduction therapy.  The primary end point was overall survival.  Results: The median overall survival was 10.0 mo among patients receiving ipilimumab plus gp100, as compared with 6.4 mo among patients receiving gp100 alone (hazard ratio for death, 0.68; P < 0.001).  The median overall survival with ipilimumab alone was 10.1 mo (hazard ratio for death in the comparison with gp100 alone, 0.66; P = 0.003).  No difference in overall survival was detected between the ipilimumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P = 0.76).  Grade 3 or 4 immune-related adverse events occurred in 10 to 15% of patients treated with ipilimumab and in 3% treated with gp100 alone.  There were 14 deaths related to the study drugs (2.1%), and 7 were assocd. with immune-related adverse events.  Conclusions: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.  Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmWp_goUg4SbVg90H21EOLACvtfcHk0lhXB_dLgq_6Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCrtrbN&md5=170a241290808ccccac26a5169e6c715</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1003466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1003466%26sid%3Dliteratum%253Aachs%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DWeber%26aufirst%3DR.%2BW.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DHassel%26aufirst%3DJ.%2BC.%26aulast%3DAkerley%26aufirst%3DW.%26aulast%3Dvan%2Bden%2BEertwegh%26aufirst%3DA.%2BJ.%26aulast%3DLutzky%26aufirst%3DJ.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DVaubel%26aufirst%3DJ.%2BM.%26aulast%3DLinette%26aufirst%3DG.%2BP.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DOttensmeier%26aufirst%3DC.%2BH.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3DQuirt%26aufirst%3DI.%26aulast%3DClark%26aufirst%3DJ.%2BI.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DYellin%26aufirst%3DM.%2BJ.%26aulast%3DNichol%26aufirst%3DG.%2BM.%26aulast%3DHoos%26aufirst%3DA.%26aulast%3DUrba%26aufirst%3DW.%2BJ.%26atitle%3DImproved%2520survival%2520with%2520ipilimumab%2520in%2520patients%2520with%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D711%26epage%3D723%26doi%3D10.1056%2FNEJMoa1003466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Ugurel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohmel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span> </span><span class="NLM_article-title">Survival of patients with advanced metastatic melanoma: The impact of novel therapies</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">134</span><span class="refDoi">Â DOI: 10.1016/j.ejca.2015.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.ejca.2015.09.013" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2016&pages=125-134&author=S.+Ugurelauthor=J.+Rohmelauthor=P.+A.+Asciertoauthor=K.+T.+Flahertyauthor=J.+J.+Grobauthor=A.+Hauschildauthor=J.+Larkinauthor=G.+V.+Longauthor=P.+Loriganauthor=G.+A.+McArthurauthor=A.+Ribasauthor=C.+Robertauthor=D.+Schadendorfauthor=C.+Garbe&title=Survival+of+patients+with+advanced+metastatic+melanoma%3A+The+impact+of+novel+therapies&doi=10.1016%2Fj.ejca.2015.09.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2015.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2015.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DUgurel%26aufirst%3DS.%26aulast%3DRohmel%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DGarbe%26aufirst%3DC.%26atitle%3DSurvival%2520of%2520patients%2520with%2520advanced%2520metastatic%2520melanoma%253A%2520The%2520impact%2520of%2520novel%2520therapies%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D53%26spage%3D125%26epage%3D134%26doi%3D10.1016%2Fj.ejca.2015.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kelderman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span> </span><span class="NLM_article-title">Acquired and intrinsic resistance in cancer immunotherapy</span> <span class="citation_source-journal">Mol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1132</span><span class="NLM_x">â</span> <span class="NLM_lpage">1139</span><span class="refDoi">Â DOI: 10.1016/j.molonc.2014.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.molonc.2014.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=25106088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlSru7%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1132-1139&author=S.+Keldermanauthor=T.+N.+Schumacherauthor=J.+B.+Haanen&title=Acquired+and+intrinsic+resistance+in+cancer+immunotherapy&doi=10.1016%2Fj.molonc.2014.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired and intrinsic resistance in cancer immunotherapy</span></div><div class="casAuthors">Kelderman, Sander; Schumacher, Ton N. M.; Haanen, John B. A. G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1132-1139</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A no. of immunotherapies, in particular immune checkpoint targeting antibodies and adoptive T-cell therapies, are starting to transform the treatment of advanced cancers.  The likelihood to respond to these immunotherapies differs strongly across tumor types, with response rates for checkpoint targeting being the highest in advanced melanoma, renal cell cancer and non-small cell lung cancer.  However, also non-responsiveness is obsd., indicating the presence of intrinsic resistance or naturally acquired resistance.  In addn., a subgroup of patients that do initially respond to immunotherapy will later recur, thereby also pointing towards a role of therapy-induced acquired resistance.Here, we review our current understanding of both intrinsic and acquired resistance mechanisms in cancer immunotherapy, and discuss potential strategies to overcome them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYW9vVRhZ6_rVg90H21EOLACvtfcHk0ljBI6UIGQ48Aw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlSru7%252FF&md5=c5eda99fe7b988ceecc2bddc2831e7cd</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DKelderman%26aufirst%3DS.%26aulast%3DSchumacher%26aufirst%3DT.%2BN.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26atitle%3DAcquired%2520and%2520intrinsic%2520resistance%2520in%2520cancer%2520immunotherapy%26jtitle%3DMol.%2520Oncol.%26date%3D2014%26volume%3D8%26spage%3D1132%26epage%3D1139%26doi%3D10.1016%2Fj.molonc.2014.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrie, P.</span><span> </span><span class="NLM_article-title">Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists</span> <span class="citation_source-journal">Eur. J. Cancer Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">867</span><span class="NLM_x">â</span> <span class="NLM_lpage">872</span><span class="refDoi">Â DOI: 10.1111/ecc.12359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1111%2Fecc.12359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=26222136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A280%3ADC%252BC28%252Fns1Oruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=867-872&author=C.+Jonesauthor=G.+Claptonauthor=Z.+Zhaoauthor=B.+Barberauthor=D.+Saltmanauthor=P.+Corrie&title=Unmet+clinical+needs+in+the+management+of+advanced+melanoma%3A+findings+from+a+survey+of+oncologists&doi=10.1111%2Fecc.12359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists</span></div><div class="casAuthors">Jones C; Clapton G; Zhao Z; Barber B; Saltman D; Saltman D; Corrie P</div><div class="citationInfo"><span class="NLM_cas:title">European journal of cancer care</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">867-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Advanced melanoma is a life-threatening cancer with limited life expectancy.  The recent introduction of new targeted systemic therapies has provided clinicians with the means to potentially extend survival for the first time.  However, the chance of cure remains very low and treatment-induced toxicity is well described.  This qualitative study was undertaken to evaluate clinicians' assessment regarding the key concerns in managing advanced melanoma following the introduction of these new treatments.  Three hundred and forty-three oncologists were surveyed online between August and November 2012 (in 11 countries) and March and April 2013 (in an additional country).  Analysis of free-text responses identified 23 clinical issues of concern across all countries.  Of these, the most common clinical concerns were drug toxicity and tolerability, followed by limited treatment effectiveness and limited treatment options.  These results suggest that despite the promise of the two new agents in the field, clinicians are still concerned about the limitations of current treatment options, recognising that there remains a significant unmet need in the treatment of advanced melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL8vVY6IA2aR0LsK7uFuY7fW6udTcc2eZuCwL21xYRlLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252Fns1Oruw%253D%253D&md5=34249d4c8d4b1c6aea9560c86b066a4c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fecc.12359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fecc.12359%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%26aulast%3DClapton%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DBarber%26aufirst%3DB.%26aulast%3DSaltman%26aufirst%3DD.%26aulast%3DCorrie%26aufirst%3DP.%26atitle%3DUnmet%2520clinical%2520needs%2520in%2520the%2520management%2520of%2520advanced%2520melanoma%253A%2520findings%2520from%2520a%2520survey%2520of%2520oncologists%26jtitle%3DEur.%2520J.%2520Cancer%2520Care%26date%3D2015%26volume%3D24%26spage%3D867%26epage%3D872%26doi%3D10.1111%2Fecc.12359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Hyngstrom, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cromwell, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mungovan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershenwald, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royal, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cormier, J. N.</span><span> </span><span class="NLM_article-title">Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma</span> <span class="citation_source-journal">Melanoma Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">290</span><span class="NLM_x">â</span> <span class="NLM_lpage">297</span><span class="refDoi">Â DOI: 10.1097/CMR.0b013e3283632c83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1097%2FCMR.0b013e3283632c83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=23752305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A280%3ADC%252BC3sjitl2rtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=290-297&author=J.+R.+Hyngstromauthor=Y.+J.+Chiangauthor=K.+D.+Cromwellauthor=M.+I.+Rossauthor=Y.+Xingauthor=K.+S.+Mungovanauthor=J.+E.+Leeauthor=J.+E.+Gershenwaldauthor=R.+E.+Royalauthor=A.+Lucciauthor=J.+M.+Armerauthor=J.+N.+Cormier&title=Prospective+assessment+of+lymphedema+incidence+and+lymphedema-associated+symptoms+following+lymph+node+surgery+for+melanoma&doi=10.1097%2FCMR.0b013e3283632c83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma</span></div><div class="casAuthors">Hyngstrom John R; Chiang Yi-Ju; Cromwell Kate D; Ross Merrick I; Xing Yan; Mungovan Kristi S; Lee Jeffrey E; Gershenwald Jeffrey E; Royal Richard E; Lucci Anthony; Armer Jane M; Cormier Janice N</div><div class="citationInfo"><span class="NLM_cas:title">Melanoma research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">290-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We aimed to prospectively assess limb volume change (LVC) and associated symptoms in patients with melanoma undergoing sentinel lymph node biopsy and/or therapeutic lymph node dissection.  Limb volume was measured preoperatively and postoperatively at 6 and 12 months using a perometer (1000 mol/l).  LVC was calculated and used to define three groups: less than 5%, 5-10%, and greater than 10%.  A 19-item lymphedema symptom questionnaire was administered at baseline, 6, and 12 months.  One hundred and eighty-two patients were enrolled.  Twelve months after axillary surgery, 9% had LVC 5-10% and 13% had LVC greater than 10%.  Twelve months after inguinofemoral surgery, 10% had LVC 5-10% and 13% had LVC greater than 10%.  There was a significant seven- to nine-fold increase in symptoms for patients with LVC greater than 10% compared with those with LVC less than 5% (P<0.05).  On multivariate analysis, therapeutic lymph node dissection versus sentinel lymph node biopsy (odds ratio=3.18; P<0.01) and borderline significance for lower-extremity versus upper-extremity procedures (odds ratio=1.72; P=0.07) were associated with LVC greater than 5%.  LVC greater than 5% is common at 12 months following nodal surgery for melanoma and is associated with symptoms.  Informed consent for melanoma patients undergoing lymph node surgery should include a discussion of the risks of postoperative lymphedema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa1L1O54WeVuvW160gIxP_fW6udTcc2eY4v0Qbg-BE0Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjitl2rtw%253D%253D&md5=2e3c339249dc0bbf95c33b0220d12c6a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2FCMR.0b013e3283632c83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCMR.0b013e3283632c83%26sid%3Dliteratum%253Aachs%26aulast%3DHyngstrom%26aufirst%3DJ.%2BR.%26aulast%3DChiang%26aufirst%3DY.%2BJ.%26aulast%3DCromwell%26aufirst%3DK.%2BD.%26aulast%3DRoss%26aufirst%3DM.%2BI.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DMungovan%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DGershenwald%26aufirst%3DJ.%2BE.%26aulast%3DRoyal%26aufirst%3DR.%2BE.%26aulast%3DLucci%26aufirst%3DA.%26aulast%3DArmer%26aufirst%3DJ.%2BM.%26aulast%3DCormier%26aufirst%3DJ.%2BN.%26atitle%3DProspective%2520assessment%2520of%2520lymphedema%2520incidence%2520and%2520lymphedema-associated%2520symptoms%2520following%2520lymph%2520node%2520surgery%2520for%2520melanoma%26jtitle%3DMelanoma%2520Res.%26date%3D2013%26volume%3D23%26spage%3D290%26epage%3D297%26doi%3D10.1097%2FCMR.0b013e3283632c83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elojeimy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckham, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bielawska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keane, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. S.</span><span> </span><span class="NLM_article-title">Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1449</span><span class="NLM_x">â</span> <span class="NLM_lpage">1458</span><span class="refDoi">Â DOI: 10.1517/14728220903357512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1517%2F14728220903357512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=19874262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCku77L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=1449-1458&author=X.+Liuauthor=J.+C.+Chengauthor=L.+S.+Turnerauthor=S.+Elojeimyauthor=T.+H.+Beckhamauthor=A.+Bielawskaauthor=T.+E.+Keaneauthor=Y.+A.+Hannunauthor=J.+S.+Norris&title=Acid+ceramidase+upregulation+in+prostate+cancer%3A+role+in+tumor+development+and+implications+for+therapy&doi=10.1517%2F14728220903357512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy</span></div><div class="casAuthors">Liu, Xiang; Cheng, Joseph C.; Turner, Lorianne S.; Elojeimy, Saeed; Beckham, Thomas H.; Bielawska, Alicja; Keane, Thomas E.; Hannun, Yusuf A.; Norris, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1449-1458</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Bioactive sphingolipids, such as ceramide, sphingosine and sphingosine-1-phosphate are known bio-effector mols. which play important roles in various aspects of cancer biol. including cell proliferation, growth arrest, apoptosis, metastasis, senescence and inflammation.  Therefore, enzymes involved in ceramide metab. are gaining recognition as being crit. regulators of cancer cell growth and/or survival.  We previously obsd. that the ceramide metabolizing enzyme, acid ceramidase (AC) is upregulated in tumor tissues.  Studies have now concluded that this creates a dysfunctional ceramide pathway, which is responsible for tumor progression and resistance to chemotherapy and radiation.  This suggests that development of small-mol. drugs that inhibit AC enzyme activity is a promising approach for improving std. cancer therapy and patient's clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozYg7wCR2HTbVg90H21EOLACvtfcHk0lhnZ4IEa1pbrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCku77L&md5=7f1be074c8aa732e766673b7786b748d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F14728220903357512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728220903357512%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DJ.%2BC.%26aulast%3DTurner%26aufirst%3DL.%2BS.%26aulast%3DElojeimy%26aufirst%3DS.%26aulast%3DBeckham%26aufirst%3DT.%2BH.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DKeane%26aufirst%3DT.%2BE.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DNorris%26aufirst%3DJ.%2BS.%26atitle%3DAcid%2520ceramidase%2520upregulation%2520in%2520prostate%2520cancer%253A%2520role%2520in%2520tumor%2520development%2520and%2520implications%2520for%2520therapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2009%26volume%3D13%26spage%3D1449%26epage%3D1458%26doi%3D10.1517%2F14728220903357512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Bedia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrieu-Abadie, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabrias, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levade, T.</span><span> </span><span class="NLM_article-title">Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">28200</span><span class="NLM_x">â</span> <span class="NLM_lpage">28209</span><span class="refDoi">Â DOI: 10.1074/jbc.M110.216382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1074%2Fjbc.M110.216382" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=28200-28209&author=C.+Bediaauthor=J.+Casasauthor=N.+Andrieu-Abadieauthor=G.+Fabriasauthor=T.+Levade&title=Acid+ceramidase+expression+modulates+the+sensitivity+of+A375+melanoma+cells+to+dacarbazine&doi=10.1074%2Fjbc.M110.216382"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.216382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.216382%26sid%3Dliteratum%253Aachs%26aulast%3DBedia%26aufirst%3DC.%26aulast%3DCasas%26aufirst%3DJ.%26aulast%3DAndrieu-Abadie%26aufirst%3DN.%26aulast%3DFabrias%26aufirst%3DG.%26aulast%3DLevade%26aufirst%3DT.%26atitle%3DAcid%2520ceramidase%2520expression%2520modulates%2520the%2520sensitivity%2520of%2520A375%2520melanoma%2520cells%2520to%2520dacarbazine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D28200%26epage%3D28209%26doi%3D10.1074%2Fjbc.M110.216382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Tan, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awwad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morad, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kester, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claxton, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabot, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchman, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughran, T. P.,  Jr.</span><span> </span><span class="NLM_article-title">Acid ceramidase is upregulated in AML and represents a novel therapeutic target</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">83208</span><span class="NLM_x">â</span> <span class="NLM_lpage">83222</span><span class="refDoi">Â DOI: 10.18632/oncotarget.13079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.18632%2Foncotarget.13079" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=83208-83222&author=S.+F.+Tanauthor=X.+Liuauthor=T.+E.+Foxauthor=B.+M.+Barthauthor=A.+Sharmaauthor=S.+D.+Turnerauthor=A.+Awwadauthor=A.+Deweyauthor=K.+Doiauthor=B.+Spitzerauthor=M.+V.+Shahauthor=S.+A.+Moradauthor=D.+Desaiauthor=S.+Aminauthor=J.+Zhuauthor=J.+Liaoauthor=J.+Yunauthor=M.+Kesterauthor=D.+F.+Claxtonauthor=H.+G.+Wangauthor=M.+C.+Cabotauthor=E.+H.+Schuchmanauthor=R.+L.+Levineauthor=D.+J.+Feithauthor=T.+P.+Loughran&title=Acid+ceramidase+is+upregulated+in+AML+and+represents+a+novel+therapeutic+target&doi=10.18632%2Foncotarget.13079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13079%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DS.%2BF.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DFox%26aufirst%3DT.%2BE.%26aulast%3DBarth%26aufirst%3DB.%2BM.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DTurner%26aufirst%3DS.%2BD.%26aulast%3DAwwad%26aufirst%3DA.%26aulast%3DDewey%26aufirst%3DA.%26aulast%3DDoi%26aufirst%3DK.%26aulast%3DSpitzer%26aufirst%3DB.%26aulast%3DShah%26aufirst%3DM.%2BV.%26aulast%3DMorad%26aufirst%3DS.%2BA.%26aulast%3DDesai%26aufirst%3DD.%26aulast%3DAmin%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DKester%26aufirst%3DM.%26aulast%3DClaxton%26aufirst%3DD.%2BF.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DCabot%26aufirst%3DM.%2BC.%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DFeith%26aufirst%3DD.%2BJ.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26atitle%3DAcid%2520ceramidase%2520is%2520upregulated%2520in%2520AML%2520and%2520represents%2520a%2520novel%2520therapeutic%2520target%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D83208%26epage%3D83222%26doi%3D10.18632%2Foncotarget.13079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Zeidan, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obeid, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span> </span><span class="NLM_article-title">Molecular targeting of acid ceramidase: implications to cancer therapy</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">653</span><span class="NLM_x">â</span> <span class="NLM_lpage">661</span><span class="refDoi">Â DOI: 10.2174/138945008785132358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.2174%2F138945008785132358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=18691012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVymu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=653-661&author=Y.+H.+Zeidanauthor=R.+W.+Jenkinsauthor=J.+B.+Kormanauthor=X.+Liuauthor=L.+M.+Obeidauthor=J.+S.+Norrisauthor=Y.+A.+Hannun&title=Molecular+targeting+of+acid+ceramidase%3A+implications+to+cancer+therapy&doi=10.2174%2F138945008785132358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeting of acid ceramidase: implications to cancer therapy</span></div><div class="casAuthors">Zeidan, Youssef H.; Jenkins, Russell W.; Korman, John B.; Liu, Xiang; Obeid, Lina M.; Norris, James S.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">653-661</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Increasingly recognized as bioactive mols., sphingolipids have been studied in a variety of disease models.  The impact of sphingolipids on cancer research facilitated the entry of sphingolipid analogs and enzyme modulators into clin. trials.  Owing to its ability to regulate two bioactive sphingolipids, ceramide and sphingosine-1-phosphate, acid ceramidase (AC) emerges as an attractive target for drug development within the sphingolipid metabolic pathway.  Indeed, there is extensive evidence supporting a pivotal role for AC in lipid metab. and cancer biol.  In this article, we review the current knowledge of the biochem. properties of AC, its relevance to tumor promotion, and its mol. targeting approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp274kz6fu5urVg90H21EOLACvtfcHk0ljCMm5ddiJnJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVymu7w%253D&md5=54d4e5eabc134304a2345c84625df23a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F138945008785132358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945008785132358%26sid%3Dliteratum%253Aachs%26aulast%3DZeidan%26aufirst%3DY.%2BH.%26aulast%3DJenkins%26aufirst%3DR.%2BW.%26aulast%3DKorman%26aufirst%3DJ.%2BB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DNorris%26aufirst%3DJ.%2BS.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DMolecular%2520targeting%2520of%2520acid%2520ceramidase%253A%2520implications%2520to%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2008%26volume%3D9%26spage%3D653%26epage%3D661%26doi%3D10.2174%2F138945008785132358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Furuya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamori, T.</span><span> </span><span class="NLM_article-title">Sphingolipids in cancer</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">â</span> <span class="NLM_lpage">576</span><span class="refDoi">Â DOI: 10.1007/s10555-011-9304-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1007%2Fs10555-011-9304-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=22005951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1emt7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=567-576&author=H.+Furuyaauthor=Y.+Shimizuauthor=T.+Kawamori&title=Sphingolipids+in+cancer&doi=10.1007%2Fs10555-011-9304-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids in cancer</span></div><div class="casAuthors">Furuya, Hideki; Shimizu, Yoshiko; Kawamori, Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">567-576</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The bioactive sphingolipids including, ceramide, sphingosine, and sphingosine-1-phosphate (S1P) have important roles in several types of signaling and regulation of many cellular processes including cell proliferation, apoptosis, senescence, angiogenesis, and transformation.  Recent accumulating evidence suggests that ceramide- and S1P-mediated pathways have been implicated in cancer development, progression, and chemotherapy.  Ceramide mediates numerous cell-stress responses, such as induction of apoptosis and cell senescence, whereas S1P plays pivotal roles in cell survival, migration, and inflammation.  These sphingolipids with opposing roles can be interconverted within cells, suggesting that the balance between them is related to cell fate.  Importantly, these sphingolipids are metabolically related through actions of enzymes including ceramidases, ceramide synthases, sphingosine kinases, and S1P phosphatases thereby forming a network of metabolically interrelated bioactive lipid mediators whose importance in normal cellular function and diseases is gaining appreciation.  In this review, we summarize involvement of sphingolipids and their related enzymes in pathogenesis and therapy of cancer and discuss future directions of sphingolipid field in cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLu6DcWczsrrVg90H21EOLACvtfcHk0ljCMm5ddiJnJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1emt7vJ&md5=625f3bac3b024f318e15fcd1b09fb888</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs10555-011-9304-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-011-9304-1%26sid%3Dliteratum%253Aachs%26aulast%3DFuruya%26aufirst%3DH.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DKawamori%26aufirst%3DT.%26atitle%3DSphingolipids%2520in%2520cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2011%26volume%3D30%26spage%3D567%26epage%3D576%26doi%3D10.1007%2Fs10555-011-9304-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Coant, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span> </span><span class="NLM_article-title">Ceramidases, roles in sphingolipid metabolism and in health and disease</span> <span class="citation_source-journal">Adv. Biol. Regul.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">122</span><span class="NLM_x">â</span> <span class="NLM_lpage">131</span><span class="refDoi">Â DOI: 10.1016/j.jbior.2016.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.jbior.2016.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=27771292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2017&pages=122-131&author=N.+Coantauthor=W.+Sakamotoauthor=C.+Maoauthor=Y.+A.+Hannun&title=Ceramidases%2C+roles+in+sphingolipid+metabolism+and+in+health+and+disease&doi=10.1016%2Fj.jbior.2016.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidases, roles in sphingolipid metabolism and in health and disease</span></div><div class="casAuthors">Coant, Nicolas; Sakamoto, Wataru; Mao, Cungui; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122-131</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over the past three decades, extensive research has been able to det. the biol. functions for the main bioactive sphingolipids, namely ceramide, sphingosine, and sphingosine 1-phosphate (S1P) (Hannun, 1996; Hannun et al., 1986; Okazaki et al., 1989).  These studies have managed to define the metab., regulation, and function of these bioactive sphingolipids.  This emerging body of literature has also implicated bioactive sphingolipids, particularly S1P and ceramide, as key regulators of cellular homeostasis.  Ceramidases have the important role of cleaving fatty acid from ceramide and producing sphingosine, thereby controlling the interconversion of these two lipids.  Thus far, five human ceramidases encoded by five different genes have been identified: acid ceramidase (AC), neutral ceramidase (NC), alk. ceramidase 1 (ACER1), alk. ceramidase 2 (ACER2), and alk. ceramidase 3 (ACER3).  These ceramidases are classified according to their optimal pH for catalytic activity.  AC, which is localized to the lysosomal compartment, has been assocd. with Farber's disease and is involved in the regulation of cell viability.  Neutral ceramidase, which is localized to the plasma membrane and primarily expressed in the small intestine and colon, is involved in digestion, and has been implicated in colon carcinogenesis.  ACER1 which can be found in the endoplasmic reticulum and is highly expressed in the skin, plays an important role in keratinocyte differentiation.  ACER2, localized to the Golgi complex and highly expressed in the placenta, is involved in programed cell death in response to DNA damage.  ACER3, also localized to the endoplasmic reticulum and the Golgi complex, is ubiquitously expressed, and is involved in motor coordination-assocd. Purkinje cell degeneration.  This review seeks to consolidate the current knowledge regarding these key cellular players.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowWeoXuPUgXrVg90H21EOLACvtfcHk0ljCMm5ddiJnJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK&md5=84e937e947b7a38256761a6ab60a7353</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2016.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2016.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCoant%26aufirst%3DN.%26aulast%3DSakamoto%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramidases%252C%2520roles%2520in%2520sphingolipid%2520metabolism%2520and%2520in%2520health%2520and%2520disease%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2017%26volume%3D63%26spage%3D122%26epage%3D131%26doi%3D10.1016%2Fj.jbior.2016.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Kartal Yandim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apohan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baran, Y.</span><span> </span><span class="NLM_article-title">Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">â</span> <span class="NLM_lpage">20</span><span class="refDoi">Â DOI: 10.1007/s00280-012-1984-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1007%2Fs00280-012-1984-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=23073611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFCntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2013&pages=13-20&author=M.+Kartal+Yandimauthor=E.+Apohanauthor=Y.+Baran&title=Therapeutic+potential+of+targeting+ceramide%2Fglucosylceramide+pathway+in+cancer&doi=10.1007%2Fs00280-012-1984-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer</span></div><div class="casAuthors">Kartal Yandim, Melis; Apohan, Elif; Baran, Yusuf</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-20</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Sphingolipids including ceramides and its derivs. such as ceramide-1-phosphate, glucosylceramide (GlcCer), and sphingosine-1-phosphate are essential structural components of cell membranes.  They now recognized as novel bioeffector mols. which control various aspects of cell growth, proliferation, apoptosis, and drug resistance.  Ceramide, the central mol. of sphingolipid metab., generally mediates anti-proliferative responses such as inhibition of cell growth, induction of apoptosis, and/or modulation of senescence.  There are two major classes of sphingolipids.  One of them is glycosphingolipids which are synthesized from the hydrophobic mol., ceramide.  GlcCer, generated by glucosylceramide synthase (GCS) that transfers the glucose from UDP-glucose to ceramide, is an important glycosphingolipid metabolic intermediate.  GCS regulates the balance between apoptotic ceramide and antiapoptotic GlcCer.  Downregulation or inhibition of GCS results in increased apoptosis and decreased drug resistance.  The mechanism underlying the drug resistance which develops with increased glucosylceramide expression is assocd. with P-glycoprotein.  In various types of cancers, overexpression of GCS has been obsd. which renders GCS a good target for the treatment of cancer.  This review summarizes our current knowledge on the structure and functions of glucosylceramide synthase and glucosylceramide and on the roles of glucosylceramide synthase in cancer therapy and drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTlwoA9_w66LVg90H21EOLACvtfcHk0lh9XyyhBfCB3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFCntw%253D%253D&md5=f7f40067e301cb50c1e02842c309b7b4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1984-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1984-x%26sid%3Dliteratum%253Aachs%26aulast%3DKartal%2BYandim%26aufirst%3DM.%26aulast%3DApohan%26aufirst%3DE.%26aulast%3DBaran%26aufirst%3DY.%26atitle%3DTherapeutic%2520potential%2520of%2520targeting%2520ceramide%252Fglucosylceramide%2520pathway%2520in%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D71%26spage%3D13%26epage%3D20%26doi%3D10.1007%2Fs00280-012-1984-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Ogretmen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span> </span><span class="NLM_article-title">Biologically active sphingolipids in cancer pathogenesis and treatment</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">604</span><span class="NLM_x">â</span> <span class="NLM_lpage">616</span><span class="refDoi">Â DOI: 10.1038/nrc1411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1038%2Fnrc1411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=15286740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=604-616&author=B.+Ogretmenauthor=Y.+A.+Hannun&title=Biologically+active+sphingolipids+in+cancer+pathogenesis+and+treatment&doi=10.1038%2Fnrc1411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biologically active sphingolipids in cancer pathogenesis and treatment</span></div><div class="casAuthors">Ogretmen, Besim; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">604-616</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Biol. active sphingolipids have key roles in the regulation of several fundamental biol. processes that are integral to cancer pathogenesis.  Recent significant progress in understanding biol. active sphingolipid synthesis, specifically within ceramide and sphingosine-1-phosphate (S1P)-mediated pathways, has identified crucial roles for these mols. both in cancer development and progression.  Ceramide - a central mol. in sphingolipid metab. - in effect functions as a tumor-suppressor lipid, inducing antiproliferative and apoptotic responses in various cancer cells.  Conversely, S1P induces responses that, on aggregate, render S1P a tumor-promoting lipid.  These discoveries are paving the way for the advancement of anticancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraIf0pY_2SrrVg90H21EOLACvtfcHk0lh9XyyhBfCB3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhsb4%253D&md5=1147c2d9741a1da2a22ac28fa5a279e7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrc1411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1411%26sid%3Dliteratum%253Aachs%26aulast%3DOgretmen%26aufirst%3DB.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DBiologically%2520active%2520sphingolipids%2520in%2520cancer%2520pathogenesis%2520and%2520treatment%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D604%26epage%3D616%26doi%3D10.1038%2Fnrc1411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Riboni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campanella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaini, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli-Boneschi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tettamanti, G.</span><span> </span><span class="NLM_article-title">Ceramide levels are inversely associated with malignant progression of human glial tumors</span> <span class="citation_source-journal">Glia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">â</span> <span class="NLM_lpage">113</span><span class="refDoi">Â DOI: 10.1002/glia.10087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1002%2Fglia.10087" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2002&pages=105-113&author=L.+Riboniauthor=R.+Campanellaauthor=R.+Bassiauthor=R.+Villaniauthor=S.+M.+Gainiauthor=F.+Martinelli-Boneschiauthor=P.+Vianiauthor=G.+Tettamanti&title=Ceramide+levels+are+inversely+associated+with+malignant+progression+of+human+glial+tumors&doi=10.1002%2Fglia.10087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fglia.10087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.10087%26sid%3Dliteratum%253Aachs%26aulast%3DRiboni%26aufirst%3DL.%26aulast%3DCampanella%26aufirst%3DR.%26aulast%3DBassi%26aufirst%3DR.%26aulast%3DVillani%26aufirst%3DR.%26aulast%3DGaini%26aufirst%3DS.%2BM.%26aulast%3DMartinelli-Boneschi%26aufirst%3DF.%26aulast%3DViani%26aufirst%3DP.%26aulast%3DTettamanti%26aufirst%3DG.%26atitle%3DCeramide%2520levels%2520are%2520inversely%2520associated%2520with%2520malignant%2520progression%2520of%2520human%2520glial%2520tumors%26jtitle%3DGlia%26date%3D2002%26volume%3D39%26spage%3D105%26epage%3D113%26doi%3D10.1002%2Fglia.10087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teitz-Tennenbaum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabel, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubman, D. M.</span><span> </span><span class="NLM_article-title">Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma</span> <span class="citation_source-journal">J. Proteome Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">6044</span><span class="NLM_x">â</span> <span class="NLM_lpage">6051</span><span class="refDoi">Â DOI: 10.1021/pr100856k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr100856k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSqt7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=6044-6051&author=Y.+Liuauthor=J.+Heauthor=X.+Xieauthor=G.+Suauthor=S.+Teitz-Tennenbaumauthor=M.+S.+Sabelauthor=D.+M.+Lubman&title=Serum+autoantibody+profiling+using+a+natural+glycoprotein+microarray+for+the+prognosis+of+early+melanoma&doi=10.1021%2Fpr100856k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Serum Autoantibody Profiling Using a Natural Glycoprotein Microarray for the Prognosis of Early Melanoma</span></div><div class="casAuthors">Liu, Yashu; He, Jintang; Xie, Xaiolei; Su, Gang; Teitz-Tennenbaum, Seagal; Sabel, Michael S.; Lubman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6044-6051</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The poor prognosis of melanoma and the high cost of lymph node biopsy for melanoma patients have led to an urgent need for the discovery of convenient and accurate prognostic indicators.  Here, the authors have developed a natural glycoprotein microarray to discover serum autoantibodies to distinguish between patients with node neg. melanoma and node pos. melanoma.  Dual-lectin affinity chromatog. was used to ext. glycoproteins from a melanoma cell line.  Liq.-based reverse phase sepn. and microarray platforms were then applied to sep. and spot these natural proteins on nitrocellulose slides.  The serum autoantibodies were investigated by exposing these proteins to sera from 43 patients that have already been diagnosed to have different stages of early melanoma.  The combination of 9 fractions provides a 55% sensitivity with 100% specificity for the detection of node pos. against node neg. and a 62% sensitivity with 100% specificity for the detection of node neg. against node pos.  Recombinant proteins were used to confirm the results using a sample set with 79 patients with diagnosed melanoma.  The response of sera against recombinant 94 kDa glucose-regulated protein (GRP94), acid ceramidase (ASAH1), cathepsin D (CTSD), and lactate dehydrogenase B (LDHB) shared a similar pattern to the fractions where they were identified.  The glycoarray platform provides a convenient and highly reproducible method to profile autoantibodies that could be used as serum biomarkers for prognosis of melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwIyhVevD3HLVg90H21EOLACvtfcHk0lh9XyyhBfCB3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSqt7bM&md5=d882257822815eea04f204f2398c6fc5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fpr100856k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr100856k%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DG.%26aulast%3DTeitz-Tennenbaum%26aufirst%3DS.%26aulast%3DSabel%26aufirst%3DM.%2BS.%26aulast%3DLubman%26aufirst%3DD.%2BM.%26atitle%3DSerum%2520autoantibody%2520profiling%2520using%2520a%2520natural%2520glycoprotein%2520microarray%2520for%2520the%2520prognosis%2520of%2520early%2520melanoma%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2010%26volume%3D9%26spage%3D6044%26epage%3D6051%26doi%3D10.1021%2Fpr100856k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Mahdy, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elojeimy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meacham, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckham, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bielawska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bielawski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keane, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taha, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammouda, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span> </span><span class="NLM_article-title">Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer</span> <span class="citation_source-journal">Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">â</span> <span class="NLM_lpage">438</span><span class="refDoi">Â DOI: 10.1038/mt.2008.281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1038%2Fmt.2008.281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=19107118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFart7fF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=430-438&author=A.+E.+Mahdyauthor=J.+C.+Chengauthor=J.+Liauthor=S.+Elojeimyauthor=W.+D.+Meachamauthor=L.+S.+Turnerauthor=A.+Baiauthor=C.+R.+Gaultauthor=A.+S.+McPhersonauthor=N.+Garciaauthor=T.+H.+Beckhamauthor=A.+Saadauthor=A.+Bielawskaauthor=J.+Bielawskiauthor=Y.+A.+Hannunauthor=T.+E.+Keaneauthor=M.+I.+Tahaauthor=H.+M.+Hammoudaauthor=J.+S.+Norrisauthor=X.+Liu&title=Acid+ceramidase+upregulation+in+prostate+cancer+cells+confers+resistance+to+radiation%3A+AC+inhibition%2C+a+potential+radiosensitizer&doi=10.1038%2Fmt.2008.281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Acid Ceramidase Upregulation in Prostate Cancer Cells Confers Resistance to Radiation: AC Inhibition, a Potential Radiosensitizer</span></div><div class="casAuthors">Mahdy, Ayman E. M.; Cheng, Joseph C.; Li, Jun; Elojeimy, Saeed; Meacham, William D.; Turner, Lorianne S.; Bai, Aiping; Gault, Christopher R.; McPherson, Alex S.; Garcia, Nicole; Beckham, Thomas H.; Saad, Antonio; Bielawska, Alicja; Bielawski, Jacek; Hannun, Yusuf A.; Keane, Thomas E.; Taha, Mohhammed I.; Hammouda, Hisham M.; Norris, James S.; Liu, Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">430-438</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Radiation resistance in a subset of prostate tumors remains a challenge to prostate cancer radiotherapy.  The current study on the effects of radiation on prostate cancer cells reveals that radiation programs an unpredicted resistance mechanism by upregulating acid ceramidase (AC).  Irradiated cells demonstrated limited changes of ceramide levels while elevating levels of sphingosine and sphingosine-1-phosphate.  By genetically downregulating AC with small interfering RNA (siRNA), we obsd. radiosensitization of cells using clonogenic and cytotoxicity assays.  Conversely, AC overexpression further decreased sensitivity to radiation.  We also obsd. that radiation-induced AC upregulation was sufficient to create cross-resistance to chemotherapy as demonstrated by decreased sensitivity to Taxol and C6 ceramide compared to controls.  Lower levels of caspase 3/7 activity were detected in cells pretreated with radiation, also indicating increased resistance.  Finally, utilization of the small mol. AC inhibitor, LCL385, sensitized PPC-1 cells to radiation and significantly decreased tumor xenograft growth.  These data suggest a new mechanism of cancer cell resistance to radiation, through upregulation of AC i.e., in part, mediated by application of the therapy itself.  An improved understanding of radiotherapy and the application of combination therapy achieved in this study offer new opportunities for the modulation of radiation effects in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcfZKQJLJrLbVg90H21EOLACvtfcHk0liilq4EaFH-Gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFart7fF&md5=96aa1d9b77ef926f93655a78e610e20a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fmt.2008.281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2008.281%26sid%3Dliteratum%253Aachs%26aulast%3DMahdy%26aufirst%3DA.%2BE.%26aulast%3DCheng%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DElojeimy%26aufirst%3DS.%26aulast%3DMeacham%26aufirst%3DW.%2BD.%26aulast%3DTurner%26aufirst%3DL.%2BS.%26aulast%3DBai%26aufirst%3DA.%26aulast%3DGault%26aufirst%3DC.%2BR.%26aulast%3DMcPherson%26aufirst%3DA.%2BS.%26aulast%3DGarcia%26aufirst%3DN.%26aulast%3DBeckham%26aufirst%3DT.%2BH.%26aulast%3DSaad%26aufirst%3DA.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DBielawski%26aufirst%3DJ.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DKeane%26aufirst%3DT.%2BE.%26aulast%3DTaha%26aufirst%3DM.%2BI.%26aulast%3DHammouda%26aufirst%3DH.%2BM.%26aulast%3DNorris%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DAcid%2520ceramidase%2520upregulation%2520in%2520prostate%2520cancer%2520cells%2520confers%2520resistance%2520to%2520radiation%253A%2520AC%2520inhibition%252C%2520a%2520potential%2520radiosensitizer%26jtitle%3DMol.%2520Ther.%26date%3D2009%26volume%3D17%26spage%3D430%26epage%3D438%26doi%3D10.1038%2Fmt.2008.281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Seelan, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokomizo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bostwick, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span> </span><span class="NLM_article-title">Human acid ceramidase is overexpressed but not mutated in prostate cancer</span> <span class="citation_source-journal">Genes, Chromosomes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">â</span> <span class="NLM_lpage">146</span><span class="refDoi">Â DOI: 10.1002/1098-2264(2000)9999:9999<::AID-GCC1018>3.0.CO;2-E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10959093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntVWiurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2000&pages=137-146&author=R.+S.+Seelanauthor=C.+Qianauthor=A.+Yokomizoauthor=D.+G.+Bostwickauthor=D.+I.+Smithauthor=W.+Liu&title=Human+acid+ceramidase+is+overexpressed+but+not+mutated+in+prostate+cancer&doi=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Human acid ceramidase is overexpressed but not mutated in prostate cancer</span></div><div class="casAuthors">Seelan, Ratnam S.; Qian, Chiping; Yokomizo, Akira; Bostwick, David G.; Smith, David I.; Liu, Wanguo</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-146</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The human acid ceramidase gene, that causes Farber disease, is located in 8p22, a region frequently altered in several cancers, including prostate cancer.  Acid ceramidase catalyzes the hydrolysis of ceramide, a potent lipid second messenger mol. that promotes apoptosis and inhibits cellular proliferation.  It is not known whether this gene, or its expression, is altered in prostate cancer.  Here, the authors report the structural organization of the human gene, its expression in human tissues, and the identification of several single nucleotide polymorphisms.  No cancer-related mutations were found in the gene in a panel of prostate tumor DNAs analyzed, but increased expression was obsd. in prostate tumor tissues when compared with matched normals.  This increase was obsd. in all three prostate tumor cell lines tested (DU145, LnCAP, and PC3) when compared to a BPH (benign prostatic hyperplasia) cell line and 15/36 prostate tumors.  These results suggest that acid ceramidase may play an important role in prostate carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Y-_n5vjRdbVg90H21EOLACvtfcHk0liilq4EaFH-Gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntVWiurg%253D&md5=9c690947f4f44a446d83608ffda02c54</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1098-2264%25282000%25299999%253A9999%253C%253A%253AAID-GCC1018%253E3.0.CO%253B2-E%26sid%3Dliteratum%253Aachs%26aulast%3DSeelan%26aufirst%3DR.%2BS.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DYokomizo%26aufirst%3DA.%26aulast%3DBostwick%26aufirst%3DD.%2BG.%26aulast%3DSmith%26aufirst%3DD.%2BI.%26aulast%3DLiu%26aufirst%3DW.%26atitle%3DHuman%2520acid%2520ceramidase%2520is%2520overexpressed%2520but%2520not%2520mutated%2520in%2520prostate%2520cancer%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2000%26volume%3D29%26spage%3D137%26epage%3D146%26doi%3D10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Roh, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, H. J.</span><span> </span><span class="NLM_article-title">Targeting acid ceramidase sensitises head and neck cancer to cisplatin</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">â</span> <span class="NLM_lpage">172</span><span class="refDoi">Â DOI: 10.1016/j.ejca.2015.10.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.ejca.2015.10.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=26687835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFems7zF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=163-172&author=J.+L.+Rohauthor=J.+Y.+Parkauthor=E.+H.+Kimauthor=H.+J.+Jang&title=Targeting+acid+ceramidase+sensitises+head+and+neck+cancer+to+cisplatin&doi=10.1016%2Fj.ejca.2015.10.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting acid ceramidase sensitises head and neck cancer to cisplatin</span></div><div class="casAuthors">Roh, Jong-Lyel; Park, Jin Young; Kim, Eun Hye; Jang, Hye Jin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-172</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Acid ceramidase (AC), a key enzyme in ceramide metab., plays a role in cancer progression and resistance to therapy.  However, the role of AC in head and neck cancer (HNC) has not been addressed.  Here, we investigate the effect of AC inhibition on the response to cisplatin-based chemotherapy for HNC.AC protein and mRNA (mRNA) expression were examd. in primary tumors and paired normal tissues, and in HNC cell lines.  The effects of genetic and pharmacol. AC inhibition using small hairpin RNA (shRNA) and N-oleoyl-ethanolamine (NOE), alone and in combination with cisplatin, were assessed in human HNC cells by measuring cell viability, cell cycle progression, apoptosis, mRNA, and protein expression, and in preclin. tumor xenograft mouse models.AC overexpression was obsd. in four of six primary tumor tissues and six of nine HNC cell lines.  Cisplatin sensitivity was significantly decreased by AC overexpression and significantly increased by AC downregulation in HNC cells (P < 0.01).  NOE or AC shRNA-mediated AC inhibition enhanced cisplatin-induced HNC cell death by increasing ceramide prodn. and activating pro-apoptotic proteins, and these effects were abrogated by PUMA small interfering RNA transfection.  AC inhibition promoted cisplatin-induced apoptosis of HNC cells in vitro and in vivo.AC overexpression is assocd. with cisplatin sensitivity, suggesting its potential role as a chemotherapeutic target for HNC.  Genetic or pharmacol. AC inhibition promotes cisplatin cytotoxicity in HNC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomDQBsoYn4e7Vg90H21EOLACvtfcHk0liilq4EaFH-Gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFems7zF&md5=21cc9a783fabe8e2147577e80841a660</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2015.10.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2015.10.056%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DJ.%2BL.%26aulast%3DPark%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DE.%2BH.%26aulast%3DJang%26aufirst%3DH.%2BJ.%26atitle%3DTargeting%2520acid%2520ceramidase%2520sensitises%2520head%2520and%2520neck%2520cancer%2520to%2520cisplatin%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D52%26spage%3D163%26epage%3D172%26doi%3D10.1016%2Fj.ejca.2015.10.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Canals, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span> </span><span class="NLM_article-title">Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">694</span><span class="NLM_x">â</span> <span class="NLM_lpage">712</span><span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01279.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1111%2Fj.1476-5381.2011.01279.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=21615386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=694-712&author=D.+Canalsauthor=D.+M.+Perryauthor=R.+W.+Jenkinsauthor=Y.+A.+Hannun&title=Drug+targeting+of+sphingolipid+metabolism%3A+sphingomyelinases+and+ceramidases&doi=10.1111%2Fj.1476-5381.2011.01279.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases</span></div><div class="casAuthors">Canals, Daniel; Perry, David M.; Jenkins, Russell W.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">694-712</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Sphingolipids represent a class of diverse bioactive lipid mols. that are increasingly appreciated as key modulators of diverse physiol. and pathophysiol. processes that include cell growth, cell death, autophagy, angiogenesis, and stress and inflammatory responses.  Sphingomyelinases and ceramidases are key enzymes of sphingolipid metab. that regulate the formation and degrdn. of ceramide, one of the most intensely studied classes of sphingolipids.  Improved understanding of these enzymes that control not only the levels of ceramide but also the complex interconversion of sphingolipid metabolites has provided the foundation for the functional anal. of the roles of sphingolipids.  Our current understanding of the roles of various sphingolipids in the regulation of different cellular processes has come from loss-of-function/gain-of-function studies utilizing genetic deletion/downregulation/overexpression of enzymes of sphingolipid metab. (e.g. knockout animals, RNA interference) and from the use of pharmacol. inhibitors of these same enzymes.  While genetic approaches to evaluate the functional roles of sphingolipid enzymes were instrumental in advancing the field, the use of pharmacol. inhibitors was equally important in identifying new roles for sphingolipids in important cellular processes.  The latter also promises the development of novel therapeutic targets with implications for cancer therapy, inflammation, diabetes, and neurodegeneration.  In this review, we focus on the status and use of pharmacol. compds. that inhibit sphingomyelinases and ceramidases, and we will review the history, current uses and future directions for various small mol. inhibitors, and will highlight in which inhibitors of sphingolipid metabolizing enzymes have been used to effectively treat models of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjvT0kSLqjbVg90H21EOLACvtfcHk0ljrhhb3v3djYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr4%253D&md5=e0ad156d9c992cd1fa549ee5e3dec3ba</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01279.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01279.x%26sid%3Dliteratum%253Aachs%26aulast%3DCanals%26aufirst%3DD.%26aulast%3DPerry%26aufirst%3DD.%2BM.%26aulast%3DJenkins%26aufirst%3DR.%2BW.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DDrug%2520targeting%2520of%2520sphingolipid%2520metabolism%253A%2520sphingomyelinases%2520and%2520ceramidases%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D694%26epage%3D712%26doi%3D10.1111%2Fj.1476-5381.2011.01279.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Morad, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kester, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claxton, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughran, T. P.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabot, M. C.</span><span> </span><span class="NLM_article-title">Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemiaâImpact on enzyme activity and response to cytotoxics</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1851</span><span class="NLM_x">, </span> <span class="NLM_fpage">919</span><span class="NLM_x">â</span> <span class="NLM_lpage">928</span><span class="refDoi">Â DOI: 10.1016/j.bbalip.2015.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.bbalip.2015.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=25769964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksFWjtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1851&publication_year=2015&pages=919-928&author=S.+A.+Moradauthor=S.-F.+Tanauthor=D.+J.+Feithauthor=M.+Kesterauthor=D.+F.+Claxtonauthor=T.+P.+Loughranauthor=B.+M.+Barthauthor=T.+E.+Foxauthor=M.+C.+Cabot&title=Modification+of+sphingolipid+metabolism+by+tamoxifen+and+N-desmethyltamoxifen+in+acute+myelogenous+leukemia%E2%80%94Impact+on+enzyme+activity+and+response+to+cytotoxics&doi=10.1016%2Fj.bbalip.2015.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia-Impact on enzyme activity and response to cytotoxics</span></div><div class="casAuthors">Morad, Samy A. F.; Tan, Su-Fern; Feith, David J.; Kester, Mark; Claxton, David F.; Loughran, Thomas P.; Barth, Brian M.; Fox, Todd E.; Cabot, Myles C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1851</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">919-928</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">The triphenylethylene antiestrogen, tamoxifen, can be an effective inhibitor of sphingolipid metab.  This off-target activity makes tamoxifen an interesting ancillary for boosting the apoptosis-inducing properties of ceramide, a sphingolipid with valuable tumor censoring activity.  Here we show for the first time that tamoxifen and metabolite, N-desmethyltamoxifen (DMT), block ceramide glycosylation and inhibit ceramide hydrolysis (by acid ceramidase, AC) in human acute myelogenous leukemia (AML) cell lines and in AML cells derived from patients.  Tamoxifen (1-10 Î¼M) inhibition of AC in AML cells was accompanied by decreases in AC protein expression.  Tamoxifen also depressed expression and activity of sphingosine kinase 1 (SphK1), the enzyme-catalyzing prodn. of mitogenic sphingosine 1-phosphate (S1-P).  Results from mass spectroscopy showed that tamoxifen and DMT (i) increased the levels of endogenous C16:0 and C24:1 ceramide mol. species, (ii) nearly totally halted prodn. of resp. glucosylceramide (GC) mol. species, (iii) drastically reduced levels of sphingosine (to 9% of control), and (iv) reduced levels of S1-P by 85%, in vincristine-resistant HL-60/VCR cells.  The co-administration of tamoxifen with either N-(4-hydroxyphenyl)retinamide (4-HPR), a ceramide-generating retinoid, or a cell-deliverable form of ceramide, C6-ceramide, resulted in marked decreases in HL-60/VCR cell viability that far exceeded single agent potency.  Combination treatments resulted in synergistic apoptotic cell death as gauged by increased Annexin V binding and DNA fragmentation and activation of caspase-3.  These results show the versatility of adjuvant triphenylethylene with ceramide-centric therapies for magnifying therapeutic potential in AML.  Such drug regimens could serve as effective strategies, even in the multidrug-resistant setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxpo2ZdGqP-bVg90H21EOLACvtfcHk0ljrhhb3v3djYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksFWjtb0%253D&md5=48b2536a04380ef70508802e6c08f0f4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2015.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2015.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DMorad%26aufirst%3DS.%2BA.%26aulast%3DTan%26aufirst%3DS.-F.%26aulast%3DFeith%26aufirst%3DD.%2BJ.%26aulast%3DKester%26aufirst%3DM.%26aulast%3DClaxton%26aufirst%3DD.%2BF.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26aulast%3DBarth%26aufirst%3DB.%2BM.%26aulast%3DFox%26aufirst%3DT.%2BE.%26aulast%3DCabot%26aufirst%3DM.%2BC.%26atitle%3DModification%2520of%2520sphingolipid%2520metabolism%2520by%2520tamoxifen%2520and%2520N-desmethyltamoxifen%2520in%2520acute%2520myelogenous%2520leukemia%25E2%2580%2594Impact%2520on%2520enzyme%2520activity%2520and%2520response%2520to%2520cytotoxics%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2015%26volume%3D1851%26spage%3D919%26epage%3D928%26doi%3D10.1016%2Fj.bbalip.2015.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Schuchman, E. H.</span><span> </span><span class="NLM_article-title">Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Basis Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1862</span><span class="NLM_x">, </span> <span class="NLM_fpage">1459</span><span class="NLM_x">â</span> <span class="NLM_lpage">1471</span><span class="refDoi">Â DOI: 10.1016/j.bbadis.2016.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.bbadis.2016.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=27155573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2016&pages=1459-1471&author=E.+H.+Schuchman&title=Acid+ceramidase+and+the+treatment+of+ceramide+diseases%3A+The+expanding+role+of+enzyme+replacement+therapy&doi=10.1016%2Fj.bbadis.2016.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy</span></div><div class="casAuthors">Schuchman, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1459-1471</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Ceramides are a diverse group of sphingolipids that play important roles in many biol. processes.  Acid ceramidase (AC) is one key enzyme that regulates ceramide metab.  Early research on AC focused on the fact that it is the enzyme deficient in the rare genetic disorder, Farber Lipogranulomatosis.  Recent research has revealed that deficiency of the same enzyme is responsible for a rare form of spinal muscular atrophy assocd. with myoclonic epilepsy (SMA-PME).  Due to their diverse role in biol., accumulation of ceramides also has been implicated in the pathobiol. of many other common diseases, including infectious lung diseases, diabetes, cancers and others.  This has revealed the potential of AC as a therapy for many of these diseases.  This review will focus on the biol. of AC and the potential role of this enzyme in the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxHxbePZKk7rVg90H21EOLACvtfcHk0lgXupbian8VlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D&md5=b44a07178d44b3de2ef72da888931fbe</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2016.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2016.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26atitle%3DAcid%2520ceramidase%2520and%2520the%2520treatment%2520of%2520ceramide%2520diseases%253A%2520The%2520expanding%2520role%2520of%2520enzyme%2520replacement%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2016%26volume%3D1862%26spage%3D1459%26epage%3D1471%26doi%3D10.1016%2Fj.bbadis.2016.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Saied, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arenz, C.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of ceramidases</span> <span class="citation_source-journal">Cell. Physiol. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">212</span><span class="refDoi">Â DOI: 10.1159/000362995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1159%2F000362995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=24977492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSrtb%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=197-212&author=E.+M.+Saiedauthor=C.+Arenz&title=Small+molecule+inhibitors+of+ceramidases&doi=10.1159%2F000362995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Ceramidases</span></div><div class="casAuthors">Saied, Essa M.; Arenz, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">197-212</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  The equil. between the pro-apoptotic ceramide and pro-vital sphingosine-1-phosphate is considered to be decisive for cell death or survival.  The different ceramidases thus play key roles in cell fate and might offer attractive targets for pharmacol. intervention.  Although until recently only moderately active inhibitors have been described, first in vivo expts. suggest activity against cancer cell survival and multi-drug resistance.  Here, we provide a brief overview on the different ceramidases, and we will review the known inhibitors and current strategies for further inhibitor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrURDaWnmkYLVg90H21EOLACvtfcHk0lgXupbian8VlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSrtb%252FK&md5=00f9852c31b223bb3ad47dafd3273036</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1159%2F000362995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000362995%26sid%3Dliteratum%253Aachs%26aulast%3DSaied%26aufirst%3DE.%2BM.%26aulast%3DArenz%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520ceramidases%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2014%26volume%3D34%26spage%3D197%26epage%3D212%26doi%3D10.1159%2F000362995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Saied, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arenz, C.</span><span> </span><span class="NLM_article-title">Inhibitors of ceramidases</span> <span class="citation_source-journal">Chem. Phys. Lipids</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">197</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">â</span> <span class="NLM_lpage">68</span><span class="refDoi">Â DOI: 10.1016/j.chemphyslip.2015.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.chemphyslip.2015.07.009" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2016&pages=60-68&author=E.+M.+Saiedauthor=C.+Arenz&title=Inhibitors+of+ceramidases&doi=10.1016%2Fj.chemphyslip.2015.07.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.chemphyslip.2015.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemphyslip.2015.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DSaied%26aufirst%3DE.%2BM.%26aulast%3DArenz%26aufirst%3DC.%26atitle%3DInhibitors%2520of%2520ceramidases%26jtitle%3DChem.%2520Phys.%2520Lipids%26date%3D2016%26volume%3D197%26spage%3D60%26epage%3D68%26doi%3D10.1016%2Fj.chemphyslip.2015.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Sugita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulaney, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moser, H. W.</span><span> </span><span class="NLM_article-title">Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Lipids Lipid Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">398</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">131</span><span class="refDoi">Â DOI: 10.1016/0005-2760(75)90176-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2F0005-2760%2875%2990176-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=238641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADyaE2MXkvFChtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=398&publication_year=1975&pages=125-131&author=M.+Sugitaauthor=M.+Williamsauthor=J.+T.+Dulaneyauthor=H.+W.+Moser&title=Ceramidase+and+ceramide+synthesis+in+human+kidney+and+cerebellum.+Description+of+a+new+alkaline+ceramidase&doi=10.1016%2F0005-2760%2875%2990176-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidase and ceramide synthesis in human kidney and cerebellum.  Description of a new alkaline ceramidase</span></div><div class="casAuthors">Sugita, Mutsumi; Williams, Marcia; Dulaney, John T.; Moser, Hugo W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Lipids and Lipid Metabolism</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">398</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-31</span>CODEN:
                <span class="NLM_cas:coden">BBLLA6</span>;
        ISSN:<span class="NLM_cas:issn">0005-2760</span>.
    </div><div class="casAbstract">In normal cerebellum ceramide cleavage and the reverse reaction, free fatty acid-dependent ceramide synthesis, both occur not only at pH 4.0 but also at pH 9.0, although normal kidney exhibits these activities only at pH 4.0.  Both tissues are capable of synthesizing ceramide via an acyl-CoA-dependent pathway at neutral pH.  The synthetic analog of ceramide, N-oleoyl-ethanolamine, is a potent inhibitor of ceramidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3dnZmqqVFYrVg90H21EOLACvtfcHk0lgXupbian8VlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXkvFChtb4%253D&md5=a59f9b1a82754943c2da77f5c9deaf19</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0005-2760%2875%2990176-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2760%252875%252990176-9%26sid%3Dliteratum%253Aachs%26aulast%3DSugita%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DDulaney%26aufirst%3DJ.%2BT.%26aulast%3DMoser%26aufirst%3DH.%2BW.%26atitle%3DCeramidase%2520and%2520ceramide%2520synthesis%2520in%2520human%2520kidney%2520and%2520cerebellum.%2520Description%2520of%2520a%2520new%2520alkaline%2520ceramidase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Lipids%2520Lipid%2520Metab.%26date%3D1975%26volume%3D398%26spage%3D125%26epage%3D131%26doi%3D10.1016%2F0005-2760%2875%2990176-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Bielawska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardic, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span> </span><span class="NLM_article-title">Ceramide-mediated biology. Determination of structural and stereospecific requirements through the use of N-acyl-phenylaminoalcohol analogs</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">18493</span><span class="NLM_x">â</span> <span class="NLM_lpage">18497</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=18493-18497&author=A.+Bielawskaauthor=C.+M.+Linardicauthor=Y.+A.+Hannun&title=Ceramide-mediated+biology.+Determination+of+structural+and+stereospecific+requirements+through+the+use+of+N-acyl-phenylaminoalcohol+analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DLinardic%26aufirst%3DC.%2BM.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramide-mediated%2520biology.%2520Determination%2520of%2520structural%2520and%2520stereospecific%2520requirements%2520through%2520the%2520use%2520of%2520N-acyl-phenylaminoalcohol%2520analogs%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D18493%26epage%3D18497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Draper, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. D.</span><span> </span><span class="NLM_article-title">Discovery and evaluation of inhibitors of human ceramidase</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2052</span><span class="NLM_x">â</span> <span class="NLM_lpage">2061</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-11-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1158%2F1535-7163.MCT-11-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=21885864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2052-2061&author=J.+M.+Draperauthor=Z.+Xiaauthor=R.+A.+Smithauthor=Y.+Zhuangauthor=W.+Wangauthor=C.+D.+Smith&title=Discovery+and+evaluation+of+inhibitors+of+human+ceramidase&doi=10.1158%2F1535-7163.MCT-11-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Evaluation of Inhibitors of Human Ceramidase</span></div><div class="casAuthors">Draper, Jeremiah M.; Xia, Zuping; Smith, Ryan A.; Zhuang, Yan; Wang, Wenxue; Smith, Charles D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The ceramide/sphingosine-1-phosphate (S1P) rheostat has been hypothesized to play a crit. role in regulating tumor cell fate, with elevated levels of ceramide inducing death and elevated levels of S1P leading to survival and proliferation.  Ceramidases are key enzymes that control this rheostat by hydrolyzing ceramide to produce sphingosine and may also confer resistance to drugs and radiation.  Therefore, ceramidase inhibitors have excellent potential for development as new anticancer drugs.  In this study, we identify a novel ceramidase inhibitor (Ceranib-1) by screening a small mol. library and describe the synthesis of a more potent analog (Ceranib-2).  In a cell-based assay, both compds. were found to inhibit cellular ceramidase activity toward an exogenous ceramide analog, induce the accumulation of multiple ceramide species, decrease levels of sphingosine and S1P, inhibit the proliferation of cells alone and in combination with paclitaxel, and induce cell-cycle arrest and cell death.  In vivo, Ceranib-2 was found to delay tumor growth in a syngeneic tumor model without hematol. suppression or overt signs of toxicity.  These data support the selection of ceramidases as suitable targets for anticancer drug development and provide the first nonlipid inhibitors of human ceramidase activity.  Mol Cancer Ther; 10(11); 2052-61.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2jpM4jQkMrVg90H21EOLACvtfcHk0lhSdS4HjIWk1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbL&md5=0adf607e83b91dff2ed50d989cdeb34e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0365%26sid%3Dliteratum%253Aachs%26aulast%3DDraper%26aufirst%3DJ.%2BM.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DZhuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DC.%2BD.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%2520inhibitors%2520of%2520human%2520ceramidase%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2052%26epage%3D2061%26doi%3D10.1158%2F1535-7163.MCT-11-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Realini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solorzano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagliuca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzirani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armirotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luciani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costi, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="refDoi">Â DOI: 10.1038/srep01035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1038%2Fsrep01035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=23301156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1035&author=N.+Realiniauthor=C.+Solorzanoauthor=C.+Pagliucaauthor=D.+Pizziraniauthor=A.+Armirottiauthor=R.+Lucianiauthor=M.+P.+Costiauthor=T.+Bandieraauthor=D.+Piomelli&title=Discovery+of+highly+potent+acid+ceramidase+inhibitors+with+in+vitro+tumor+chemosensitizing+activity&doi=10.1038%2Fsrep01035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span></div><div class="casAuthors">Realini, Natalia; Solorzano, Carlos; Pagliuca, Chiara; Pizzirani, Daniela; Armirotti, Andrea; Luciani, Rosaria; Costi, Maria Paola; Bandiera, Tiziano; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">srep01035, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The expression of acid ceramidase (AC) - a cysteine amidase that hydrolyzes the proapoptotic lipid ceramide - is abnormally high in several human tumors, which is suggestive of a role in chemoresistance.  Available AC inhibitors lack, however, the potency and drug-likeness necessary to test this idea.  Here we show that the antineoplastic drug carmofur, which is used in the clinic to treat colorectal cancers, is a potent AC inhibitor and that this property is essential to its anti-proliferative effects.  Modifications in the chem. scaffold of carmofur yield new AC inhibitors that act synergistically with std. antitumoral drugs to prevent cancer cell proliferation.  These findings identify AC as an unexpected target for carmofur, and suggest that this mol. can be used as starting point for the design of novel chemosensitizing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoknWbdLSLhRbVg90H21EOLACvtfcHk0lhSdS4HjIWk1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D&md5=7ff74388fc2bea42c0e97fa8cbcfe61f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fsrep01035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep01035%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DSolorzano%26aufirst%3DC.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DLuciani%26aufirst%3DR.%26aulast%3DCosti%26aufirst%3DM.%2BP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520acid%2520ceramidase%2520inhibitors%2520with%2520in%2520vitro%2520tumor%2520chemosensitizing%2520activity%26jtitle%3DSci.%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D1035%26doi%3D10.1038%2Fsrep01035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Mescic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harej, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klobucar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glavac, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cetina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavelic, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raic-Malic, S.</span><span> </span><span class="NLM_article-title">Discovery of new acid ceramidase-targeted acyclic 5-alkynyl and 5-heteroaryl uracil nucleosides</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1150</span><span class="NLM_x">â</span> <span class="NLM_lpage">1155</span><span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1150-1155&author=A.+Mescicauthor=A.+Harejauthor=M.+Klobucarauthor=D.+Glavacauthor=M.+Cetinaauthor=S.+K.+Pavelicauthor=S.+Raic-Malic&title=Discovery+of+new+acid+ceramidase-targeted+acyclic+5-alkynyl+and+5-heteroaryl+uracil+nucleosides&doi=10.1021%2Facsmedchemlett.5b00298"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00298%26sid%3Dliteratum%253Aachs%26aulast%3DMescic%26aufirst%3DA.%26aulast%3DHarej%26aufirst%3DA.%26aulast%3DKlobucar%26aufirst%3DM.%26aulast%3DGlavac%26aufirst%3DD.%26aulast%3DCetina%26aufirst%3DM.%26aulast%3DPavelic%26aufirst%3DS.%2BK.%26aulast%3DRaic-Malic%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520new%2520acid%2520ceramidase-targeted%2520acyclic%25205-alkynyl%2520and%25205-heteroaryl%2520uracil%2520nucleosides%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D1150%26epage%3D1155%26doi%3D10.1021%2Facsmedchemlett.5b00298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Pizzirani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Realini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armirotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengatto, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagliuca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Benzoxazolone carboxamides: potent and systemically active inhibitors of intracellular acid ceramidase</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">â</span> <span class="NLM_lpage">489</span><span class="refDoi">Â DOI: 10.1002/anie.201409042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1002%2Fanie.201409042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWnt7zN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=485-489&author=D.+Pizziraniauthor=A.+Bachauthor=N.+Realiniauthor=A.+Armirottiauthor=L.+Mengattoauthor=I.+Bauerauthor=S.+Girottoauthor=C.+Pagliucaauthor=M.+De+Vivoauthor=M.+Summaauthor=A.+Ribeiroauthor=D.+Piomelli&title=Benzoxazolone+carboxamides%3A+potent+and+systemically+active+inhibitors+of+intracellular+acid+ceramidase&doi=10.1002%2Fanie.201409042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Benzoxazolone Carboxamides: Potent and Systemically Active Inhibitors of Intracellular Acid Ceramidase</span></div><div class="casAuthors">Pizzirani, Daniela; Bach, Anders; Realini, Natalia; Armirotti, Andrea; Mengatto, Luisa; Bauer, Inga; Girotto, Stefania; Pagliuca, Chiara; De Vivo, Marco; Summa, Maria; Ribeiro, Alison; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">485-489</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ceramides are a family of bioactive lipid-derived messengers involved in the control of cellular senescence, inflammation, and apoptosis.  Ceramide hydrolysis by acid ceramidase (AC) stops the biol. activity of these substances and influences survival and function of normal and neoplastic cells.  Because of its central role in the ceramide metab., AC may offer a novel mol. target in disorders with dysfunctional ceramide-mediated signaling.  Here, a class of benzoxazolone carboxamides is identified as the first potent and systemically active inhibitors of AC.  Prototype members of this class inhibit AC with low nanomolar potency by covalent binding to the catalytic cysteine.  Their metabolic stability and high in vivo efficacy suggest that these compds. may be used as probes to investigate the roles of ceramide in health and disease, and that this scaffold may represent a promising starting point for the development of novel therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKEJBNB_ka5bVg90H21EOLACvtfcHk0lhSdS4HjIWk1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWnt7zN&md5=46bf9fa7ccee9c7936660b6576dd03db</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fanie.201409042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201409042%26sid%3Dliteratum%253Aachs%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DMengatto%26aufirst%3DL.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%253A%2520potent%2520and%2520systemically%2520active%2520inhibitors%2520of%2520intracellular%2520acid%2520ceramidase%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D485%26epage%3D489%26doi%3D10.1002%2Fanie.201409042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Bach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzirani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Realini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vozella, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penna, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melzig, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Benzoxazolone carboxamides as potent acid Ceramidase inhibitors: Synthesis and structure-activity relationship (SAR) studies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9258</span><span class="NLM_x">â</span> <span class="NLM_lpage">9272</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9258-9272&author=A.+Bachauthor=D.+Pizziraniauthor=N.+Realiniauthor=V.+Vozellaauthor=D.+Russoauthor=I.+Pennaauthor=L.+Melzigauthor=R.+Scarpelliauthor=D.+Piomelli&title=Benzoxazolone+carboxamides+as+potent+acid+Ceramidase+inhibitors%3A+Synthesis+and+structure-activity+relationship+%28SAR%29+studies&doi=10.1021%2Facs.jmedchem.5b01188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Benzoxazolone Carboxamides as Potent Acid Ceramidase Inhibitors: Synthesis and Structure-Activity Relationship (SAR) Studies</span></div><div class="casAuthors">Bach, Anders; Pizzirani, Daniela; Realini, Natalia; Vozella, Valentina; Russo, Debora; Penna, Ilaria; Melzig, Laurin; Scarpelli, Rita; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9258-9272</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ceramides are lipid-derived intracellular messengers involved in the control of senescence, inflammation, and apoptosis.  The cysteine amidase, acid ceramidase (AC), hydrolyzes these substances into sphingosine and fatty acid and, by doing so, regulates their signaling activity.  AC inhibitors may be useful in the treatment of pathol. conditions, such as cancer, in which ceramide levels are abnormally reduced.  Here, we present a systematic SAR investigation of the benzoxazolone carboxamides, a recently described class of AC inhibitors that display high potency and systemic activity in mice.  We examd. a diverse series of substitutions on both benzoxazolone ring and carboxamide side chain.  Several modifications enhanced potency and stability, and one key compd. with a balanced activity-stability profile I was found to inhibit AC activity in mouse lungs and cerebral cortex after systemic administration.  The results expand our arsenal of AC inhibitors, thereby facilitating the use of these compds. as pharmacol. tools and their potential development as drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXKrFwyTWVt7Vg90H21EOLACvtfcHk0lgi6fMmrqcFyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI&md5=1b8de2b433b0e1b42299cf224d53e33a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01188%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DA.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DVozella%26aufirst%3DV.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DPenna%26aufirst%3DI.%26aulast%3DMelzig%26aufirst%3DL.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%2520as%2520potent%2520acid%2520Ceramidase%2520inhibitors%253A%2520Synthesis%2520and%2520structure-activity%2520relationship%2520%2528SAR%2529%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9258%26epage%3D9272%26doi%3D10.1021%2Facs.jmedchem.5b01188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Kaboudin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khodamorady, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abedi, Y.</span><span> </span><span class="NLM_article-title">A practical and convenient method for the synthesis of some benzimidazoles</span> <span class="citation_source-journal">Org. Prep. Proced. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">â</span> <span class="NLM_lpage">167</span><span class="refDoi">Â DOI: 10.1080/00304948.2013.765294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1080%2F00304948.2013.765294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFagtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=162-167&author=B.+Kaboudinauthor=M.+Khodamoradyauthor=Y.+Abedi&title=A+practical+and+convenient+method+for+the+synthesis+of+some+benzimidazoles&doi=10.1080%2F00304948.2013.765294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Practical and Convenient Method for the Synthesis of Some Benzimidazoles</span></div><div class="casAuthors">Kaboudin, Babak; Khodamorady, Minoo; Abedi, Yaghoub</div><div class="citationInfo"><span class="NLM_cas:title">Organic Preparations and Procedures International</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-167</span>CODEN:
                <span class="NLM_cas:coden">OPPIAK</span>;
        ISSN:<span class="NLM_cas:issn">0030-4948</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A new method for the synthesis of some benzimidazoles by the reaction of o-phenylenediamines with orthoesters under solvent-free conditions without any additives such as base, acid or catalyst is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW-GpuN39yvrVg90H21EOLACvtfcHk0lgi6fMmrqcFyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFagtr4%253D&md5=ea123193bf508d6b2d659809791e2505</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1080%2F00304948.2013.765294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00304948.2013.765294%26sid%3Dliteratum%253Aachs%26aulast%3DKaboudin%26aufirst%3DB.%26aulast%3DKhodamorady%26aufirst%3DM.%26aulast%3DAbedi%26aufirst%3DY.%26atitle%3DA%2520practical%2520and%2520convenient%2520method%2520for%2520the%2520synthesis%2520of%2520some%2520benzimidazoles%26jtitle%3DOrg.%2520Prep.%2520Proced.%2520Int.%26date%3D2013%26volume%3D45%26spage%3D162%26epage%3D167%26doi%3D10.1080%2F00304948.2013.765294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Quada, J. C.; Agyin, J. K.; Camden, J. B.</span><span> </span><span class="NLM_article-title">Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections</span>. WO 2002026716A2,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+C.+Quada&author=J.+K.+Agyin&author=J.+B.+Camden&title=Compounds+and+Methods+for+Use+Thereof+in+the+Treatment+of+Cancer+or+Viral+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DQuada%26aufirst%3DJ.%2BC.%26atitle%3DCompounds%2520and%2520Methods%2520for%2520Use%2520Thereof%2520in%2520the%2520Treatment%2520of%2520Cancer%2520or%2520Viral%2520Infections%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Bahadoor, A.; Castro, A. C.; Chan, L. K.; Keaney, G. F.; Nevalainen, M.; Nevalainen, V.; Peluso, S.; Tibbitts, T.</span><span> </span><span class="NLM_article-title">Triazoles as Inhibitors of Fatty Acid Synthase</span>. WO 2011140296A1,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Bahadoor&author=A.+C.+Castro&author=L.+K.+Chan&author=G.+F.+Keaney&author=M.+Nevalainen&author=V.+Nevalainen&author=S.+Peluso&author=T.+Tibbitts&title=Triazoles+as+Inhibitors+of+Fatty+Acid+Synthase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBahadoor%26aufirst%3DA.%26atitle%3DTriazoles%2520as%2520Inhibitors%2520of%2520Fatty%2520Acid%2520Synthase%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Fabbrizzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raspanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guarna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabocchi, A.</span><span> </span><span class="NLM_article-title">Role of side-chain bioisosteres in determining the binding affinity of click chemistry derived RGD peptidomimetics to alpha(v)beta(3) integrin</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2014</span><span class="NLM_x">, </span> <span class="NLM_fpage">7595</span><span class="NLM_x">â</span> <span class="NLM_lpage">7604</span><span class="refDoi">Â DOI: 10.1002/ejoc.201403129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1002%2Fejoc.201403129" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=7595-7604&author=P.+Fabbrizziauthor=G.+Menchiauthor=S.+Raspantiauthor=A.+Guarnaauthor=A.+Trabocchi&title=Role+of+side-chain+bioisosteres+in+determining+the+binding+affinity+of+click+chemistry+derived+RGD+peptidomimetics+to+alpha%28v%29beta%283%29+integrin&doi=10.1002%2Fejoc.201403129"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201403129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201403129%26sid%3Dliteratum%253Aachs%26aulast%3DFabbrizzi%26aufirst%3DP.%26aulast%3DMenchi%26aufirst%3DG.%26aulast%3DRaspanti%26aufirst%3DS.%26aulast%3DGuarna%26aufirst%3DA.%26aulast%3DTrabocchi%26aufirst%3DA.%26atitle%3DRole%2520of%2520side-chain%2520bioisosteres%2520in%2520determining%2520the%2520binding%2520affinity%2520of%2520click%2520chemistry%2520derived%2520RGD%2520peptidomimetics%2520to%2520alpha%2528v%2529beta%25283%2529%2520integrin%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2014%26volume%3D2014%26spage%3D7595%26epage%3D7604%26doi%3D10.1002%2Fejoc.201403129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Momoi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Yoseph, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadler, H. L.</span><span> </span><span class="NLM_article-title">Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">205</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">â</span> <span class="NLM_lpage">425</span><span class="refDoi">Â DOI: 10.1042/bj2050419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1042%2Fbj2050419" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=1982&pages=419-425&author=T.+Momoiauthor=Y.+Ben-Yosephauthor=H.+L.+Nadler&title=Substrate-specificities+of+acid+and+alkaline+ceramidases+in+fibroblasts+from+patients+with+Farber+disease+and+controls&doi=10.1042%2Fbj2050419"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1042%2Fbj2050419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj2050419%26sid%3Dliteratum%253Aachs%26aulast%3DMomoi%26aufirst%3DT.%26aulast%3DBen-Yoseph%26aufirst%3DY.%26aulast%3DNadler%26aufirst%3DH.%2BL.%26atitle%3DSubstrate-specificities%2520of%2520acid%2520and%2520alkaline%2520ceramidases%2520in%2520fibroblasts%2520from%2520patients%2520with%2520Farber%2520disease%2520and%2520controls%26jtitle%3DBiochem.%2520J.%26date%3D1982%26volume%3D205%26spage%3D419%26epage%3D425%26doi%3D10.1042%2Fbj2050419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Palermo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campomanes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlisberger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Wagging the tail: essential role of substrate flexibility in FAAH catalysis</span> <span class="citation_source-journal">J. Chem. Theory Comput.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1202</span><span class="NLM_x">â</span> <span class="NLM_lpage">1213</span><span class="refDoi">Â DOI: 10.1021/ct300611q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct300611q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVCgtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=1202-1213&author=G.+Palermoauthor=P.+Campomanesauthor=M.+Neriauthor=D.+Piomelliauthor=A.+Cavalliauthor=U.+Rothlisbergerauthor=M.+De+Vivo&title=Wagging+the+tail%3A+essential+role+of+substrate+flexibility+in+FAAH+catalysis&doi=10.1021%2Fct300611q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Wagging the Tail: Essential Role of Substrate Flexibility in FAAH Catalysis</span></div><div class="casAuthors">Palermo, Giulia; Campomanes, Pablo; Neri, Marilisa; Piomelli, Daniele; Cavalli, Andrea; Rothlisberger, Ursula; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1202-1213</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The serine hydrolase, fatty acid amide hydrolase (FAAH), is responsible for the intracellular degrdn. of anandamide and other bioactive fatty acid ethanolamides involved in the regulation of pain, inflammation, and other pathophysiol. processes.  The catalytic site of FAAH is composed of multiple cavities with mixed hydrophobic and hydrophilic properties, the role of which remains incompletely understood.  Anandamide is thought to enter the active site through a "membrane-access" (MA) channel and position its flexible fatty acyl chain in a highly hydrophobic "acyl chain-binding" (AB) cavity to allow for hydrolysis to occur.  Using microsecond mol. dynamics (MD) simulations of FAAH embedded in a realistic membrane/water environment, we show now that anandamide may not lock itself into the AB cavity but may rather assume catalytically significant conformations required for hydrolysis by moving its flexible arachidonoyl tail between the MA and AB cavities.  This process is regulated by a phenylalanine residue (Phe432) located at the boundary between the two cavities, which may act as a "dynamic paddle." The results identify structural flexibility as a key determinant by which FAAH recognizes its primary lipid substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcJrmcv6YEzLVg90H21EOLACvtfcHk0li8R9zabbOvsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVCgtg%253D%253D&md5=c9d8bec4b97b8318ae09383400624f66</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fct300611q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct300611q%26sid%3Dliteratum%253Aachs%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DCampomanes%26aufirst%3DP.%26aulast%3DNeri%26aufirst%3DM.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRothlisberger%26aufirst%3DU.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DWagging%2520the%2520tail%253A%2520essential%2520role%2520of%2520substrate%2520flexibility%2520in%2520FAAH%2520catalysis%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2013%26volume%3D9%26spage%3D1202%26epage%3D1213%26doi%3D10.1021%2Fct300611q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Riccardi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arencibia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armirotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Lid domain plasticity and lipid flexibility modulate enzyme specificity in human monoacylglycerol lipase</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">1862</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">451</span><span class="refDoi">Â DOI: 10.1016/j.bbalip.2017.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.bbalip.2017.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=28088576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1Kqsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2017&pages=441-451&author=L.+Riccardiauthor=J.+M.+Arencibiaauthor=L.+Bonoauthor=A.+Armirottiauthor=S.+Girottoauthor=M.+De+Vivo&title=Lid+domain+plasticity+and+lipid+flexibility+modulate+enzyme+specificity+in+human+monoacylglycerol+lipase&doi=10.1016%2Fj.bbalip.2017.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Lid domain plasticity and lipid flexibility modulate enzyme specificity in human monoacylglycerol lipase</span></div><div class="casAuthors">Riccardi, Laura; Arencibia, Jose M.; Bono, Luca; Armirotti, Andrea; Girotto, Stefania; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-451</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Human monoacylglycerol lipase (MAGL) is a membrane-interacting enzyme that generates pro-inflammatory signaling mols.  For this reason, MAGL inhibition is a promising strategy to treat pain, cancer, and neuroinflammatory diseases.  MAGL can hydrolyze monoacylglycerols bearing an acyl chain of different lengths and degrees of unsatn., cleaving primarily the endocannabinoid 2-arachidonoylglycerol.  Importantly, the enzymic binding site of MAGL is confined by a 75-amino-acid-long, flexible cap domain, named 'lid domain', which is structurally similar to that found in several other lipases.  However, it is unclear how lid domain plasticity affects catalysis in MAGL.  By integrating extensive mol. dynamics simulations and free-energy calcns. with mutagenesis and kinetic expts., we here define a lid-domain-mediated mechanism for substrate selection and binding in MAGL catalysis.  In particular, we clarify the key role of Phe159 and Ile179, two conserved residues within the lid domain, in regulating substrate specificity in MAGL.  We conclude by proposing that other structurally related lipases may share this lid-domain-mediated mechanism for substrate specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcSfOcMvzTNLVg90H21EOLACvtfcHk0li8R9zabbOvsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1Kqsro%253D&md5=0c3c69bcd19d783e7da65da6988d86dd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2017.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2017.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DRiccardi%26aufirst%3DL.%26aulast%3DArencibia%26aufirst%3DJ.%2BM.%26aulast%3DBono%26aufirst%3DL.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DLid%2520domain%2520plasticity%2520and%2520lipid%2520flexibility%2520modulate%2520enzyme%2520specificity%2520in%2520human%2520monoacylglycerol%2520lipase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2017%26volume%3D1862%26spage%3D441%26epage%3D451%26doi%3D10.1016%2Fj.bbalip.2017.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Palermo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branduardi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodoa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Covalent inhibitors of fatty acid amide hydrolase: A rationale for the activity of piperidine and piperazine aryl ureas</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6612</span><span class="NLM_x">â</span> <span class="NLM_lpage">6623</span><span class="refDoi">Â DOI: 10.1021/jm2004283</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2004283" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCgsb3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6612-6623&author=G.+Palermoauthor=D.+Branduardiauthor=M.+Masettiauthor=A.+Lodoaauthor=M.+Morauthor=D.+Piomelliauthor=A.+Cavalliauthor=M.+De+Vivo&title=Covalent+inhibitors+of+fatty+acid+amide+hydrolase%3A+A+rationale+for+the+activity+of+piperidine+and+piperazine+aryl+ureas&doi=10.1021%2Fjm2004283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Inhibitors of Fatty Acid Amide Hydrolase: A Rationale for the Activity of Piperidine and Piperazine Aryl Ureas</span></div><div class="casAuthors">Palermo, Giulia; Branduardi, Davide; Masetti, Matteo; Lodola, Alessio; Mor, Marco; Piomelli, Daniele; Cavalli, Andrea; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6612-6623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, covalent drugs have attracted great interest in the drug discovery community, with successful examples that have demonstrated their therapeutic effects.  Here, we focus on the covalent inhibition of the fatty acid amide hydrolase (FAAH), which is a promising strategy in the treatment of pain and inflammation.  Among the most recent and potent FAAH inhibitors (FAAHi), there are the cyclic piperidine and piperazine aryl ureas.  FAAH hydrolyzes efficiently the amide bond of these compds., forming a covalent enzyme-inhibitor adduct.  To rationalize this exptl. evidence, we performed an extensive computational anal. centered on piperidine-based PF750 (1) and piperazine-based JNJ1661010 (2), two potent lead compds. used to generate covalent inhibitors as clin. candidates.  We found that FAAH induces a distortion of the amide bond of the piperidine and piperazine aryl ureas.  Quantum mechanics/mol. mechanics ÎELUMO-HOMO energies indicate that the obsd. enzyme-induced distortion of the amide bond favors the formation of a covalent FAAH-inhibitor adduct.  These findings could help in the rational structure-based design of novel covalent FAAHi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXM0Vnrifb87Vg90H21EOLACvtfcHk0li8R9zabbOvsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCgsb3O&md5=3130e9ef929a52cc0900ad77b38a7453</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm2004283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2004283%26sid%3Dliteratum%253Aachs%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DBranduardi%26aufirst%3DD.%26aulast%3DMasetti%26aufirst%3DM.%26aulast%3DLodoa%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DCovalent%2520inhibitors%2520of%2520fatty%2520acid%2520amide%2520hydrolase%253A%2520A%2520rationale%2520for%2520the%2520activity%2520of%2520piperidine%2520and%2520piperazine%2520aryl%2520ureas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6612%26epage%3D6623%26doi%3D10.1021%2Fjm2004283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branduardi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capoferri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span> </span><span class="NLM_article-title">A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e32397</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0032397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1371%2Fjournal.pone.0032397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=22389698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ehsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e32397&author=A.+Lodolaauthor=D.+Branduardiauthor=M.+De+Vivoauthor=L.+Capoferriauthor=M.+Morauthor=D.+Piomelliauthor=A.+Cavalli&title=A+catalytic+mechanism+for+cysteine+N-terminal+nucleophile+hydrolases%2C+as+revealed+by+free+energy+simulations&doi=10.1371%2Fjournal.pone.0032397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations</span></div><div class="casAuthors">Lodola, Alessio; Branduardi, Davide; De Vivo, Marco; Capoferri, Luigi; Mor, Marco; Piomelli, Daniele; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e32397</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The N-terminal nucleophile (Ntn) hydrolases are a superfamily of enzymes specialized in the hydrolytic cleavage of amide bonds.  Even though several members of this family are emerging as innovative drug targets for cancer, inflammation, and pain, the processes through which they catalyze amide hydrolysis remains poorly understood.  In particular, the catalytic reactions of cysteine Ntn-hydrolases have never been investigated from a mechanistic point of view.  In the present study, we used free energy simulations in the quantum mechanics/mol. mechanics framework to det. the reaction mechanism of amide hydrolysis catalyzed by the prototypical cysteine Ntn-hydrolase, conjugated bile acid hydrolase (CBAH).  The computational analyses, which were confirmed in water and using different CBAH mutants, revealed the existence of a chair-like transition state, which might be one of the specific features of the catalytic cycle of Ntn-hydrolases.  Our results offer new insights on Ntn-mediated hydrolysis and suggest possible strategies for the creation of therapeutically useful inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9fegIlwKNS7Vg90H21EOLACvtfcHk0lgV87vsXH-x8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ehsbg%253D&md5=a74ef4b0ae6afbf23907bf3ee4f0da6e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0032397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0032397%26sid%3Dliteratum%253Aachs%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DBranduardi%26aufirst%3DD.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DCapoferri%26aufirst%3DL.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DA%2520catalytic%2520mechanism%2520for%2520cysteine%2520N-terminal%2520nucleophile%2520hydrolases%252C%2520as%2520revealed%2520by%2520free%2520energy%2520simulations%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De32397%26doi%3D10.1371%2Fjournal.pone.0032397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Palermo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlisberger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Computational insights into function and inhibition of fatty acid amide hydrolase</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">â</span> <span class="NLM_lpage">26</span><span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.09.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.ejmech.2014.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=25240419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOls7jJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2015&pages=15-26&author=G.+Palermoauthor=U.+Rothlisbergerauthor=A.+Cavalliauthor=M.+De+Vivo&title=Computational+insights+into+function+and+inhibition+of+fatty+acid+amide+hydrolase&doi=10.1016%2Fj.ejmech.2014.09.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Computational insights into function and inhibition of fatty acid amide hydrolase</span></div><div class="casAuthors">Palermo, Giulia; Rothlisberger, Ursula; Cavalli, Andrea; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-26</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The Fatty Acid Amide Hydrolase (FAAH) enzyme is a membrane-bound serine hydrolase responsible for the deactivating hydrolysis of a family of naturally occurring fatty acid amides.  FAAH is a crit. enzyme of the endocannabinoid system, being mainly responsible for regulating the level of its main cannabinoid substrate anandamide.  For this reason, pharmacol. inhibition of FAAH, which increases the level of endogenous anandamide, is a promising strategy to cure a variety of diseases including pain, inflammation, and cancer.Much structural, mutagenesis, and kinetic data on FAAH has been generated over the last couple of decades.  This has prompted several informative computational investigations to elucidate, at the at.-level, mechanistic details on catalysis and inhibition of this pharmaceutically relevant enzyme.  Here, we review how these computational studies - based on classical mol. dynamics, full quantum mechanics, and hybrid QM/MM methods - have clarified the binding and reactivity of some relevant substrates and inhibitors of FAAH.  We also discuss the exptl. implications of these computational insights, which have provided a thoughtful elucidation of the complex phys. and chem. steps of the enzymic mechanism of FAAH.  Finally, we discuss how computations have been helpful for building structure-activity relationships of potent FAAH inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-xquSauxYo7Vg90H21EOLACvtfcHk0lgV87vsXH-x8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOls7jJ&md5=5dd76bb3eda21ebdfe66e956a46f7858</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DRothlisberger%26aufirst%3DU.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DComputational%2520insights%2520into%2520function%2520and%2520inhibition%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D91%26spage%3D15%26epage%3D26%26doi%3D10.1016%2Fj.ejmech.2014.09.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Pavlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carloni, P.</span><span> </span><span class="NLM_article-title">Carnosine and homocarnosine degradation mechanisms by the human carnosinase enzyme CN1: Insights from multiscale simulations</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2772</span><span class="NLM_x">â</span> <span class="NLM_lpage">2784</span><span class="refDoi">Â DOI: 10.1021/acs.biochem.5b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=2772-2784&author=M.+Pavlinauthor=G.+Rossettiauthor=M.+De+Vivoauthor=P.+Carloni&title=Carnosine+and+homocarnosine+degradation+mechanisms+by+the+human+carnosinase+enzyme+CN1%3A+Insights+from+multiscale+simulations&doi=10.1021%2Facs.biochem.5b01263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b01263%26sid%3Dliteratum%253Aachs%26aulast%3DPavlin%26aufirst%3DM.%26aulast%3DRossetti%26aufirst%3DG.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DCarloni%26aufirst%3DP.%26atitle%3DCarnosine%2520and%2520homocarnosine%2520degradation%2520mechanisms%2520by%2520the%2520human%2520carnosinase%2520enzyme%2520CN1%253A%2520Insights%2520from%2520multiscale%2520simulations%26jtitle%3DBiochemistry%26date%3D2016%26volume%3D55%26spage%3D2772%26epage%3D2784%26doi%3D10.1021%2Facs.biochem.5b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Palermo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campomanes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlisberger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Anandamide hydrolysis in FAAH reveals a dual strategy for efficient enzyme-assisted amide bond cleavage via nitrogen inversion</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">â</span> <span class="NLM_lpage">801</span><span class="refDoi">Â DOI: 10.1021/jp5052276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp5052276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFWjsr7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2015&pages=789-801&author=G.+Palermoauthor=P.+Campomanesauthor=A.+Cavalliauthor=U.+Rothlisbergerauthor=M.+De+Vivo&title=Anandamide+hydrolysis+in+FAAH+reveals+a+dual+strategy+for+efficient+enzyme-assisted+amide+bond+cleavage+via+nitrogen+inversion&doi=10.1021%2Fjp5052276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Anandamide Hydrolysis in FAAH Reveals a Dual Strategy for Efficient Enzyme-Assisted Amide Bond Cleavage via Nitrogen Inversion</span></div><div class="casAuthors">Palermo, Giulia; Campomanes, Pablo; Cavalli, Andrea; Rothlisberger, Ursula; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">789-801</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-5207</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we combined classical mol. dynamics (MD) and quantum mech./mol. mechanics (QM/MM) simulations to unravel the whole catalytic cycle of fatty acid amide hydrolase (FAAH) in complex with anandamide, the main neurotransmitters involved in the control of pain.  While microsecond MD simulations of FAAH in a realistic membrane/water environment provided a solid model for the reactant state of the enzymic complex, QM/MM simulations depict now a highly concerted two-step catalytic mechanism characterized by (1) acyl-enzyme formation after hydrolysis of the substrate amide bond and (2) deacylation reaction with restoration of the catalytic machinery.  We found that a crucial event for anandamide hydrolysis is the inversion of the reactive nitrogen of the scissile amide bond, which occurs during the acylation rate-limiting step.  We show that FAAH uses an exquisite catalytic strategy to induce amide bond distortion, reactive nitrogen inversion, and amide bond hydrolysis, promoting catalysis to completion.  This new strategy is likely to be of general applicability to other amidases/peptidases that show similar catalytic site architectures, providing crucial insights for de novo enzyme design or drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUuuanDLcJLVg90H21EOLACvtfcHk0lgV87vsXH-x8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFWjsr7N&md5=b6c738e9eb18172771070f5d7e8974b4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjp5052276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp5052276%26sid%3Dliteratum%253Aachs%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DCampomanes%26aufirst%3DP.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRothlisberger%26aufirst%3DU.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DAnandamide%2520hydrolysis%2520in%2520FAAH%2520reveals%2520a%2520dual%2520strategy%2520for%2520efficient%2520enzyme-assisted%2520amide%2520bond%2520cleavage%2520via%2520nitrogen%2520inversion%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2015%26volume%3D119%26spage%3D789%26epage%3D801%26doi%3D10.1021%2Fjp5052276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Palermo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campomanes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armirotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlisberger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Keys to lipid selection in fatty acid amide hydrolase catalysis: Structural flexibility, gating residues and multiple binding pockets</span> <span class="citation_source-journal">PLoS Comput. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1004231</span><span class="refDoi">Â DOI: 10.1371/journal.pcbi.1004231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1371%2Fjournal.pcbi.1004231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=26111155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsV2htLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1004231&author=G.+Palermoauthor=I.+Bauerauthor=P.+Campomanesauthor=A.+Cavalliauthor=A.+Armirottiauthor=S.+Girottoauthor=U.+Rothlisbergerauthor=M.+De+Vivo&title=Keys+to+lipid+selection+in+fatty+acid+amide+hydrolase+catalysis%3A+Structural+flexibility%2C+gating+residues+and+multiple+binding+pockets&doi=10.1371%2Fjournal.pcbi.1004231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Keys to lipid selection in fatty acid amide hydrolase catalysis: structural flexibility, gating residues and multiple binding pockets</span></div><div class="casAuthors">Palermo, Giulia; Bauer, Inga; Campomanes, Pablo; Cavalli, Andrea; Armirotti, Andrea; Girotto, Stefania; Rothlisberger, Ursula; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1004231/1-e1004231/25</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The fatty acid amide hydrolase (FAAH) regulates the endocannabinoid system, cleaving primarily the lipid messenger anandamide.  FAAH has been well characterized over the years, and importantly, it represents a promising drug target to treat several diseases, including inflammatory-related diseases and cancer.  But its enzymic mechanism for lipid selection to specifically hydrolyze anandamide, rather than similar bioactive lipids, remains elusive.  Here, we clarify this mechanism in FAAH, examg. the role of the dynamic paddle, which is formed by the gating residues Phe432 and Trp531 at the boundary between two cavities that form the FAAH catalytic site (the "membrane-access" and the "acyl chain-binding" pockets).  We integrate microsecond-long MD simulations of wild type and double mutant model systems (Phe432Ala and Trp531Ala) of FAAH, embedded in a realistic membrane/water environment, with mutagenesis and kinetic expts.  We comparatively analyze three fatty acid substrates with different hydrolysis rates (anandamide > oleamide > palmitoylethanolamide).  Our findings identify FAAH's mechanism to selectively accommodate anandamide into a multi-pocket binding site, and to properly orient the substrate in pre-reactive conformations for efficient hydrolysis that is interceded by the dynamic paddle.  Our findings therefore endorse a structural framework for a lipid selection mechanism mediated by structural flexibility and gating residues between multiple binding cavities, as found in FAAH.  Based on the available structural data, this exquisite catalytic strategy for substrate specificity seems to be shared by other lipid-degrading enzymes with similar enzymic architecture.  The mechanistic insights for lipid selection might assist de novo enzyme design or drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjpXtbYx6P0LVg90H21EOLACvtfcHk0lhEf5K2oAVtiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsV2htLY%253D&md5=33224e5dcd45d20a14b6e3f60f7ca8e6</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1004231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1004231%26sid%3Dliteratum%253Aachs%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DCampomanes%26aufirst%3DP.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DRothlisberger%26aufirst%3DU.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DKeys%2520to%2520lipid%2520selection%2520in%2520fatty%2520acid%2520amide%2520hydrolase%2520catalysis%253A%2520Structural%2520flexibility%252C%2520gating%2520residues%2520and%2520multiple%2520binding%2520pockets%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3De1004231%26doi%3D10.1371%2Fjournal.pcbi.1004231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Favia, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habrant, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertozzi, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionisi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarozzo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8807</span><span class="NLM_x">â</span> <span class="NLM_lpage">8826</span><span class="refDoi">Â DOI: 10.1021/jm3011146</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3011146" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOiu7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8807-8826&author=A.+D.+Faviaauthor=D.+Habrantauthor=R.+Scarpelliauthor=M.+Miglioreauthor=C.+Albaniauthor=S.+M.+Bertozziauthor=M.+Dionisiauthor=G.+Tarozzoauthor=D.+Piomelliauthor=A.+Cavalliauthor=M.+De+Vivo&title=Identification+and+characterization+of+carprofen+as+a+multitarget+fatty+acid+amide+hydrolase%2Fcyclooxygenase+inhibitor&doi=10.1021%2Fjm3011146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of Carprofen as a Multitarget Fatty Acid Amide Hydrolase/Cyclooxygenase Inhibitor</span></div><div class="casAuthors">Favia, Angelo D.; Habrant, Damien; Scarpelli, Rita; Migliore, Marco; Albani, Clara; Bertozzi, Sine Mandrup; Dionisi, Mauro; Tarozzo, Glauco; Piomelli, Daniele; Cavalli, Andrea; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8807-8826</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pain and inflammation are major therapeutic areas for drug discovery.  Current drugs for these pathologies have limited efficacy, however, and often cause a no. of unwanted side effects.  In the present study, we identify the nonsteroidal anti-inflammatory drug carprofen as a multitarget-directed ligand that simultaneously inhibits cyclooxygenase-1 (COX-1), COX-2, and fatty acid amide hydrolase (FAAH).  Addnl., we synthesized and tested several derivs. of carprofen, sharing this multitarget activity.  This may result in improved analgesic efficacy and reduced side effects (Naidu et al. J. Pharmacol. Exp. Ther.2009, 329, 48-56; Fowler, C. J.; et al. J. Enzyme Inhib. Med. Chem.2012, in press; Sasso et al. Pharmacol. Res.2012, 65, 553).  The new compds., e.g., I, are among the most potent multitarget FAAH/COX inhibitors reported so far in the literature and thus may represent promising starting points for the discovery of new analgesic and anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoPehzqVv8BLVg90H21EOLACvtfcHk0lhEf5K2oAVtiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOiu7%252FO&md5=8fe3710c1b067f671f8cee331959b7a0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm3011146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3011146%26sid%3Dliteratum%253Aachs%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DHabrant%26aufirst%3DD.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DMigliore%26aufirst%3DM.%26aulast%3DAlbani%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DS.%2BM.%26aulast%3DDionisi%26aufirst%3DM.%26aulast%3DTarozzo%26aufirst%3DG.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520carprofen%2520as%2520a%2520multitarget%2520fatty%2520acid%2520amide%2520hydrolase%252Fcyclooxygenase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8807%26epage%3D8826%26doi%3D10.1021%2Fjm3011146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Realini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palese, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzirani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pontis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Acid ceramidase in melanoma: Expression, localization, and effects of pharmacological inhibtion</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">291</span><span class="NLM_x">, </span> <span class="NLM_fpage">2422</span><span class="NLM_x">â</span> <span class="NLM_lpage">34</span><span class="refDoi">Â DOI: 10.1074/jbc.M115.666909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1074%2Fjbc.M115.666909" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=2422-34&author=N.+Realiniauthor=F.+Paleseauthor=D.+Pizziraniauthor=S.+Pontisauthor=A.+Basitauthor=A.+Bachauthor=A.+Ganesanauthor=D.+Piomelli&title=Acid+ceramidase+in+melanoma%3A+Expression%2C+localization%2C+and+effects+of+pharmacological+inhibtion&doi=10.1074%2Fjbc.M115.666909"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.666909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.666909%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DPalese%26aufirst%3DF.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DPontis%26aufirst%3DS.%26aulast%3DBasit%26aufirst%3DA.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DAcid%2520ceramidase%2520in%2520melanoma%253A%2520Expression%252C%2520localization%252C%2520and%2520effects%2520of%2520pharmacological%2520inhibtion%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D2422%26epage%3D34%26doi%3D10.1074%2Fjbc.M115.666909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Bedia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camacho, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abad, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabrias, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levade, T.</span><span> </span><span class="NLM_article-title">A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease</span> <span class="citation_source-journal">J. Lipid Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3542</span><span class="NLM_x">â</span> <span class="NLM_lpage">3547</span><span class="refDoi">Â DOI: 10.1194/jlr.D010033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1194%2Fjlr.D010033" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=3542-3547&author=C.+Bediaauthor=L.+Camachoauthor=J.+L.+Abadauthor=G.+Fabriasauthor=T.+Levade&title=A+simple+fluorogenic+method+for+determination+of+acid+ceramidase+activity+and+diagnosis+of+Farber+disease&doi=10.1194%2Fjlr.D010033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1194%2Fjlr.D010033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.D010033%26sid%3Dliteratum%253Aachs%26aulast%3DBedia%26aufirst%3DC.%26aulast%3DCamacho%26aufirst%3DL.%26aulast%3DAbad%26aufirst%3DJ.%2BL.%26aulast%3DFabrias%26aufirst%3DG.%26aulast%3DLevade%26aufirst%3DT.%26atitle%3DA%2520simple%2520fluorogenic%2520method%2520for%2520determination%2520of%2520acid%2520ceramidase%2520activity%2520and%2520diagnosis%2520of%2520Farber%2520disease%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2010%26volume%3D51%26spage%3D3542%26epage%3D3547%26doi%3D10.1194%2Fjlr.D010033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Bedia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levade, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabrias, G.</span><span> </span><span class="NLM_article-title">Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">â</span> <span class="NLM_lpage">648</span><span class="refDoi">Â DOI: 10.1002/cbic.200600533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1002%2Fcbic.200600533" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=642-648&author=C.+Bediaauthor=J.+Casasauthor=V.+Garciaauthor=T.+Levadeauthor=G.+Fabrias&title=Synthesis+of+a+novel+ceramide+analogue+and+its+use+in+a+high-throughput+fluorogenic+assay+for+ceramidases&doi=10.1002%2Fcbic.200600533"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200600533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200600533%26sid%3Dliteratum%253Aachs%26aulast%3DBedia%26aufirst%3DC.%26aulast%3DCasas%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DV.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DFabrias%26aufirst%3DG.%26atitle%3DSynthesis%2520of%2520a%2520novel%2520ceramide%2520analogue%2520and%2520its%2520use%2520in%2520a%2520high-throughput%2520fluorogenic%2520assay%2520for%2520ceramidases%26jtitle%3DChemBioChem%26date%3D2007%26volume%3D8%26spage%3D642%26epage%3D648%26doi%3D10.1002%2Fcbic.200600533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Samantha Caputo, Simona Di Martino, Vincenzo Cilibrasi, Piero Tardia, Marco Mazzonna, Debora Russo, Ilaria Penna, Maria Summa, Sine Mandrup Bertozzi, Natalia Realini, Natasha Margaroli, Marco Migliore, Giuliana Ottonello, Min Liu, Peter Lansbury, Andrea Armirotti, Rosalia Bertorelli, Soumya S. Ray, Renato Skerlj, <span class="NLM_string-name hlFld-ContribAuthor">Rita Scarpelli</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15821-15851. <a href="https://doi.org/10.1021/acs.jmedchem.0c01561" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01561%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252Ba%252BSeries%252Bof%252BOxazolone%252BCarboxamides%252Bas%252Ba%252BNovel%252BClass%252Bof%252BAcid%252BCeramidase%252BInhibitors%26aulast%3DCaputo%26aufirst%3DSamantha%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07092020%26date%3D08122020%26volume%3D63%26issue%3D24%26spage%3D15821%26epage%3D15851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mookda Pattarawarapan, Dolnapa Yamano, Nittaya Wiriya, Saranphong Yimklan, <span class="NLM_string-name hlFld-ContribAuthor">Wong Phakhodee</span>. </span><span class="cited-content_cbyCitation_article-title">Simultaneous Formation and Functionalization of Aryliminophosphoranes Using 1,3-Dihydro-1H-benzimidazol-2-ones as Precursors. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (20)
                                     , 13330-13338. <a href="https://doi.org/10.1021/acs.joc.0c01979" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01979</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01979%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSimultaneous%252BFormation%252Band%252BFunctionalization%252Bof%252BAryliminophosphoranes%252BUsing%252B1%25252C3-Dihydro-1H-benzimidazol-2-ones%252Bas%252BPrecursors%26aulast%3DPattarawarapan%26aufirst%3DMookda%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17082020%26date%3D02102020%26volume%3D85%26issue%3D20%26spage%3D13330%26epage%3D13338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Simona Di Martino, Piero Tardia, Vincenzo Cilibrasi, Samantha Caputo, Marco Mazzonna, Debora Russo, Ilaria Penna, Natalia Realini, Natasha Margaroli, Marco Migliore, Daniela Pizzirani, Giuliana Ottonello, Sine Mandrup Bertozzi, Andrea Armirotti, Duc Nguyen, Ying Sun, Ernesto R. Bongarzone, Peter Lansbury, Min Liu, Renato Skerlj, <span class="NLM_string-name hlFld-ContribAuthor">Rita Scarpelli</span>. </span><span class="cited-content_cbyCitation_article-title">Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (7)
                                     , 3634-3664. <a href="https://doi.org/10.1021/acs.jmedchem.9b02004" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02004%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLead%252BOptimization%252Bof%252BBenzoxazolone%252BCarboxamides%252Bas%252BOrally%252BBioavailable%252Band%252BCNS%252BPenetrant%252BAcid%252BCeramidase%252BInhibitors%26aulast%3DDi%2BMartino%26aufirst%3DSimona%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D18122019%26date%3D26032020%26date%3D16032020%26volume%3D63%26issue%3D7%26spage%3D3634%26epage%3D3664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia Ð.  Syrota</span>, <span class="hlFld-ContribAuthor ">Sergiy V.  Kemskiy</span>, <span class="hlFld-ContribAuthor ">Andriy V.  Bolâbut</span>, <span class="hlFld-ContribAuthor ">Igor I.  Chernobaev</span>, <span class="hlFld-ContribAuthor ">Mikhailo V.  Vovk</span>. </span><span class="cited-content_cbyCitation_article-title">An efficient method for accessing carboannulated and functionalized [1,2,3]triazolo[4,5-b]pyridines. </span><span class="cited-content_cbyCitation_journal-name">Chemistry of Heterocyclic Compounds</span><span> <strong>2020,</strong> <em>56 </em>
                                    (8)
                                     , 1048-1053. <a href="https://doi.org/10.1007/s10593-020-02771-9" title="DOI URL">https://doi.org/10.1007/s10593-020-02771-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10593-020-02771-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10593-020-02771-9%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520of%2520Heterocyclic%2520Compounds%26atitle%3DAn%252Befficient%252Bmethod%252Bfor%252Baccessing%252Bcarboannulated%252Band%252Bfunctionalized%252B%25255B1%25252C2%25252C3%25255Dtriazolo%25255B4%25252C5-b%25255Dpyridines%26aulast%3DSyrota%26aufirst%3DNatalia%2B%25D0%2590.%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D8%26spage%3D1048%26epage%3D1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Btissam  Bouchal</span>, <span class="hlFld-ContribAuthor ">Mounia Elidrissi  Errahhali</span>, <span class="hlFld-ContribAuthor ">Manal Elidrissi  Errahhali</span>, <span class="hlFld-ContribAuthor ">Redouane  Boulouiz</span>, <span class="hlFld-ContribAuthor ">Meryem  Ouarzane</span>, <span class="hlFld-ContribAuthor ">Mariam  Tajir</span>, <span class="hlFld-ContribAuthor ">Katsuyoshi  Matsunami</span>, <span class="hlFld-ContribAuthor ">Mohammed  Bellaoui</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the Antimicrobial Properties Against Human Pathogens and Mode of Action of Various Extracts from Fredolia aretioides, an Endemic Medicinal Plant of Morocco and Algeria. </span><span class="cited-content_cbyCitation_journal-name">The Natural Products Journal</span><span> <strong>2019,</strong> <em>9 </em>
                                    (4)
                                     , 321-329. <a href="https://doi.org/10.2174/2210315509666190117144936" title="DOI URL">https://doi.org/10.2174/2210315509666190117144936</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/2210315509666190117144936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F2210315509666190117144936%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Natural%2520Products%2520Journal%26atitle%3DExploring%252Bthe%252BAntimicrobial%252BProperties%252BAgainst%252BHuman%252BPathogens%252Band%252BMode%252Bof%252BAction%252Bof%252BVarious%252BExtracts%252Bfrom%252BFredolia%252Baretioides%25252C%252Ban%252BEndemic%252BMedicinal%252BPlant%252Bof%252BMorocco%252Band%252BAlgeria%26aulast%3DBouchal%26aufirst%3DBtissam%26date%3D2019%26volume%3D9%26issue%3D4%26spage%3D321%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michele  Lai</span>, <span class="hlFld-ContribAuthor ">Veronica  La Rocca</span>, <span class="hlFld-ContribAuthor ">Rachele  Amato</span>, <span class="hlFld-ContribAuthor ">Giulia  Freer</span>, <span class="hlFld-ContribAuthor ">Mauro  Pistello</span>. </span><span class="cited-content_cbyCitation_article-title">Sphingolipid/Ceramide Pathways and Autophagy in the Onset and Progression of Melanoma: Novel Therapeutic Targets and Opportunities. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (14)
                                     , 3436. <a href="https://doi.org/10.3390/ijms20143436" title="DOI URL">https://doi.org/10.3390/ijms20143436</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20143436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20143436%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DSphingolipid%25252FCeramide%252BPathways%252Band%252BAutophagy%252Bin%252Bthe%252BOnset%252Band%252BProgression%252Bof%252BMelanoma%25253A%252BNovel%252BTherapeutic%252BTargets%252Band%252BOpportunities%26aulast%3DLai%26aufirst%3DMichele%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D14%26spage%3D3436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew J.  Annalora</span>, <span class="hlFld-ContribAuthor ">Shawn  OâNeil</span>, <span class="hlFld-ContribAuthor ">Jeremy D.  Bushman</span>, <span class="hlFld-ContribAuthor ">James E.  Summerton</span>, <span class="hlFld-ContribAuthor ">Craig B.  Marcus</span>, <span class="hlFld-ContribAuthor ">Patrick L.  Iversen</span>. </span><span class="cited-content_cbyCitation_article-title">A k-mer based transcriptomics approach for antisense drug discovery targeting the Ewingâs family of tumors. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (55)
                                     , 30568-30586. <a href="https://doi.org/10.18632/oncotarget.25736" title="DOI URL">https://doi.org/10.18632/oncotarget.25736</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.25736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.25736%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DA%252Bk-mer%252Bbased%252Btranscriptomics%252Bapproach%252Bfor%252Bantisense%252Bdrug%252Bdiscovery%252Btargeting%252Bthe%252BEwing%2525E2%252580%252599s%252Bfamily%252Bof%252Btumors%26aulast%3DAnnalora%26aufirst%3DAndrew%2BJ.%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D55%26spage%3D30568%26epage%3D30586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ha  Nguyen</span>, <span class="hlFld-ContribAuthor ">Ahmed  Awad</span>, <span class="hlFld-ContribAuthor ">Saman  Shabani</span>, <span class="hlFld-ContribAuthor ">Ninh  Doan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Targeting of Acid Ceramidase in Glioblastoma: A Review of Its Role, Potential Treatment, and Challenges. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2018,</strong> <em>10 </em>
                                    (2)
                                     , 45. <a href="https://doi.org/10.3390/pharmaceutics10020045" title="DOI URL">https://doi.org/10.3390/pharmaceutics10020045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics10020045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics10020045%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DMolecular%252BTargeting%252Bof%252BAcid%252BCeramidase%252Bin%252BGlioblastoma%25253A%252BA%252BReview%252Bof%252BIts%252BRole%25252C%252BPotential%252BTreatment%25252C%252Band%252BChallenges%26aulast%3DNguyen%26aufirst%3DHa%26date%3D2018%26date%3D2018%26volume%3D10%26issue%3D2%26spage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oleksandr  Grytsai</span>, <span class="hlFld-ContribAuthor ">Tetiana  Druzhenko</span>, <span class="hlFld-ContribAuthor ">Luc  Demange</span>, <span class="hlFld-ContribAuthor ">Cyril  Ronco</span>, <span class="hlFld-ContribAuthor ">Rachid  Benhida</span>. </span><span class="cited-content_cbyCitation_article-title">Cyanoguanidine as a versatile, eco-friendly and inexpensive reagent for the synthesis of 2-aminobenzoxazoles and 2-guanidinobenzoxazoles. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (17)
                                     , 1642-1645. <a href="https://doi.org/10.1016/j.tetlet.2018.03.036" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.03.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.03.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.03.036%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DCyanoguanidine%252Bas%252Ba%252Bversatile%25252C%252Beco-friendly%252Band%252Binexpensive%252Breagent%252Bfor%252Bthe%252Bsynthesis%252Bof%252B2-aminobenzoxazoles%252Band%252B2-guanidinobenzoxazoles%26aulast%3DGrytsai%26aufirst%3DOleksandr%26date%3D2018%26volume%3D59%26issue%3D17%26spage%3D1642%26epage%3D1645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Ceramide and known acid ceramidase (AC) inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed pharmacophore for AC covalent inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Pathway for Urea Synthesis<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) DMAP (0.1 equiv), pyridine, N<sub>2</sub>, room temperature, 5 h.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 2-Methoxy-1<i>H</i>-benzimidazole<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) tetramethylortho carbonate (1.4 equiv), Ar, 90 Â°C, 24 h.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 2-Aminobenzimidazole Exocyclic Ureas <b>5</b> and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Boc<sub>2</sub>O (1 equiv), Et<sub>3</sub>N (3 equiv), THF (dry), room temperature, 5 h, yield 95%. (ii) R-NCO (1 equiv), DMAP (0.1 equiv), pyridine, N<sub>2</sub>, 80 Â°C, 3 h. For R = hexyl yield 11%. For R = 4-phenylbutyl yield 12%. (iii) Pyridine, 80 Â°C, 16 h. For R = hexyl yield 70%. For R = 4-phenylbutyl yield 70%.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Adduct formed by covalent modification of catalytic Cys-143 by a reported benzoxazolone AC inhibitor<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> and possible adducts formed upon nucleophilic attack of the catalytic Cys-143 on compounds <b>10</b> and <b>21</b>. (B) Chromatograms of peptide analysis after trypsin digestion of AC incubated with compound <b>10</b> or <b>21</b> (red trace) and DMSO (blue trace). (C) Tandem mass spectrum confirming the CTSIVAEDK peptide sequence and mass increased of covalently modified Cys-143 (+ 175.10 Da), in concordance with adduct A formation (+ C<sub>11</sub>H<sub>13</sub>NO). See also <a href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/medium/jm-2017-00472n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Coordinate scan of the urea torsional angles of compounds <b>8</b>, <b>10</b>, and <b>19</b>â<b>22</b>. The pink sphere represents the global minimum conformation, which is shown as a 2D structure. The <i>exo</i> conformation is preferred for <b>8</b>, <b>10</b>, and <b>22</b> and the <i>endo</i> conformation for <b>19</b>â<b>21</b>. The dark gray spheres in position 1 represent the phenylbutyl moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00472/20170707/images/large/jm-2017-00472n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00472&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66472" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66472" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Maverakis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, F. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzmaurice, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrall, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kloxin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sultani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, F.</span><span> </span><span class="NLM_article-title">Metastatic melanoma - a review of current and future treatment options</span> <span class="citation_source-journal">Acta Derm. Venereol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">â</span> <span class="NLM_lpage">524</span><span class="refDoi">Â DOI: 10.2340/00015555-2035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.2340%2F00015555-2035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=25520039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCqsL%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=516-524&author=E.+Maverakisauthor=L.+A.+Corneliusauthor=G.+M.+Bowenauthor=T.+Phanauthor=F.+B.+Patelauthor=S.+Fitzmauriceauthor=Y.+Heauthor=B.+Burrallauthor=C.+Duongauthor=A.+M.+Kloxinauthor=H.+Sultaniauthor=R.+Wilkenauthor=S.+R.+Martinezauthor=F.+Patel&title=Metastatic+melanoma+-+a+review+of+current+and+future+treatment+options&doi=10.2340%2F00015555-2035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Metastatic melanoma - a review of current and future treatment options</span></div><div class="casAuthors">Maverakis, Emanual; Cornelius, Lynn A.; Bowen, Glen M.; Phan, Tiffany; Patel, Falin B.; Fitzmaurice, Sarah; He, Young; Burrall, Barbara; Duong, Christopher; Kloxin, April M.; Sultani, Hawa; Wilken, Reason; Martinez, Steve R.; Patel, Forum</div><div class="citationInfo"><span class="NLM_cas:title">Acta Dermato-Venereologica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">516-524</span>CODEN:
                <span class="NLM_cas:coden">ADVEA4</span>;
        ISSN:<span class="NLM_cas:issn">1651-2057</span>.
    
            (<span class="NLM_cas:orgname">Acta Dermato-Venereologica</span>)
        </div><div class="casAbstract">Despite advances in treatment and surveillance, melanoma continues to claim approx. 9,000 lives in the US annually (SEER 2013).  The National Comprehensive Cancer Network currently recommends ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma.  Little data exists to guide management of cutaneous and s.c. metastases despite the fact that they are relatively common.  Existing options include intralesional Bacillus Calmette-GuÂ´erin, isolated limb perfusion/infusion, interferon-Î±, topical imiquimod, cryotherapy, radiation therapy, interferon therapy, and intratumoral interleukin-2 injections.  Newly emerging treatments include the anti-programmed cell death 1 receptor agents (nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec).  Available treatments for select sites include adoptive T-cell therapies and dendritic cell vaccines.  In addn. to reviewing the above agents and their mechanisms of action, this review will also focus on combination therapy as these strategies have shown promising results in clin. trials for metastatic melanoma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAa0FXSOBmpbVg90H21EOLACvtfcHk0lh94XbntoCyyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCqsL%252FN&md5=35e168f336e024eabcf0900894e4d268</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2340%2F00015555-2035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2340%252F00015555-2035%26sid%3Dliteratum%253Aachs%26aulast%3DMaverakis%26aufirst%3DE.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DBowen%26aufirst%3DG.%2BM.%26aulast%3DPhan%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DF.%2BB.%26aulast%3DFitzmaurice%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBurrall%26aufirst%3DB.%26aulast%3DDuong%26aufirst%3DC.%26aulast%3DKloxin%26aufirst%3DA.%2BM.%26aulast%3DSultani%26aufirst%3DH.%26aulast%3DWilken%26aufirst%3DR.%26aulast%3DMartinez%26aufirst%3DS.%2BR.%26aulast%3DPatel%26aufirst%3DF.%26atitle%3DMetastatic%2520melanoma%2520-%2520a%2520review%2520of%2520current%2520and%2520future%2520treatment%2520options%26jtitle%3DActa%2520Derm.%2520Venereol.%26date%3D2015%26volume%3D95%26spage%3D516%26epage%3D524%26doi%3D10.2340%2F00015555-2035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Lens, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawes, M.</span><span> </span><span class="NLM_article-title">Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">â</span> <span class="NLM_lpage">185</span><span class="refDoi">Â DOI: 10.1111/j.1365-2133.2004.05708.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1111%2Fj.1365-2133.2004.05708.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=14996086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A280%3ADC%252BD2c7gsFarsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2004&pages=179-185&author=M.+B.+Lensauthor=M.+Dawes&title=Global+perspectives+of+contemporary+epidemiological+trends+of+cutaneous+malignant+melanoma&doi=10.1111%2Fj.1365-2133.2004.05708.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma</span></div><div class="casAuthors">Lens M B; Dawes M</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of dermatology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-85</span>
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    </div><div class="casAbstract">During the past several decades, there has been a substantial increase in the incidence of cutaneous melanoma among all caucasian populations.  The number of deaths due to cutaneous malignant melanoma has also increased in most fair-skinned populations throughout the world in the past few decades.  Trends in melanoma incidence worldwide are examined.  The most recent data on the mortality from cutaneous melanoma are reported.  The role of different environmental, genetic and host factors in the aetiology of melanoma is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQT-_PG-lkWcZZoeNcnHOQ9fW6udTcc2eYf9F5LSPt1-7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7gsFarsg%253D%253D&md5=3fc0be1a3dc58c7e9dfbeddbc573b56d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2004.05708.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2004.05708.x%26sid%3Dliteratum%253Aachs%26aulast%3DLens%26aufirst%3DM.%2BB.%26aulast%3DDawes%26aufirst%3DM.%26atitle%3DGlobal%2520perspectives%2520of%2520contemporary%2520epidemiological%2520trends%2520of%2520cutaneous%2520malignant%2520melanoma%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2004%26volume%3D150%26spage%3D179%26epage%3D185%26doi%3D10.1111%2Fj.1365-2133.2004.05708.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Eigentler, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caroli, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radny, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span> </span><span class="NLM_article-title">Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">748</span><span class="NLM_x">â</span> <span class="NLM_lpage">759</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(03)01280-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2FS1470-2045%2803%2901280-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=14662431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1OgsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=748-759&author=T.+K.+Eigentlerauthor=U.+M.+Caroliauthor=P.+Radnyauthor=C.+Garbe&title=Palliative+therapy+of+disseminated+malignant+melanoma%3A+a+systematic+review+of+41+randomised+clinical+trials&doi=10.1016%2FS1470-2045%2803%2901280-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials</span></div><div class="casAuthors">Eigentler, Thomas K.; Caroli, Ulrich M.; Radny, Peter; Garbe, Claus</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">748-759</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">A review.  We undertook a systematic review of 41 randomized studies in disseminated melanoma, identified by a comprehensive search.  We aimed to investigate rates of response to various treatment modalities and the outcome for the patients.  We analyzed seven studies that compared polychemotherapy with single-agent dacarbazine, six that compared different chemotherapeutic schedules with each other, five on the addn. of tamoxifen to a ref. therapy, and six that included non-specific immunostimulators.  In 17 studies, the addn. of interferon alfa, interleukin 2, or both, to a ref. therapy was investigated, including trials with biochemotherapy.  Many trials had small sample sizes and did not report a power anal.; not all were analyzed by intention to treat.  Although some treatment regimens, esp. polychemotherapeutic schedules, seem to increase response rates, none of the treatment schedules was proven to prolong overall survival.  Patients with disseminated melanoma should be treated with well-tolerated drug regimens, such as single-agent treatments or in combination with interferon alfa.  Systemic treatments should preferably be investigated in randomized trials so that the potential benefits of new treatment concepts can be thoroughly examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ7b4WSQa3LLVg90H21EOLACvtfcHk0ljmi9Exb97TCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1OgsLo%253D&md5=d8c835b5e696b2b47d8ff848c3462018</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2803%2901280-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252803%252901280-4%26sid%3Dliteratum%253Aachs%26aulast%3DEigentler%26aufirst%3DT.%2BK.%26aulast%3DCaroli%26aufirst%3DU.%2BM.%26aulast%3DRadny%26aufirst%3DP.%26aulast%3DGarbe%26aufirst%3DC.%26atitle%3DPalliative%2520therapy%2520of%2520disseminated%2520malignant%2520melanoma%253A%2520a%2520systematic%2520review%2520of%252041%2520randomised%2520clinical%2520trials%26jtitle%3DLancet%2520Oncol.%26date%3D2003%26volume%3D4%26spage%3D748%26epage%3D759%26doi%3D10.1016%2FS1470-2045%2803%2901280-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cebon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudchadkar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchook, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Algazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Little, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J.</span><span> </span><span class="NLM_article-title">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">1694</span><span class="NLM_x">â</span> <span class="NLM_lpage">1703</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1210093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1056%2FNEJMoa1210093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=23020132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1694-1703&author=K.+T.+Flahertyauthor=J.+R.+Infanteauthor=A.+Daudauthor=R.+Gonzalezauthor=R.+F.+Keffordauthor=J.+Sosmanauthor=O.+Hamidauthor=L.+Schuchterauthor=J.+Cebonauthor=N.+Ibrahimauthor=R.+Kudchadkarauthor=H.+A.+Burrisauthor=G.+Falchookauthor=A.+Algaziauthor=K.+Lewisauthor=G.+V.+Longauthor=I.+Puzanovauthor=P.+Lebowitzauthor=A.+Singhauthor=S.+Littleauthor=P.+Sunauthor=A.+Allredauthor=D.+Ouelletauthor=K.+B.+Kimauthor=K.+Patelauthor=J.+Weber&title=Combined+BRAF+and+MEK+inhibition+in+melanoma+with+BRAF+V600+mutations&doi=10.1056%2FNEJMoa1210093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span></div><div class="casAuthors">Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Richard F.; Sosman, Jeffrey; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; Kudchadkar, Ragini; Burris, Howard A., III; Falchook, Gerald; Algazi, Alain; Lewis, Karl; Long, Georgina V.; Puzanov, Igor; Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Kim, Kevin B.; Patel, Kiran; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Resistance to therapy with BRAF kinase inhibitors is assocd. with reactivation of the mitogen-activated protein kinase (MAPK) pathway.  To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.  METHODS In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy.  The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response.  Secondary end points were overall survival and pharmacokinetic activity.  RESULTS Dose-limiting toxic effects were infrequently obsd. in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2).  Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%).  Median progression-free survival in the combination 150/2 group was 9.4 mo, as compared with 5.8 mo in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001).  The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03).  CONCLUSIONS Dabrafenib and trametinib were safely combined at full monotherapy doses.  The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced.  Progression-free survival was significantly improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk7I8zrGTVbVg90H21EOLACvtfcHk0ljmi9Exb97TCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ&md5=199ae281d44c3b41309b934d88674cd3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1210093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1210093%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLittle%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DAllred%26aufirst%3DA.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520inhibition%2520in%2520melanoma%2520with%2520BRAF%2520V600%2520mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1694%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1210093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Hodi, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâDay, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Eertwegh, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutzky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaubel, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linette, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottensmeier, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peschel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quirt, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolchok, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yellin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichol, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urba, W. J.</span><span> </span><span class="NLM_article-title">Improved survival with ipilimumab in patients with metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">â</span> <span class="NLM_lpage">723</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1003466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1056%2FNEJMoa1003466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=20525992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCrtrbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=711-723&author=F.+S.+Hodiauthor=S.+J.+O%E2%80%99Dayauthor=D.+F.+McDermottauthor=R.+W.+Weberauthor=J.+A.+Sosmanauthor=J.+B.+Haanenauthor=R.+Gonzalezauthor=C.+Robertauthor=D.+Schadendorfauthor=J.+C.+Hasselauthor=W.+Akerleyauthor=A.+J.+van+den+Eertweghauthor=J.+Lutzkyauthor=P.+Loriganauthor=J.+M.+Vaubelauthor=G.+P.+Linetteauthor=D.+Hoggauthor=C.+H.+Ottensmeierauthor=C.+Lebbeauthor=C.+Peschelauthor=I.+Quirtauthor=J.+I.+Clarkauthor=J.+D.+Wolchokauthor=J.+S.+Weberauthor=J.+Tianauthor=M.+J.+Yellinauthor=G.+M.+Nicholauthor=A.+Hoosauthor=W.+J.+Urba&title=Improved+survival+with+ipilimumab+in+patients+with+metastatic+melanoma&doi=10.1056%2FNEJMoa1003466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with ipilimumab in patients with metastatic melanoma</span></div><div class="casAuthors">Hodi, F. Stephen; O'day, Steven J.; McDermott, David F.; Weber, Robert W.; Sosman, Jeffrey A.; Haanen, John B.; Gonzalez, Rene; Robert, Caroline; Schadendorf, Dirk; Hassel, Jessica C.; Akerley, Wallace; van den Eertwegh, Alfons J. M.; Lutzky, Jose; Lorigan, Paul; Vaubel, Julia M.; Linette, Gerald P.; Hogg, David; Ottensmeier, Christian H.; Lebbe, Celeste; Peschel, Christian; Quirt, Ian; Clark, Joseph I.; Wolchok, Jedd D.; Weber, Jeffrey S.; Tian, Jason; Yellin, Michael J.; Nichol, Geoffrey M.; Hoos, Axel; Urba, Walter J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-723</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal.  In this phase 3 study, ipilimumab - which blocks cytotoxic T-lymphocyte-assocd. antigen 4 to potentiate an antitumor T-cell response - administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma.  Methods: A total of 676 HLA-A*0201-pos. patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136).  Ipilimumab, at a dose of 3 mg per kg of body wt., was administered with or without gp100 every 3 wk for up to four treatments (induction).  Eligible patients could receive reinduction therapy.  The primary end point was overall survival.  Results: The median overall survival was 10.0 mo among patients receiving ipilimumab plus gp100, as compared with 6.4 mo among patients receiving gp100 alone (hazard ratio for death, 0.68; P < 0.001).  The median overall survival with ipilimumab alone was 10.1 mo (hazard ratio for death in the comparison with gp100 alone, 0.66; P = 0.003).  No difference in overall survival was detected between the ipilimumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P = 0.76).  Grade 3 or 4 immune-related adverse events occurred in 10 to 15% of patients treated with ipilimumab and in 3% treated with gp100 alone.  There were 14 deaths related to the study drugs (2.1%), and 7 were assocd. with immune-related adverse events.  Conclusions: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.  Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmWp_goUg4SbVg90H21EOLACvtfcHk0liV2a3blXiHFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCrtrbN&md5=170a241290808ccccac26a5169e6c715</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1003466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1003466%26sid%3Dliteratum%253Aachs%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DWeber%26aufirst%3DR.%2BW.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DHassel%26aufirst%3DJ.%2BC.%26aulast%3DAkerley%26aufirst%3DW.%26aulast%3Dvan%2Bden%2BEertwegh%26aufirst%3DA.%2BJ.%26aulast%3DLutzky%26aufirst%3DJ.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DVaubel%26aufirst%3DJ.%2BM.%26aulast%3DLinette%26aufirst%3DG.%2BP.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DOttensmeier%26aufirst%3DC.%2BH.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3DQuirt%26aufirst%3DI.%26aulast%3DClark%26aufirst%3DJ.%2BI.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DYellin%26aufirst%3DM.%2BJ.%26aulast%3DNichol%26aufirst%3DG.%2BM.%26aulast%3DHoos%26aufirst%3DA.%26aulast%3DUrba%26aufirst%3DW.%2BJ.%26atitle%3DImproved%2520survival%2520with%2520ipilimumab%2520in%2520patients%2520with%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D711%26epage%3D723%26doi%3D10.1056%2FNEJMoa1003466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Ugurel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohmel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span> </span><span class="NLM_article-title">Survival of patients with advanced metastatic melanoma: The impact of novel therapies</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">134</span><span class="refDoi">Â DOI: 10.1016/j.ejca.2015.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.ejca.2015.09.013" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2016&pages=125-134&author=S.+Ugurelauthor=J.+Rohmelauthor=P.+A.+Asciertoauthor=K.+T.+Flahertyauthor=J.+J.+Grobauthor=A.+Hauschildauthor=J.+Larkinauthor=G.+V.+Longauthor=P.+Loriganauthor=G.+A.+McArthurauthor=A.+Ribasauthor=C.+Robertauthor=D.+Schadendorfauthor=C.+Garbe&title=Survival+of+patients+with+advanced+metastatic+melanoma%3A+The+impact+of+novel+therapies&doi=10.1016%2Fj.ejca.2015.09.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2015.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2015.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DUgurel%26aufirst%3DS.%26aulast%3DRohmel%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DGarbe%26aufirst%3DC.%26atitle%3DSurvival%2520of%2520patients%2520with%2520advanced%2520metastatic%2520melanoma%253A%2520The%2520impact%2520of%2520novel%2520therapies%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D53%26spage%3D125%26epage%3D134%26doi%3D10.1016%2Fj.ejca.2015.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kelderman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span> </span><span class="NLM_article-title">Acquired and intrinsic resistance in cancer immunotherapy</span> <span class="citation_source-journal">Mol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1132</span><span class="NLM_x">â</span> <span class="NLM_lpage">1139</span><span class="refDoi">Â DOI: 10.1016/j.molonc.2014.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.molonc.2014.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=25106088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlSru7%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1132-1139&author=S.+Keldermanauthor=T.+N.+Schumacherauthor=J.+B.+Haanen&title=Acquired+and+intrinsic+resistance+in+cancer+immunotherapy&doi=10.1016%2Fj.molonc.2014.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired and intrinsic resistance in cancer immunotherapy</span></div><div class="casAuthors">Kelderman, Sander; Schumacher, Ton N. M.; Haanen, John B. A. G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1132-1139</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A no. of immunotherapies, in particular immune checkpoint targeting antibodies and adoptive T-cell therapies, are starting to transform the treatment of advanced cancers.  The likelihood to respond to these immunotherapies differs strongly across tumor types, with response rates for checkpoint targeting being the highest in advanced melanoma, renal cell cancer and non-small cell lung cancer.  However, also non-responsiveness is obsd., indicating the presence of intrinsic resistance or naturally acquired resistance.  In addn., a subgroup of patients that do initially respond to immunotherapy will later recur, thereby also pointing towards a role of therapy-induced acquired resistance.Here, we review our current understanding of both intrinsic and acquired resistance mechanisms in cancer immunotherapy, and discuss potential strategies to overcome them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYW9vVRhZ6_rVg90H21EOLACvtfcHk0liV2a3blXiHFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlSru7%252FF&md5=c5eda99fe7b988ceecc2bddc2831e7cd</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DKelderman%26aufirst%3DS.%26aulast%3DSchumacher%26aufirst%3DT.%2BN.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26atitle%3DAcquired%2520and%2520intrinsic%2520resistance%2520in%2520cancer%2520immunotherapy%26jtitle%3DMol.%2520Oncol.%26date%3D2014%26volume%3D8%26spage%3D1132%26epage%3D1139%26doi%3D10.1016%2Fj.molonc.2014.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrie, P.</span><span> </span><span class="NLM_article-title">Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists</span> <span class="citation_source-journal">Eur. J. Cancer Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">867</span><span class="NLM_x">â</span> <span class="NLM_lpage">872</span><span class="refDoi">Â DOI: 10.1111/ecc.12359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1111%2Fecc.12359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=26222136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A280%3ADC%252BC28%252Fns1Oruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=867-872&author=C.+Jonesauthor=G.+Claptonauthor=Z.+Zhaoauthor=B.+Barberauthor=D.+Saltmanauthor=P.+Corrie&title=Unmet+clinical+needs+in+the+management+of+advanced+melanoma%3A+findings+from+a+survey+of+oncologists&doi=10.1111%2Fecc.12359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists</span></div><div class="casAuthors">Jones C; Clapton G; Zhao Z; Barber B; Saltman D; Saltman D; Corrie P</div><div class="citationInfo"><span class="NLM_cas:title">European journal of cancer care</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">867-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Advanced melanoma is a life-threatening cancer with limited life expectancy.  The recent introduction of new targeted systemic therapies has provided clinicians with the means to potentially extend survival for the first time.  However, the chance of cure remains very low and treatment-induced toxicity is well described.  This qualitative study was undertaken to evaluate clinicians' assessment regarding the key concerns in managing advanced melanoma following the introduction of these new treatments.  Three hundred and forty-three oncologists were surveyed online between August and November 2012 (in 11 countries) and March and April 2013 (in an additional country).  Analysis of free-text responses identified 23 clinical issues of concern across all countries.  Of these, the most common clinical concerns were drug toxicity and tolerability, followed by limited treatment effectiveness and limited treatment options.  These results suggest that despite the promise of the two new agents in the field, clinicians are still concerned about the limitations of current treatment options, recognising that there remains a significant unmet need in the treatment of advanced melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL8vVY6IA2aR0LsK7uFuY7fW6udTcc2eadJmxjwm2YTrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252Fns1Oruw%253D%253D&md5=34249d4c8d4b1c6aea9560c86b066a4c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fecc.12359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fecc.12359%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%26aulast%3DClapton%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DBarber%26aufirst%3DB.%26aulast%3DSaltman%26aufirst%3DD.%26aulast%3DCorrie%26aufirst%3DP.%26atitle%3DUnmet%2520clinical%2520needs%2520in%2520the%2520management%2520of%2520advanced%2520melanoma%253A%2520findings%2520from%2520a%2520survey%2520of%2520oncologists%26jtitle%3DEur.%2520J.%2520Cancer%2520Care%26date%3D2015%26volume%3D24%26spage%3D867%26epage%3D872%26doi%3D10.1111%2Fecc.12359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Hyngstrom, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cromwell, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mungovan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershenwald, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royal, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cormier, J. N.</span><span> </span><span class="NLM_article-title">Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma</span> <span class="citation_source-journal">Melanoma Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">290</span><span class="NLM_x">â</span> <span class="NLM_lpage">297</span><span class="refDoi">Â DOI: 10.1097/CMR.0b013e3283632c83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1097%2FCMR.0b013e3283632c83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=23752305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A280%3ADC%252BC3sjitl2rtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=290-297&author=J.+R.+Hyngstromauthor=Y.+J.+Chiangauthor=K.+D.+Cromwellauthor=M.+I.+Rossauthor=Y.+Xingauthor=K.+S.+Mungovanauthor=J.+E.+Leeauthor=J.+E.+Gershenwaldauthor=R.+E.+Royalauthor=A.+Lucciauthor=J.+M.+Armerauthor=J.+N.+Cormier&title=Prospective+assessment+of+lymphedema+incidence+and+lymphedema-associated+symptoms+following+lymph+node+surgery+for+melanoma&doi=10.1097%2FCMR.0b013e3283632c83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma</span></div><div class="casAuthors">Hyngstrom John R; Chiang Yi-Ju; Cromwell Kate D; Ross Merrick I; Xing Yan; Mungovan Kristi S; Lee Jeffrey E; Gershenwald Jeffrey E; Royal Richard E; Lucci Anthony; Armer Jane M; Cormier Janice N</div><div class="citationInfo"><span class="NLM_cas:title">Melanoma research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">290-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We aimed to prospectively assess limb volume change (LVC) and associated symptoms in patients with melanoma undergoing sentinel lymph node biopsy and/or therapeutic lymph node dissection.  Limb volume was measured preoperatively and postoperatively at 6 and 12 months using a perometer (1000 mol/l).  LVC was calculated and used to define three groups: less than 5%, 5-10%, and greater than 10%.  A 19-item lymphedema symptom questionnaire was administered at baseline, 6, and 12 months.  One hundred and eighty-two patients were enrolled.  Twelve months after axillary surgery, 9% had LVC 5-10% and 13% had LVC greater than 10%.  Twelve months after inguinofemoral surgery, 10% had LVC 5-10% and 13% had LVC greater than 10%.  There was a significant seven- to nine-fold increase in symptoms for patients with LVC greater than 10% compared with those with LVC less than 5% (P<0.05).  On multivariate analysis, therapeutic lymph node dissection versus sentinel lymph node biopsy (odds ratio=3.18; P<0.01) and borderline significance for lower-extremity versus upper-extremity procedures (odds ratio=1.72; P=0.07) were associated with LVC greater than 5%.  LVC greater than 5% is common at 12 months following nodal surgery for melanoma and is associated with symptoms.  Informed consent for melanoma patients undergoing lymph node surgery should include a discussion of the risks of postoperative lymphedema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa1L1O54WeVuvW160gIxP_fW6udTcc2eadJmxjwm2YTrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjitl2rtw%253D%253D&md5=2e3c339249dc0bbf95c33b0220d12c6a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2FCMR.0b013e3283632c83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCMR.0b013e3283632c83%26sid%3Dliteratum%253Aachs%26aulast%3DHyngstrom%26aufirst%3DJ.%2BR.%26aulast%3DChiang%26aufirst%3DY.%2BJ.%26aulast%3DCromwell%26aufirst%3DK.%2BD.%26aulast%3DRoss%26aufirst%3DM.%2BI.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DMungovan%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DGershenwald%26aufirst%3DJ.%2BE.%26aulast%3DRoyal%26aufirst%3DR.%2BE.%26aulast%3DLucci%26aufirst%3DA.%26aulast%3DArmer%26aufirst%3DJ.%2BM.%26aulast%3DCormier%26aufirst%3DJ.%2BN.%26atitle%3DProspective%2520assessment%2520of%2520lymphedema%2520incidence%2520and%2520lymphedema-associated%2520symptoms%2520following%2520lymph%2520node%2520surgery%2520for%2520melanoma%26jtitle%3DMelanoma%2520Res.%26date%3D2013%26volume%3D23%26spage%3D290%26epage%3D297%26doi%3D10.1097%2FCMR.0b013e3283632c83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elojeimy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckham, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bielawska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keane, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. S.</span><span> </span><span class="NLM_article-title">Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1449</span><span class="NLM_x">â</span> <span class="NLM_lpage">1458</span><span class="refDoi">Â DOI: 10.1517/14728220903357512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1517%2F14728220903357512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=19874262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCku77L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=1449-1458&author=X.+Liuauthor=J.+C.+Chengauthor=L.+S.+Turnerauthor=S.+Elojeimyauthor=T.+H.+Beckhamauthor=A.+Bielawskaauthor=T.+E.+Keaneauthor=Y.+A.+Hannunauthor=J.+S.+Norris&title=Acid+ceramidase+upregulation+in+prostate+cancer%3A+role+in+tumor+development+and+implications+for+therapy&doi=10.1517%2F14728220903357512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy</span></div><div class="casAuthors">Liu, Xiang; Cheng, Joseph C.; Turner, Lorianne S.; Elojeimy, Saeed; Beckham, Thomas H.; Bielawska, Alicja; Keane, Thomas E.; Hannun, Yusuf A.; Norris, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1449-1458</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Bioactive sphingolipids, such as ceramide, sphingosine and sphingosine-1-phosphate are known bio-effector mols. which play important roles in various aspects of cancer biol. including cell proliferation, growth arrest, apoptosis, metastasis, senescence and inflammation.  Therefore, enzymes involved in ceramide metab. are gaining recognition as being crit. regulators of cancer cell growth and/or survival.  We previously obsd. that the ceramide metabolizing enzyme, acid ceramidase (AC) is upregulated in tumor tissues.  Studies have now concluded that this creates a dysfunctional ceramide pathway, which is responsible for tumor progression and resistance to chemotherapy and radiation.  This suggests that development of small-mol. drugs that inhibit AC enzyme activity is a promising approach for improving std. cancer therapy and patient's clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozYg7wCR2HTbVg90H21EOLACvtfcHk0lhDA1Ca_n4h5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCku77L&md5=7f1be074c8aa732e766673b7786b748d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F14728220903357512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728220903357512%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DJ.%2BC.%26aulast%3DTurner%26aufirst%3DL.%2BS.%26aulast%3DElojeimy%26aufirst%3DS.%26aulast%3DBeckham%26aufirst%3DT.%2BH.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DKeane%26aufirst%3DT.%2BE.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DNorris%26aufirst%3DJ.%2BS.%26atitle%3DAcid%2520ceramidase%2520upregulation%2520in%2520prostate%2520cancer%253A%2520role%2520in%2520tumor%2520development%2520and%2520implications%2520for%2520therapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2009%26volume%3D13%26spage%3D1449%26epage%3D1458%26doi%3D10.1517%2F14728220903357512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Bedia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrieu-Abadie, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabrias, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levade, T.</span><span> </span><span class="NLM_article-title">Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">28200</span><span class="NLM_x">â</span> <span class="NLM_lpage">28209</span><span class="refDoi">Â DOI: 10.1074/jbc.M110.216382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1074%2Fjbc.M110.216382" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=28200-28209&author=C.+Bediaauthor=J.+Casasauthor=N.+Andrieu-Abadieauthor=G.+Fabriasauthor=T.+Levade&title=Acid+ceramidase+expression+modulates+the+sensitivity+of+A375+melanoma+cells+to+dacarbazine&doi=10.1074%2Fjbc.M110.216382"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.216382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.216382%26sid%3Dliteratum%253Aachs%26aulast%3DBedia%26aufirst%3DC.%26aulast%3DCasas%26aufirst%3DJ.%26aulast%3DAndrieu-Abadie%26aufirst%3DN.%26aulast%3DFabrias%26aufirst%3DG.%26aulast%3DLevade%26aufirst%3DT.%26atitle%3DAcid%2520ceramidase%2520expression%2520modulates%2520the%2520sensitivity%2520of%2520A375%2520melanoma%2520cells%2520to%2520dacarbazine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D28200%26epage%3D28209%26doi%3D10.1074%2Fjbc.M110.216382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Tan, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awwad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morad, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kester, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claxton, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabot, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchman, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughran, T. P.,  Jr.</span><span> </span><span class="NLM_article-title">Acid ceramidase is upregulated in AML and represents a novel therapeutic target</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">83208</span><span class="NLM_x">â</span> <span class="NLM_lpage">83222</span><span class="refDoi">Â DOI: 10.18632/oncotarget.13079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.18632%2Foncotarget.13079" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=83208-83222&author=S.+F.+Tanauthor=X.+Liuauthor=T.+E.+Foxauthor=B.+M.+Barthauthor=A.+Sharmaauthor=S.+D.+Turnerauthor=A.+Awwadauthor=A.+Deweyauthor=K.+Doiauthor=B.+Spitzerauthor=M.+V.+Shahauthor=S.+A.+Moradauthor=D.+Desaiauthor=S.+Aminauthor=J.+Zhuauthor=J.+Liaoauthor=J.+Yunauthor=M.+Kesterauthor=D.+F.+Claxtonauthor=H.+G.+Wangauthor=M.+C.+Cabotauthor=E.+H.+Schuchmanauthor=R.+L.+Levineauthor=D.+J.+Feithauthor=T.+P.+Loughran&title=Acid+ceramidase+is+upregulated+in+AML+and+represents+a+novel+therapeutic+target&doi=10.18632%2Foncotarget.13079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13079%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DS.%2BF.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DFox%26aufirst%3DT.%2BE.%26aulast%3DBarth%26aufirst%3DB.%2BM.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DTurner%26aufirst%3DS.%2BD.%26aulast%3DAwwad%26aufirst%3DA.%26aulast%3DDewey%26aufirst%3DA.%26aulast%3DDoi%26aufirst%3DK.%26aulast%3DSpitzer%26aufirst%3DB.%26aulast%3DShah%26aufirst%3DM.%2BV.%26aulast%3DMorad%26aufirst%3DS.%2BA.%26aulast%3DDesai%26aufirst%3DD.%26aulast%3DAmin%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DKester%26aufirst%3DM.%26aulast%3DClaxton%26aufirst%3DD.%2BF.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DCabot%26aufirst%3DM.%2BC.%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DFeith%26aufirst%3DD.%2BJ.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26atitle%3DAcid%2520ceramidase%2520is%2520upregulated%2520in%2520AML%2520and%2520represents%2520a%2520novel%2520therapeutic%2520target%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D83208%26epage%3D83222%26doi%3D10.18632%2Foncotarget.13079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Zeidan, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obeid, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span> </span><span class="NLM_article-title">Molecular targeting of acid ceramidase: implications to cancer therapy</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">653</span><span class="NLM_x">â</span> <span class="NLM_lpage">661</span><span class="refDoi">Â DOI: 10.2174/138945008785132358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.2174%2F138945008785132358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=18691012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVymu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=653-661&author=Y.+H.+Zeidanauthor=R.+W.+Jenkinsauthor=J.+B.+Kormanauthor=X.+Liuauthor=L.+M.+Obeidauthor=J.+S.+Norrisauthor=Y.+A.+Hannun&title=Molecular+targeting+of+acid+ceramidase%3A+implications+to+cancer+therapy&doi=10.2174%2F138945008785132358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeting of acid ceramidase: implications to cancer therapy</span></div><div class="casAuthors">Zeidan, Youssef H.; Jenkins, Russell W.; Korman, John B.; Liu, Xiang; Obeid, Lina M.; Norris, James S.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">653-661</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Increasingly recognized as bioactive mols., sphingolipids have been studied in a variety of disease models.  The impact of sphingolipids on cancer research facilitated the entry of sphingolipid analogs and enzyme modulators into clin. trials.  Owing to its ability to regulate two bioactive sphingolipids, ceramide and sphingosine-1-phosphate, acid ceramidase (AC) emerges as an attractive target for drug development within the sphingolipid metabolic pathway.  Indeed, there is extensive evidence supporting a pivotal role for AC in lipid metab. and cancer biol.  In this article, we review the current knowledge of the biochem. properties of AC, its relevance to tumor promotion, and its mol. targeting approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp274kz6fu5urVg90H21EOLACvtfcHk0liie-tBJgjacQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVymu7w%253D&md5=54d4e5eabc134304a2345c84625df23a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F138945008785132358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945008785132358%26sid%3Dliteratum%253Aachs%26aulast%3DZeidan%26aufirst%3DY.%2BH.%26aulast%3DJenkins%26aufirst%3DR.%2BW.%26aulast%3DKorman%26aufirst%3DJ.%2BB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DNorris%26aufirst%3DJ.%2BS.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DMolecular%2520targeting%2520of%2520acid%2520ceramidase%253A%2520implications%2520to%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2008%26volume%3D9%26spage%3D653%26epage%3D661%26doi%3D10.2174%2F138945008785132358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Furuya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamori, T.</span><span> </span><span class="NLM_article-title">Sphingolipids in cancer</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">â</span> <span class="NLM_lpage">576</span><span class="refDoi">Â DOI: 10.1007/s10555-011-9304-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1007%2Fs10555-011-9304-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=22005951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1emt7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=567-576&author=H.+Furuyaauthor=Y.+Shimizuauthor=T.+Kawamori&title=Sphingolipids+in+cancer&doi=10.1007%2Fs10555-011-9304-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids in cancer</span></div><div class="casAuthors">Furuya, Hideki; Shimizu, Yoshiko; Kawamori, Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">567-576</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The bioactive sphingolipids including, ceramide, sphingosine, and sphingosine-1-phosphate (S1P) have important roles in several types of signaling and regulation of many cellular processes including cell proliferation, apoptosis, senescence, angiogenesis, and transformation.  Recent accumulating evidence suggests that ceramide- and S1P-mediated pathways have been implicated in cancer development, progression, and chemotherapy.  Ceramide mediates numerous cell-stress responses, such as induction of apoptosis and cell senescence, whereas S1P plays pivotal roles in cell survival, migration, and inflammation.  These sphingolipids with opposing roles can be interconverted within cells, suggesting that the balance between them is related to cell fate.  Importantly, these sphingolipids are metabolically related through actions of enzymes including ceramidases, ceramide synthases, sphingosine kinases, and S1P phosphatases thereby forming a network of metabolically interrelated bioactive lipid mediators whose importance in normal cellular function and diseases is gaining appreciation.  In this review, we summarize involvement of sphingolipids and their related enzymes in pathogenesis and therapy of cancer and discuss future directions of sphingolipid field in cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLu6DcWczsrrVg90H21EOLACvtfcHk0liie-tBJgjacQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1emt7vJ&md5=625f3bac3b024f318e15fcd1b09fb888</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs10555-011-9304-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-011-9304-1%26sid%3Dliteratum%253Aachs%26aulast%3DFuruya%26aufirst%3DH.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DKawamori%26aufirst%3DT.%26atitle%3DSphingolipids%2520in%2520cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2011%26volume%3D30%26spage%3D567%26epage%3D576%26doi%3D10.1007%2Fs10555-011-9304-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Coant, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span> </span><span class="NLM_article-title">Ceramidases, roles in sphingolipid metabolism and in health and disease</span> <span class="citation_source-journal">Adv. Biol. Regul.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">122</span><span class="NLM_x">â</span> <span class="NLM_lpage">131</span><span class="refDoi">Â DOI: 10.1016/j.jbior.2016.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.jbior.2016.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=27771292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2017&pages=122-131&author=N.+Coantauthor=W.+Sakamotoauthor=C.+Maoauthor=Y.+A.+Hannun&title=Ceramidases%2C+roles+in+sphingolipid+metabolism+and+in+health+and+disease&doi=10.1016%2Fj.jbior.2016.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidases, roles in sphingolipid metabolism and in health and disease</span></div><div class="casAuthors">Coant, Nicolas; Sakamoto, Wataru; Mao, Cungui; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122-131</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over the past three decades, extensive research has been able to det. the biol. functions for the main bioactive sphingolipids, namely ceramide, sphingosine, and sphingosine 1-phosphate (S1P) (Hannun, 1996; Hannun et al., 1986; Okazaki et al., 1989).  These studies have managed to define the metab., regulation, and function of these bioactive sphingolipids.  This emerging body of literature has also implicated bioactive sphingolipids, particularly S1P and ceramide, as key regulators of cellular homeostasis.  Ceramidases have the important role of cleaving fatty acid from ceramide and producing sphingosine, thereby controlling the interconversion of these two lipids.  Thus far, five human ceramidases encoded by five different genes have been identified: acid ceramidase (AC), neutral ceramidase (NC), alk. ceramidase 1 (ACER1), alk. ceramidase 2 (ACER2), and alk. ceramidase 3 (ACER3).  These ceramidases are classified according to their optimal pH for catalytic activity.  AC, which is localized to the lysosomal compartment, has been assocd. with Farber's disease and is involved in the regulation of cell viability.  Neutral ceramidase, which is localized to the plasma membrane and primarily expressed in the small intestine and colon, is involved in digestion, and has been implicated in colon carcinogenesis.  ACER1 which can be found in the endoplasmic reticulum and is highly expressed in the skin, plays an important role in keratinocyte differentiation.  ACER2, localized to the Golgi complex and highly expressed in the placenta, is involved in programed cell death in response to DNA damage.  ACER3, also localized to the endoplasmic reticulum and the Golgi complex, is ubiquitously expressed, and is involved in motor coordination-assocd. Purkinje cell degeneration.  This review seeks to consolidate the current knowledge regarding these key cellular players.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowWeoXuPUgXrVg90H21EOLACvtfcHk0lgKbYnjAkFelg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK&md5=84e937e947b7a38256761a6ab60a7353</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2016.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2016.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCoant%26aufirst%3DN.%26aulast%3DSakamoto%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramidases%252C%2520roles%2520in%2520sphingolipid%2520metabolism%2520and%2520in%2520health%2520and%2520disease%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2017%26volume%3D63%26spage%3D122%26epage%3D131%26doi%3D10.1016%2Fj.jbior.2016.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Kartal Yandim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apohan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baran, Y.</span><span> </span><span class="NLM_article-title">Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">â</span> <span class="NLM_lpage">20</span><span class="refDoi">Â DOI: 10.1007/s00280-012-1984-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1007%2Fs00280-012-1984-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=23073611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFCntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2013&pages=13-20&author=M.+Kartal+Yandimauthor=E.+Apohanauthor=Y.+Baran&title=Therapeutic+potential+of+targeting+ceramide%2Fglucosylceramide+pathway+in+cancer&doi=10.1007%2Fs00280-012-1984-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer</span></div><div class="casAuthors">Kartal Yandim, Melis; Apohan, Elif; Baran, Yusuf</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-20</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Sphingolipids including ceramides and its derivs. such as ceramide-1-phosphate, glucosylceramide (GlcCer), and sphingosine-1-phosphate are essential structural components of cell membranes.  They now recognized as novel bioeffector mols. which control various aspects of cell growth, proliferation, apoptosis, and drug resistance.  Ceramide, the central mol. of sphingolipid metab., generally mediates anti-proliferative responses such as inhibition of cell growth, induction of apoptosis, and/or modulation of senescence.  There are two major classes of sphingolipids.  One of them is glycosphingolipids which are synthesized from the hydrophobic mol., ceramide.  GlcCer, generated by glucosylceramide synthase (GCS) that transfers the glucose from UDP-glucose to ceramide, is an important glycosphingolipid metabolic intermediate.  GCS regulates the balance between apoptotic ceramide and antiapoptotic GlcCer.  Downregulation or inhibition of GCS results in increased apoptosis and decreased drug resistance.  The mechanism underlying the drug resistance which develops with increased glucosylceramide expression is assocd. with P-glycoprotein.  In various types of cancers, overexpression of GCS has been obsd. which renders GCS a good target for the treatment of cancer.  This review summarizes our current knowledge on the structure and functions of glucosylceramide synthase and glucosylceramide and on the roles of glucosylceramide synthase in cancer therapy and drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTlwoA9_w66LVg90H21EOLACvtfcHk0lgKbYnjAkFelg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFCntw%253D%253D&md5=f7f40067e301cb50c1e02842c309b7b4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1984-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1984-x%26sid%3Dliteratum%253Aachs%26aulast%3DKartal%2BYandim%26aufirst%3DM.%26aulast%3DApohan%26aufirst%3DE.%26aulast%3DBaran%26aufirst%3DY.%26atitle%3DTherapeutic%2520potential%2520of%2520targeting%2520ceramide%252Fglucosylceramide%2520pathway%2520in%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D71%26spage%3D13%26epage%3D20%26doi%3D10.1007%2Fs00280-012-1984-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Ogretmen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span> </span><span class="NLM_article-title">Biologically active sphingolipids in cancer pathogenesis and treatment</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">604</span><span class="NLM_x">â</span> <span class="NLM_lpage">616</span><span class="refDoi">Â DOI: 10.1038/nrc1411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1038%2Fnrc1411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=15286740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=604-616&author=B.+Ogretmenauthor=Y.+A.+Hannun&title=Biologically+active+sphingolipids+in+cancer+pathogenesis+and+treatment&doi=10.1038%2Fnrc1411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biologically active sphingolipids in cancer pathogenesis and treatment</span></div><div class="casAuthors">Ogretmen, Besim; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">604-616</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Biol. active sphingolipids have key roles in the regulation of several fundamental biol. processes that are integral to cancer pathogenesis.  Recent significant progress in understanding biol. active sphingolipid synthesis, specifically within ceramide and sphingosine-1-phosphate (S1P)-mediated pathways, has identified crucial roles for these mols. both in cancer development and progression.  Ceramide - a central mol. in sphingolipid metab. - in effect functions as a tumor-suppressor lipid, inducing antiproliferative and apoptotic responses in various cancer cells.  Conversely, S1P induces responses that, on aggregate, render S1P a tumor-promoting lipid.  These discoveries are paving the way for the advancement of anticancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraIf0pY_2SrrVg90H21EOLACvtfcHk0lgKbYnjAkFelg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhsb4%253D&md5=1147c2d9741a1da2a22ac28fa5a279e7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrc1411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1411%26sid%3Dliteratum%253Aachs%26aulast%3DOgretmen%26aufirst%3DB.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DBiologically%2520active%2520sphingolipids%2520in%2520cancer%2520pathogenesis%2520and%2520treatment%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D604%26epage%3D616%26doi%3D10.1038%2Fnrc1411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Riboni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campanella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaini, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli-Boneschi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tettamanti, G.</span><span> </span><span class="NLM_article-title">Ceramide levels are inversely associated with malignant progression of human glial tumors</span> <span class="citation_source-journal">Glia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">â</span> <span class="NLM_lpage">113</span><span class="refDoi">Â DOI: 10.1002/glia.10087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1002%2Fglia.10087" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2002&pages=105-113&author=L.+Riboniauthor=R.+Campanellaauthor=R.+Bassiauthor=R.+Villaniauthor=S.+M.+Gainiauthor=F.+Martinelli-Boneschiauthor=P.+Vianiauthor=G.+Tettamanti&title=Ceramide+levels+are+inversely+associated+with+malignant+progression+of+human+glial+tumors&doi=10.1002%2Fglia.10087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fglia.10087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.10087%26sid%3Dliteratum%253Aachs%26aulast%3DRiboni%26aufirst%3DL.%26aulast%3DCampanella%26aufirst%3DR.%26aulast%3DBassi%26aufirst%3DR.%26aulast%3DVillani%26aufirst%3DR.%26aulast%3DGaini%26aufirst%3DS.%2BM.%26aulast%3DMartinelli-Boneschi%26aufirst%3DF.%26aulast%3DViani%26aufirst%3DP.%26aulast%3DTettamanti%26aufirst%3DG.%26atitle%3DCeramide%2520levels%2520are%2520inversely%2520associated%2520with%2520malignant%2520progression%2520of%2520human%2520glial%2520tumors%26jtitle%3DGlia%26date%3D2002%26volume%3D39%26spage%3D105%26epage%3D113%26doi%3D10.1002%2Fglia.10087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teitz-Tennenbaum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabel, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubman, D. M.</span><span> </span><span class="NLM_article-title">Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma</span> <span class="citation_source-journal">J. Proteome Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">6044</span><span class="NLM_x">â</span> <span class="NLM_lpage">6051</span><span class="refDoi">Â DOI: 10.1021/pr100856k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr100856k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSqt7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=6044-6051&author=Y.+Liuauthor=J.+Heauthor=X.+Xieauthor=G.+Suauthor=S.+Teitz-Tennenbaumauthor=M.+S.+Sabelauthor=D.+M.+Lubman&title=Serum+autoantibody+profiling+using+a+natural+glycoprotein+microarray+for+the+prognosis+of+early+melanoma&doi=10.1021%2Fpr100856k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Serum Autoantibody Profiling Using a Natural Glycoprotein Microarray for the Prognosis of Early Melanoma</span></div><div class="casAuthors">Liu, Yashu; He, Jintang; Xie, Xaiolei; Su, Gang; Teitz-Tennenbaum, Seagal; Sabel, Michael S.; Lubman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6044-6051</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The poor prognosis of melanoma and the high cost of lymph node biopsy for melanoma patients have led to an urgent need for the discovery of convenient and accurate prognostic indicators.  Here, the authors have developed a natural glycoprotein microarray to discover serum autoantibodies to distinguish between patients with node neg. melanoma and node pos. melanoma.  Dual-lectin affinity chromatog. was used to ext. glycoproteins from a melanoma cell line.  Liq.-based reverse phase sepn. and microarray platforms were then applied to sep. and spot these natural proteins on nitrocellulose slides.  The serum autoantibodies were investigated by exposing these proteins to sera from 43 patients that have already been diagnosed to have different stages of early melanoma.  The combination of 9 fractions provides a 55% sensitivity with 100% specificity for the detection of node pos. against node neg. and a 62% sensitivity with 100% specificity for the detection of node neg. against node pos.  Recombinant proteins were used to confirm the results using a sample set with 79 patients with diagnosed melanoma.  The response of sera against recombinant 94 kDa glucose-regulated protein (GRP94), acid ceramidase (ASAH1), cathepsin D (CTSD), and lactate dehydrogenase B (LDHB) shared a similar pattern to the fractions where they were identified.  The glycoarray platform provides a convenient and highly reproducible method to profile autoantibodies that could be used as serum biomarkers for prognosis of melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwIyhVevD3HLVg90H21EOLACvtfcHk0lhQroR7udk6Sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSqt7bM&md5=d882257822815eea04f204f2398c6fc5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fpr100856k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr100856k%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DG.%26aulast%3DTeitz-Tennenbaum%26aufirst%3DS.%26aulast%3DSabel%26aufirst%3DM.%2BS.%26aulast%3DLubman%26aufirst%3DD.%2BM.%26atitle%3DSerum%2520autoantibody%2520profiling%2520using%2520a%2520natural%2520glycoprotein%2520microarray%2520for%2520the%2520prognosis%2520of%2520early%2520melanoma%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2010%26volume%3D9%26spage%3D6044%26epage%3D6051%26doi%3D10.1021%2Fpr100856k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Mahdy, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elojeimy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meacham, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckham, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bielawska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bielawski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keane, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taha, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammouda, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span> </span><span class="NLM_article-title">Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer</span> <span class="citation_source-journal">Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">â</span> <span class="NLM_lpage">438</span><span class="refDoi">Â DOI: 10.1038/mt.2008.281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1038%2Fmt.2008.281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=19107118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFart7fF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=430-438&author=A.+E.+Mahdyauthor=J.+C.+Chengauthor=J.+Liauthor=S.+Elojeimyauthor=W.+D.+Meachamauthor=L.+S.+Turnerauthor=A.+Baiauthor=C.+R.+Gaultauthor=A.+S.+McPhersonauthor=N.+Garciaauthor=T.+H.+Beckhamauthor=A.+Saadauthor=A.+Bielawskaauthor=J.+Bielawskiauthor=Y.+A.+Hannunauthor=T.+E.+Keaneauthor=M.+I.+Tahaauthor=H.+M.+Hammoudaauthor=J.+S.+Norrisauthor=X.+Liu&title=Acid+ceramidase+upregulation+in+prostate+cancer+cells+confers+resistance+to+radiation%3A+AC+inhibition%2C+a+potential+radiosensitizer&doi=10.1038%2Fmt.2008.281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Acid Ceramidase Upregulation in Prostate Cancer Cells Confers Resistance to Radiation: AC Inhibition, a Potential Radiosensitizer</span></div><div class="casAuthors">Mahdy, Ayman E. M.; Cheng, Joseph C.; Li, Jun; Elojeimy, Saeed; Meacham, William D.; Turner, Lorianne S.; Bai, Aiping; Gault, Christopher R.; McPherson, Alex S.; Garcia, Nicole; Beckham, Thomas H.; Saad, Antonio; Bielawska, Alicja; Bielawski, Jacek; Hannun, Yusuf A.; Keane, Thomas E.; Taha, Mohhammed I.; Hammouda, Hisham M.; Norris, James S.; Liu, Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">430-438</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Radiation resistance in a subset of prostate tumors remains a challenge to prostate cancer radiotherapy.  The current study on the effects of radiation on prostate cancer cells reveals that radiation programs an unpredicted resistance mechanism by upregulating acid ceramidase (AC).  Irradiated cells demonstrated limited changes of ceramide levels while elevating levels of sphingosine and sphingosine-1-phosphate.  By genetically downregulating AC with small interfering RNA (siRNA), we obsd. radiosensitization of cells using clonogenic and cytotoxicity assays.  Conversely, AC overexpression further decreased sensitivity to radiation.  We also obsd. that radiation-induced AC upregulation was sufficient to create cross-resistance to chemotherapy as demonstrated by decreased sensitivity to Taxol and C6 ceramide compared to controls.  Lower levels of caspase 3/7 activity were detected in cells pretreated with radiation, also indicating increased resistance.  Finally, utilization of the small mol. AC inhibitor, LCL385, sensitized PPC-1 cells to radiation and significantly decreased tumor xenograft growth.  These data suggest a new mechanism of cancer cell resistance to radiation, through upregulation of AC i.e., in part, mediated by application of the therapy itself.  An improved understanding of radiotherapy and the application of combination therapy achieved in this study offer new opportunities for the modulation of radiation effects in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcfZKQJLJrLbVg90H21EOLACvtfcHk0lhQroR7udk6Sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFart7fF&md5=96aa1d9b77ef926f93655a78e610e20a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fmt.2008.281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2008.281%26sid%3Dliteratum%253Aachs%26aulast%3DMahdy%26aufirst%3DA.%2BE.%26aulast%3DCheng%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DElojeimy%26aufirst%3DS.%26aulast%3DMeacham%26aufirst%3DW.%2BD.%26aulast%3DTurner%26aufirst%3DL.%2BS.%26aulast%3DBai%26aufirst%3DA.%26aulast%3DGault%26aufirst%3DC.%2BR.%26aulast%3DMcPherson%26aufirst%3DA.%2BS.%26aulast%3DGarcia%26aufirst%3DN.%26aulast%3DBeckham%26aufirst%3DT.%2BH.%26aulast%3DSaad%26aufirst%3DA.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DBielawski%26aufirst%3DJ.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DKeane%26aufirst%3DT.%2BE.%26aulast%3DTaha%26aufirst%3DM.%2BI.%26aulast%3DHammouda%26aufirst%3DH.%2BM.%26aulast%3DNorris%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DAcid%2520ceramidase%2520upregulation%2520in%2520prostate%2520cancer%2520cells%2520confers%2520resistance%2520to%2520radiation%253A%2520AC%2520inhibition%252C%2520a%2520potential%2520radiosensitizer%26jtitle%3DMol.%2520Ther.%26date%3D2009%26volume%3D17%26spage%3D430%26epage%3D438%26doi%3D10.1038%2Fmt.2008.281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Seelan, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokomizo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bostwick, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span> </span><span class="NLM_article-title">Human acid ceramidase is overexpressed but not mutated in prostate cancer</span> <span class="citation_source-journal">Genes, Chromosomes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">â</span> <span class="NLM_lpage">146</span><span class="refDoi">Â DOI: 10.1002/1098-2264(2000)9999:9999<::AID-GCC1018>3.0.CO;2-E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10959093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntVWiurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2000&pages=137-146&author=R.+S.+Seelanauthor=C.+Qianauthor=A.+Yokomizoauthor=D.+G.+Bostwickauthor=D.+I.+Smithauthor=W.+Liu&title=Human+acid+ceramidase+is+overexpressed+but+not+mutated+in+prostate+cancer&doi=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Human acid ceramidase is overexpressed but not mutated in prostate cancer</span></div><div class="casAuthors">Seelan, Ratnam S.; Qian, Chiping; Yokomizo, Akira; Bostwick, David G.; Smith, David I.; Liu, Wanguo</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-146</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The human acid ceramidase gene, that causes Farber disease, is located in 8p22, a region frequently altered in several cancers, including prostate cancer.  Acid ceramidase catalyzes the hydrolysis of ceramide, a potent lipid second messenger mol. that promotes apoptosis and inhibits cellular proliferation.  It is not known whether this gene, or its expression, is altered in prostate cancer.  Here, the authors report the structural organization of the human gene, its expression in human tissues, and the identification of several single nucleotide polymorphisms.  No cancer-related mutations were found in the gene in a panel of prostate tumor DNAs analyzed, but increased expression was obsd. in prostate tumor tissues when compared with matched normals.  This increase was obsd. in all three prostate tumor cell lines tested (DU145, LnCAP, and PC3) when compared to a BPH (benign prostatic hyperplasia) cell line and 15/36 prostate tumors.  These results suggest that acid ceramidase may play an important role in prostate carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Y-_n5vjRdbVg90H21EOLACvtfcHk0lhQroR7udk6Sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntVWiurg%253D&md5=9c690947f4f44a446d83608ffda02c54</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1098-2264%25282000%25299999%253A9999%253C%253A%253AAID-GCC1018%253E3.0.CO%253B2-E%26sid%3Dliteratum%253Aachs%26aulast%3DSeelan%26aufirst%3DR.%2BS.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DYokomizo%26aufirst%3DA.%26aulast%3DBostwick%26aufirst%3DD.%2BG.%26aulast%3DSmith%26aufirst%3DD.%2BI.%26aulast%3DLiu%26aufirst%3DW.%26atitle%3DHuman%2520acid%2520ceramidase%2520is%2520overexpressed%2520but%2520not%2520mutated%2520in%2520prostate%2520cancer%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2000%26volume%3D29%26spage%3D137%26epage%3D146%26doi%3D10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Roh, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, H. J.</span><span> </span><span class="NLM_article-title">Targeting acid ceramidase sensitises head and neck cancer to cisplatin</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">â</span> <span class="NLM_lpage">172</span><span class="refDoi">Â DOI: 10.1016/j.ejca.2015.10.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.ejca.2015.10.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=26687835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFems7zF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=163-172&author=J.+L.+Rohauthor=J.+Y.+Parkauthor=E.+H.+Kimauthor=H.+J.+Jang&title=Targeting+acid+ceramidase+sensitises+head+and+neck+cancer+to+cisplatin&doi=10.1016%2Fj.ejca.2015.10.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting acid ceramidase sensitises head and neck cancer to cisplatin</span></div><div class="casAuthors">Roh, Jong-Lyel; Park, Jin Young; Kim, Eun Hye; Jang, Hye Jin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-172</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Acid ceramidase (AC), a key enzyme in ceramide metab., plays a role in cancer progression and resistance to therapy.  However, the role of AC in head and neck cancer (HNC) has not been addressed.  Here, we investigate the effect of AC inhibition on the response to cisplatin-based chemotherapy for HNC.AC protein and mRNA (mRNA) expression were examd. in primary tumors and paired normal tissues, and in HNC cell lines.  The effects of genetic and pharmacol. AC inhibition using small hairpin RNA (shRNA) and N-oleoyl-ethanolamine (NOE), alone and in combination with cisplatin, were assessed in human HNC cells by measuring cell viability, cell cycle progression, apoptosis, mRNA, and protein expression, and in preclin. tumor xenograft mouse models.AC overexpression was obsd. in four of six primary tumor tissues and six of nine HNC cell lines.  Cisplatin sensitivity was significantly decreased by AC overexpression and significantly increased by AC downregulation in HNC cells (P < 0.01).  NOE or AC shRNA-mediated AC inhibition enhanced cisplatin-induced HNC cell death by increasing ceramide prodn. and activating pro-apoptotic proteins, and these effects were abrogated by PUMA small interfering RNA transfection.  AC inhibition promoted cisplatin-induced apoptosis of HNC cells in vitro and in vivo.AC overexpression is assocd. with cisplatin sensitivity, suggesting its potential role as a chemotherapeutic target for HNC.  Genetic or pharmacol. AC inhibition promotes cisplatin cytotoxicity in HNC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomDQBsoYn4e7Vg90H21EOLACvtfcHk0ljGshqxpkD0Hg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFems7zF&md5=21cc9a783fabe8e2147577e80841a660</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2015.10.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2015.10.056%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DJ.%2BL.%26aulast%3DPark%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DE.%2BH.%26aulast%3DJang%26aufirst%3DH.%2BJ.%26atitle%3DTargeting%2520acid%2520ceramidase%2520sensitises%2520head%2520and%2520neck%2520cancer%2520to%2520cisplatin%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D52%26spage%3D163%26epage%3D172%26doi%3D10.1016%2Fj.ejca.2015.10.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Canals, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span> </span><span class="NLM_article-title">Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">694</span><span class="NLM_x">â</span> <span class="NLM_lpage">712</span><span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01279.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1111%2Fj.1476-5381.2011.01279.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=21615386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=694-712&author=D.+Canalsauthor=D.+M.+Perryauthor=R.+W.+Jenkinsauthor=Y.+A.+Hannun&title=Drug+targeting+of+sphingolipid+metabolism%3A+sphingomyelinases+and+ceramidases&doi=10.1111%2Fj.1476-5381.2011.01279.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases</span></div><div class="casAuthors">Canals, Daniel; Perry, David M.; Jenkins, Russell W.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">694-712</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Sphingolipids represent a class of diverse bioactive lipid mols. that are increasingly appreciated as key modulators of diverse physiol. and pathophysiol. processes that include cell growth, cell death, autophagy, angiogenesis, and stress and inflammatory responses.  Sphingomyelinases and ceramidases are key enzymes of sphingolipid metab. that regulate the formation and degrdn. of ceramide, one of the most intensely studied classes of sphingolipids.  Improved understanding of these enzymes that control not only the levels of ceramide but also the complex interconversion of sphingolipid metabolites has provided the foundation for the functional anal. of the roles of sphingolipids.  Our current understanding of the roles of various sphingolipids in the regulation of different cellular processes has come from loss-of-function/gain-of-function studies utilizing genetic deletion/downregulation/overexpression of enzymes of sphingolipid metab. (e.g. knockout animals, RNA interference) and from the use of pharmacol. inhibitors of these same enzymes.  While genetic approaches to evaluate the functional roles of sphingolipid enzymes were instrumental in advancing the field, the use of pharmacol. inhibitors was equally important in identifying new roles for sphingolipids in important cellular processes.  The latter also promises the development of novel therapeutic targets with implications for cancer therapy, inflammation, diabetes, and neurodegeneration.  In this review, we focus on the status and use of pharmacol. compds. that inhibit sphingomyelinases and ceramidases, and we will review the history, current uses and future directions for various small mol. inhibitors, and will highlight in which inhibitors of sphingolipid metabolizing enzymes have been used to effectively treat models of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjvT0kSLqjbVg90H21EOLACvtfcHk0ljGshqxpkD0Hg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr4%253D&md5=e0ad156d9c992cd1fa549ee5e3dec3ba</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01279.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01279.x%26sid%3Dliteratum%253Aachs%26aulast%3DCanals%26aufirst%3DD.%26aulast%3DPerry%26aufirst%3DD.%2BM.%26aulast%3DJenkins%26aufirst%3DR.%2BW.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DDrug%2520targeting%2520of%2520sphingolipid%2520metabolism%253A%2520sphingomyelinases%2520and%2520ceramidases%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D694%26epage%3D712%26doi%3D10.1111%2Fj.1476-5381.2011.01279.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Morad, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kester, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claxton, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughran, T. P.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabot, M. C.</span><span> </span><span class="NLM_article-title">Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemiaâImpact on enzyme activity and response to cytotoxics</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1851</span><span class="NLM_x">, </span> <span class="NLM_fpage">919</span><span class="NLM_x">â</span> <span class="NLM_lpage">928</span><span class="refDoi">Â DOI: 10.1016/j.bbalip.2015.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.bbalip.2015.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=25769964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksFWjtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1851&publication_year=2015&pages=919-928&author=S.+A.+Moradauthor=S.-F.+Tanauthor=D.+J.+Feithauthor=M.+Kesterauthor=D.+F.+Claxtonauthor=T.+P.+Loughranauthor=B.+M.+Barthauthor=T.+E.+Foxauthor=M.+C.+Cabot&title=Modification+of+sphingolipid+metabolism+by+tamoxifen+and+N-desmethyltamoxifen+in+acute+myelogenous+leukemia%E2%80%94Impact+on+enzyme+activity+and+response+to+cytotoxics&doi=10.1016%2Fj.bbalip.2015.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia-Impact on enzyme activity and response to cytotoxics</span></div><div class="casAuthors">Morad, Samy A. F.; Tan, Su-Fern; Feith, David J.; Kester, Mark; Claxton, David F.; Loughran, Thomas P.; Barth, Brian M.; Fox, Todd E.; Cabot, Myles C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1851</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">919-928</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">The triphenylethylene antiestrogen, tamoxifen, can be an effective inhibitor of sphingolipid metab.  This off-target activity makes tamoxifen an interesting ancillary for boosting the apoptosis-inducing properties of ceramide, a sphingolipid with valuable tumor censoring activity.  Here we show for the first time that tamoxifen and metabolite, N-desmethyltamoxifen (DMT), block ceramide glycosylation and inhibit ceramide hydrolysis (by acid ceramidase, AC) in human acute myelogenous leukemia (AML) cell lines and in AML cells derived from patients.  Tamoxifen (1-10 Î¼M) inhibition of AC in AML cells was accompanied by decreases in AC protein expression.  Tamoxifen also depressed expression and activity of sphingosine kinase 1 (SphK1), the enzyme-catalyzing prodn. of mitogenic sphingosine 1-phosphate (S1-P).  Results from mass spectroscopy showed that tamoxifen and DMT (i) increased the levels of endogenous C16:0 and C24:1 ceramide mol. species, (ii) nearly totally halted prodn. of resp. glucosylceramide (GC) mol. species, (iii) drastically reduced levels of sphingosine (to 9% of control), and (iv) reduced levels of S1-P by 85%, in vincristine-resistant HL-60/VCR cells.  The co-administration of tamoxifen with either N-(4-hydroxyphenyl)retinamide (4-HPR), a ceramide-generating retinoid, or a cell-deliverable form of ceramide, C6-ceramide, resulted in marked decreases in HL-60/VCR cell viability that far exceeded single agent potency.  Combination treatments resulted in synergistic apoptotic cell death as gauged by increased Annexin V binding and DNA fragmentation and activation of caspase-3.  These results show the versatility of adjuvant triphenylethylene with ceramide-centric therapies for magnifying therapeutic potential in AML.  Such drug regimens could serve as effective strategies, even in the multidrug-resistant setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxpo2ZdGqP-bVg90H21EOLACvtfcHk0lgciEmEyoy1BQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksFWjtb0%253D&md5=48b2536a04380ef70508802e6c08f0f4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2015.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2015.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DMorad%26aufirst%3DS.%2BA.%26aulast%3DTan%26aufirst%3DS.-F.%26aulast%3DFeith%26aufirst%3DD.%2BJ.%26aulast%3DKester%26aufirst%3DM.%26aulast%3DClaxton%26aufirst%3DD.%2BF.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26aulast%3DBarth%26aufirst%3DB.%2BM.%26aulast%3DFox%26aufirst%3DT.%2BE.%26aulast%3DCabot%26aufirst%3DM.%2BC.%26atitle%3DModification%2520of%2520sphingolipid%2520metabolism%2520by%2520tamoxifen%2520and%2520N-desmethyltamoxifen%2520in%2520acute%2520myelogenous%2520leukemia%25E2%2580%2594Impact%2520on%2520enzyme%2520activity%2520and%2520response%2520to%2520cytotoxics%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2015%26volume%3D1851%26spage%3D919%26epage%3D928%26doi%3D10.1016%2Fj.bbalip.2015.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Schuchman, E. H.</span><span> </span><span class="NLM_article-title">Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Basis Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1862</span><span class="NLM_x">, </span> <span class="NLM_fpage">1459</span><span class="NLM_x">â</span> <span class="NLM_lpage">1471</span><span class="refDoi">Â DOI: 10.1016/j.bbadis.2016.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.bbadis.2016.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=27155573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2016&pages=1459-1471&author=E.+H.+Schuchman&title=Acid+ceramidase+and+the+treatment+of+ceramide+diseases%3A+The+expanding+role+of+enzyme+replacement+therapy&doi=10.1016%2Fj.bbadis.2016.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy</span></div><div class="casAuthors">Schuchman, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1459-1471</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Ceramides are a diverse group of sphingolipids that play important roles in many biol. processes.  Acid ceramidase (AC) is one key enzyme that regulates ceramide metab.  Early research on AC focused on the fact that it is the enzyme deficient in the rare genetic disorder, Farber Lipogranulomatosis.  Recent research has revealed that deficiency of the same enzyme is responsible for a rare form of spinal muscular atrophy assocd. with myoclonic epilepsy (SMA-PME).  Due to their diverse role in biol., accumulation of ceramides also has been implicated in the pathobiol. of many other common diseases, including infectious lung diseases, diabetes, cancers and others.  This has revealed the potential of AC as a therapy for many of these diseases.  This review will focus on the biol. of AC and the potential role of this enzyme in the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxHxbePZKk7rVg90H21EOLACvtfcHk0lgciEmEyoy1BQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D&md5=b44a07178d44b3de2ef72da888931fbe</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2016.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2016.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26atitle%3DAcid%2520ceramidase%2520and%2520the%2520treatment%2520of%2520ceramide%2520diseases%253A%2520The%2520expanding%2520role%2520of%2520enzyme%2520replacement%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2016%26volume%3D1862%26spage%3D1459%26epage%3D1471%26doi%3D10.1016%2Fj.bbadis.2016.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Saied, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arenz, C.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of ceramidases</span> <span class="citation_source-journal">Cell. Physiol. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">212</span><span class="refDoi">Â DOI: 10.1159/000362995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1159%2F000362995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=24977492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSrtb%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=197-212&author=E.+M.+Saiedauthor=C.+Arenz&title=Small+molecule+inhibitors+of+ceramidases&doi=10.1159%2F000362995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Ceramidases</span></div><div class="casAuthors">Saied, Essa M.; Arenz, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">197-212</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  The equil. between the pro-apoptotic ceramide and pro-vital sphingosine-1-phosphate is considered to be decisive for cell death or survival.  The different ceramidases thus play key roles in cell fate and might offer attractive targets for pharmacol. intervention.  Although until recently only moderately active inhibitors have been described, first in vivo expts. suggest activity against cancer cell survival and multi-drug resistance.  Here, we provide a brief overview on the different ceramidases, and we will review the known inhibitors and current strategies for further inhibitor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrURDaWnmkYLVg90H21EOLACvtfcHk0lgciEmEyoy1BQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSrtb%252FK&md5=00f9852c31b223bb3ad47dafd3273036</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1159%2F000362995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000362995%26sid%3Dliteratum%253Aachs%26aulast%3DSaied%26aufirst%3DE.%2BM.%26aulast%3DArenz%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520ceramidases%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2014%26volume%3D34%26spage%3D197%26epage%3D212%26doi%3D10.1159%2F000362995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Saied, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arenz, C.</span><span> </span><span class="NLM_article-title">Inhibitors of ceramidases</span> <span class="citation_source-journal">Chem. Phys. Lipids</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">197</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">â</span> <span class="NLM_lpage">68</span><span class="refDoi">Â DOI: 10.1016/j.chemphyslip.2015.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.chemphyslip.2015.07.009" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2016&pages=60-68&author=E.+M.+Saiedauthor=C.+Arenz&title=Inhibitors+of+ceramidases&doi=10.1016%2Fj.chemphyslip.2015.07.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.chemphyslip.2015.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemphyslip.2015.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DSaied%26aufirst%3DE.%2BM.%26aulast%3DArenz%26aufirst%3DC.%26atitle%3DInhibitors%2520of%2520ceramidases%26jtitle%3DChem.%2520Phys.%2520Lipids%26date%3D2016%26volume%3D197%26spage%3D60%26epage%3D68%26doi%3D10.1016%2Fj.chemphyslip.2015.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Sugita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulaney, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moser, H. W.</span><span> </span><span class="NLM_article-title">Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Lipids Lipid Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">398</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">131</span><span class="refDoi">Â DOI: 10.1016/0005-2760(75)90176-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2F0005-2760%2875%2990176-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=238641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADyaE2MXkvFChtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=398&publication_year=1975&pages=125-131&author=M.+Sugitaauthor=M.+Williamsauthor=J.+T.+Dulaneyauthor=H.+W.+Moser&title=Ceramidase+and+ceramide+synthesis+in+human+kidney+and+cerebellum.+Description+of+a+new+alkaline+ceramidase&doi=10.1016%2F0005-2760%2875%2990176-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidase and ceramide synthesis in human kidney and cerebellum.  Description of a new alkaline ceramidase</span></div><div class="casAuthors">Sugita, Mutsumi; Williams, Marcia; Dulaney, John T.; Moser, Hugo W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Lipids and Lipid Metabolism</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">398</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-31</span>CODEN:
                <span class="NLM_cas:coden">BBLLA6</span>;
        ISSN:<span class="NLM_cas:issn">0005-2760</span>.
    </div><div class="casAbstract">In normal cerebellum ceramide cleavage and the reverse reaction, free fatty acid-dependent ceramide synthesis, both occur not only at pH 4.0 but also at pH 9.0, although normal kidney exhibits these activities only at pH 4.0.  Both tissues are capable of synthesizing ceramide via an acyl-CoA-dependent pathway at neutral pH.  The synthetic analog of ceramide, N-oleoyl-ethanolamine, is a potent inhibitor of ceramidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3dnZmqqVFYrVg90H21EOLACvtfcHk0licMPCZ0gBHlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXkvFChtb4%253D&md5=a59f9b1a82754943c2da77f5c9deaf19</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0005-2760%2875%2990176-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2760%252875%252990176-9%26sid%3Dliteratum%253Aachs%26aulast%3DSugita%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DDulaney%26aufirst%3DJ.%2BT.%26aulast%3DMoser%26aufirst%3DH.%2BW.%26atitle%3DCeramidase%2520and%2520ceramide%2520synthesis%2520in%2520human%2520kidney%2520and%2520cerebellum.%2520Description%2520of%2520a%2520new%2520alkaline%2520ceramidase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Lipids%2520Lipid%2520Metab.%26date%3D1975%26volume%3D398%26spage%3D125%26epage%3D131%26doi%3D10.1016%2F0005-2760%2875%2990176-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Bielawska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardic, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannun, Y. A.</span><span> </span><span class="NLM_article-title">Ceramide-mediated biology. Determination of structural and stereospecific requirements through the use of N-acyl-phenylaminoalcohol analogs</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">18493</span><span class="NLM_x">â</span> <span class="NLM_lpage">18497</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=18493-18497&author=A.+Bielawskaauthor=C.+M.+Linardicauthor=Y.+A.+Hannun&title=Ceramide-mediated+biology.+Determination+of+structural+and+stereospecific+requirements+through+the+use+of+N-acyl-phenylaminoalcohol+analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DLinardic%26aufirst%3DC.%2BM.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramide-mediated%2520biology.%2520Determination%2520of%2520structural%2520and%2520stereospecific%2520requirements%2520through%2520the%2520use%2520of%2520N-acyl-phenylaminoalcohol%2520analogs%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D18493%26epage%3D18497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Draper, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. D.</span><span> </span><span class="NLM_article-title">Discovery and evaluation of inhibitors of human ceramidase</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2052</span><span class="NLM_x">â</span> <span class="NLM_lpage">2061</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-11-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1158%2F1535-7163.MCT-11-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=21885864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2052-2061&author=J.+M.+Draperauthor=Z.+Xiaauthor=R.+A.+Smithauthor=Y.+Zhuangauthor=W.+Wangauthor=C.+D.+Smith&title=Discovery+and+evaluation+of+inhibitors+of+human+ceramidase&doi=10.1158%2F1535-7163.MCT-11-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Evaluation of Inhibitors of Human Ceramidase</span></div><div class="casAuthors">Draper, Jeremiah M.; Xia, Zuping; Smith, Ryan A.; Zhuang, Yan; Wang, Wenxue; Smith, Charles D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The ceramide/sphingosine-1-phosphate (S1P) rheostat has been hypothesized to play a crit. role in regulating tumor cell fate, with elevated levels of ceramide inducing death and elevated levels of S1P leading to survival and proliferation.  Ceramidases are key enzymes that control this rheostat by hydrolyzing ceramide to produce sphingosine and may also confer resistance to drugs and radiation.  Therefore, ceramidase inhibitors have excellent potential for development as new anticancer drugs.  In this study, we identify a novel ceramidase inhibitor (Ceranib-1) by screening a small mol. library and describe the synthesis of a more potent analog (Ceranib-2).  In a cell-based assay, both compds. were found to inhibit cellular ceramidase activity toward an exogenous ceramide analog, induce the accumulation of multiple ceramide species, decrease levels of sphingosine and S1P, inhibit the proliferation of cells alone and in combination with paclitaxel, and induce cell-cycle arrest and cell death.  In vivo, Ceranib-2 was found to delay tumor growth in a syngeneic tumor model without hematol. suppression or overt signs of toxicity.  These data support the selection of ceramidases as suitable targets for anticancer drug development and provide the first nonlipid inhibitors of human ceramidase activity.  Mol Cancer Ther; 10(11); 2052-61.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2jpM4jQkMrVg90H21EOLACvtfcHk0licMPCZ0gBHlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbL&md5=0adf607e83b91dff2ed50d989cdeb34e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0365%26sid%3Dliteratum%253Aachs%26aulast%3DDraper%26aufirst%3DJ.%2BM.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DZhuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DC.%2BD.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%2520inhibitors%2520of%2520human%2520ceramidase%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2052%26epage%3D2061%26doi%3D10.1158%2F1535-7163.MCT-11-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Realini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solorzano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagliuca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzirani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armirotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luciani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costi, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="refDoi">Â DOI: 10.1038/srep01035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1038%2Fsrep01035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=23301156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1035&author=N.+Realiniauthor=C.+Solorzanoauthor=C.+Pagliucaauthor=D.+Pizziraniauthor=A.+Armirottiauthor=R.+Lucianiauthor=M.+P.+Costiauthor=T.+Bandieraauthor=D.+Piomelli&title=Discovery+of+highly+potent+acid+ceramidase+inhibitors+with+in+vitro+tumor+chemosensitizing+activity&doi=10.1038%2Fsrep01035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span></div><div class="casAuthors">Realini, Natalia; Solorzano, Carlos; Pagliuca, Chiara; Pizzirani, Daniela; Armirotti, Andrea; Luciani, Rosaria; Costi, Maria Paola; Bandiera, Tiziano; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">srep01035, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The expression of acid ceramidase (AC) - a cysteine amidase that hydrolyzes the proapoptotic lipid ceramide - is abnormally high in several human tumors, which is suggestive of a role in chemoresistance.  Available AC inhibitors lack, however, the potency and drug-likeness necessary to test this idea.  Here we show that the antineoplastic drug carmofur, which is used in the clinic to treat colorectal cancers, is a potent AC inhibitor and that this property is essential to its anti-proliferative effects.  Modifications in the chem. scaffold of carmofur yield new AC inhibitors that act synergistically with std. antitumoral drugs to prevent cancer cell proliferation.  These findings identify AC as an unexpected target for carmofur, and suggest that this mol. can be used as starting point for the design of novel chemosensitizing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoknWbdLSLhRbVg90H21EOLACvtfcHk0li1-F0uJ8y0ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D&md5=7ff74388fc2bea42c0e97fa8cbcfe61f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fsrep01035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep01035%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DSolorzano%26aufirst%3DC.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DLuciani%26aufirst%3DR.%26aulast%3DCosti%26aufirst%3DM.%2BP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520acid%2520ceramidase%2520inhibitors%2520with%2520in%2520vitro%2520tumor%2520chemosensitizing%2520activity%26jtitle%3DSci.%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D1035%26doi%3D10.1038%2Fsrep01035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Mescic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harej, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klobucar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glavac, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cetina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavelic, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raic-Malic, S.</span><span> </span><span class="NLM_article-title">Discovery of new acid ceramidase-targeted acyclic 5-alkynyl and 5-heteroaryl uracil nucleosides</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1150</span><span class="NLM_x">â</span> <span class="NLM_lpage">1155</span><span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1150-1155&author=A.+Mescicauthor=A.+Harejauthor=M.+Klobucarauthor=D.+Glavacauthor=M.+Cetinaauthor=S.+K.+Pavelicauthor=S.+Raic-Malic&title=Discovery+of+new+acid+ceramidase-targeted+acyclic+5-alkynyl+and+5-heteroaryl+uracil+nucleosides&doi=10.1021%2Facsmedchemlett.5b00298"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00298%26sid%3Dliteratum%253Aachs%26aulast%3DMescic%26aufirst%3DA.%26aulast%3DHarej%26aufirst%3DA.%26aulast%3DKlobucar%26aufirst%3DM.%26aulast%3DGlavac%26aufirst%3DD.%26aulast%3DCetina%26aufirst%3DM.%26aulast%3DPavelic%26aufirst%3DS.%2BK.%26aulast%3DRaic-Malic%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520new%2520acid%2520ceramidase-targeted%2520acyclic%25205-alkynyl%2520and%25205-heteroaryl%2520uracil%2520nucleosides%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D1150%26epage%3D1155%26doi%3D10.1021%2Facsmedchemlett.5b00298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Pizzirani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Realini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armirotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengatto, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagliuca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Benzoxazolone carboxamides: potent and systemically active inhibitors of intracellular acid ceramidase</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">â</span> <span class="NLM_lpage">489</span><span class="refDoi">Â DOI: 10.1002/anie.201409042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1002%2Fanie.201409042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWnt7zN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=485-489&author=D.+Pizziraniauthor=A.+Bachauthor=N.+Realiniauthor=A.+Armirottiauthor=L.+Mengattoauthor=I.+Bauerauthor=S.+Girottoauthor=C.+Pagliucaauthor=M.+De+Vivoauthor=M.+Summaauthor=A.+Ribeiroauthor=D.+Piomelli&title=Benzoxazolone+carboxamides%3A+potent+and+systemically+active+inhibitors+of+intracellular+acid+ceramidase&doi=10.1002%2Fanie.201409042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Benzoxazolone Carboxamides: Potent and Systemically Active Inhibitors of Intracellular Acid Ceramidase</span></div><div class="casAuthors">Pizzirani, Daniela; Bach, Anders; Realini, Natalia; Armirotti, Andrea; Mengatto, Luisa; Bauer, Inga; Girotto, Stefania; Pagliuca, Chiara; De Vivo, Marco; Summa, Maria; Ribeiro, Alison; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">485-489</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ceramides are a family of bioactive lipid-derived messengers involved in the control of cellular senescence, inflammation, and apoptosis.  Ceramide hydrolysis by acid ceramidase (AC) stops the biol. activity of these substances and influences survival and function of normal and neoplastic cells.  Because of its central role in the ceramide metab., AC may offer a novel mol. target in disorders with dysfunctional ceramide-mediated signaling.  Here, a class of benzoxazolone carboxamides is identified as the first potent and systemically active inhibitors of AC.  Prototype members of this class inhibit AC with low nanomolar potency by covalent binding to the catalytic cysteine.  Their metabolic stability and high in vivo efficacy suggest that these compds. may be used as probes to investigate the roles of ceramide in health and disease, and that this scaffold may represent a promising starting point for the development of novel therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKEJBNB_ka5bVg90H21EOLACvtfcHk0li1-F0uJ8y0ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWnt7zN&md5=46bf9fa7ccee9c7936660b6576dd03db</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fanie.201409042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201409042%26sid%3Dliteratum%253Aachs%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DMengatto%26aufirst%3DL.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%253A%2520potent%2520and%2520systemically%2520active%2520inhibitors%2520of%2520intracellular%2520acid%2520ceramidase%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D485%26epage%3D489%26doi%3D10.1002%2Fanie.201409042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Bach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzirani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Realini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vozella, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penna, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melzig, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Benzoxazolone carboxamides as potent acid Ceramidase inhibitors: Synthesis and structure-activity relationship (SAR) studies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9258</span><span class="NLM_x">â</span> <span class="NLM_lpage">9272</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9258-9272&author=A.+Bachauthor=D.+Pizziraniauthor=N.+Realiniauthor=V.+Vozellaauthor=D.+Russoauthor=I.+Pennaauthor=L.+Melzigauthor=R.+Scarpelliauthor=D.+Piomelli&title=Benzoxazolone+carboxamides+as+potent+acid+Ceramidase+inhibitors%3A+Synthesis+and+structure-activity+relationship+%28SAR%29+studies&doi=10.1021%2Facs.jmedchem.5b01188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Benzoxazolone Carboxamides as Potent Acid Ceramidase Inhibitors: Synthesis and Structure-Activity Relationship (SAR) Studies</span></div><div class="casAuthors">Bach, Anders; Pizzirani, Daniela; Realini, Natalia; Vozella, Valentina; Russo, Debora; Penna, Ilaria; Melzig, Laurin; Scarpelli, Rita; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9258-9272</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ceramides are lipid-derived intracellular messengers involved in the control of senescence, inflammation, and apoptosis.  The cysteine amidase, acid ceramidase (AC), hydrolyzes these substances into sphingosine and fatty acid and, by doing so, regulates their signaling activity.  AC inhibitors may be useful in the treatment of pathol. conditions, such as cancer, in which ceramide levels are abnormally reduced.  Here, we present a systematic SAR investigation of the benzoxazolone carboxamides, a recently described class of AC inhibitors that display high potency and systemic activity in mice.  We examd. a diverse series of substitutions on both benzoxazolone ring and carboxamide side chain.  Several modifications enhanced potency and stability, and one key compd. with a balanced activity-stability profile I was found to inhibit AC activity in mouse lungs and cerebral cortex after systemic administration.  The results expand our arsenal of AC inhibitors, thereby facilitating the use of these compds. as pharmacol. tools and their potential development as drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXKrFwyTWVt7Vg90H21EOLACvtfcHk0li1-F0uJ8y0ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI&md5=1b8de2b433b0e1b42299cf224d53e33a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01188%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DA.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DVozella%26aufirst%3DV.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DPenna%26aufirst%3DI.%26aulast%3DMelzig%26aufirst%3DL.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%2520as%2520potent%2520acid%2520Ceramidase%2520inhibitors%253A%2520Synthesis%2520and%2520structure-activity%2520relationship%2520%2528SAR%2529%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9258%26epage%3D9272%26doi%3D10.1021%2Facs.jmedchem.5b01188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Kaboudin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khodamorady, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abedi, Y.</span><span> </span><span class="NLM_article-title">A practical and convenient method for the synthesis of some benzimidazoles</span> <span class="citation_source-journal">Org. Prep. Proced. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">â</span> <span class="NLM_lpage">167</span><span class="refDoi">Â DOI: 10.1080/00304948.2013.765294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1080%2F00304948.2013.765294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFagtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=162-167&author=B.+Kaboudinauthor=M.+Khodamoradyauthor=Y.+Abedi&title=A+practical+and+convenient+method+for+the+synthesis+of+some+benzimidazoles&doi=10.1080%2F00304948.2013.765294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Practical and Convenient Method for the Synthesis of Some Benzimidazoles</span></div><div class="casAuthors">Kaboudin, Babak; Khodamorady, Minoo; Abedi, Yaghoub</div><div class="citationInfo"><span class="NLM_cas:title">Organic Preparations and Procedures International</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-167</span>CODEN:
                <span class="NLM_cas:coden">OPPIAK</span>;
        ISSN:<span class="NLM_cas:issn">0030-4948</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A new method for the synthesis of some benzimidazoles by the reaction of o-phenylenediamines with orthoesters under solvent-free conditions without any additives such as base, acid or catalyst is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW-GpuN39yvrVg90H21EOLACvtfcHk0liZtI3geITTkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFagtr4%253D&md5=ea123193bf508d6b2d659809791e2505</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1080%2F00304948.2013.765294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00304948.2013.765294%26sid%3Dliteratum%253Aachs%26aulast%3DKaboudin%26aufirst%3DB.%26aulast%3DKhodamorady%26aufirst%3DM.%26aulast%3DAbedi%26aufirst%3DY.%26atitle%3DA%2520practical%2520and%2520convenient%2520method%2520for%2520the%2520synthesis%2520of%2520some%2520benzimidazoles%26jtitle%3DOrg.%2520Prep.%2520Proced.%2520Int.%26date%3D2013%26volume%3D45%26spage%3D162%26epage%3D167%26doi%3D10.1080%2F00304948.2013.765294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Quada, J. C.; Agyin, J. K.; Camden, J. B.</span><span> </span><span class="NLM_article-title">Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections</span>. WO 2002026716A2,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+C.+Quada&author=J.+K.+Agyin&author=J.+B.+Camden&title=Compounds+and+Methods+for+Use+Thereof+in+the+Treatment+of+Cancer+or+Viral+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DQuada%26aufirst%3DJ.%2BC.%26atitle%3DCompounds%2520and%2520Methods%2520for%2520Use%2520Thereof%2520in%2520the%2520Treatment%2520of%2520Cancer%2520or%2520Viral%2520Infections%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Bahadoor, A.; Castro, A. C.; Chan, L. K.; Keaney, G. F.; Nevalainen, M.; Nevalainen, V.; Peluso, S.; Tibbitts, T.</span><span> </span><span class="NLM_article-title">Triazoles as Inhibitors of Fatty Acid Synthase</span>. WO 2011140296A1,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Bahadoor&author=A.+C.+Castro&author=L.+K.+Chan&author=G.+F.+Keaney&author=M.+Nevalainen&author=V.+Nevalainen&author=S.+Peluso&author=T.+Tibbitts&title=Triazoles+as+Inhibitors+of+Fatty+Acid+Synthase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBahadoor%26aufirst%3DA.%26atitle%3DTriazoles%2520as%2520Inhibitors%2520of%2520Fatty%2520Acid%2520Synthase%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Fabbrizzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raspanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guarna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabocchi, A.</span><span> </span><span class="NLM_article-title">Role of side-chain bioisosteres in determining the binding affinity of click chemistry derived RGD peptidomimetics to alpha(v)beta(3) integrin</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2014</span><span class="NLM_x">, </span> <span class="NLM_fpage">7595</span><span class="NLM_x">â</span> <span class="NLM_lpage">7604</span><span class="refDoi">Â DOI: 10.1002/ejoc.201403129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1002%2Fejoc.201403129" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=7595-7604&author=P.+Fabbrizziauthor=G.+Menchiauthor=S.+Raspantiauthor=A.+Guarnaauthor=A.+Trabocchi&title=Role+of+side-chain+bioisosteres+in+determining+the+binding+affinity+of+click+chemistry+derived+RGD+peptidomimetics+to+alpha%28v%29beta%283%29+integrin&doi=10.1002%2Fejoc.201403129"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201403129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201403129%26sid%3Dliteratum%253Aachs%26aulast%3DFabbrizzi%26aufirst%3DP.%26aulast%3DMenchi%26aufirst%3DG.%26aulast%3DRaspanti%26aufirst%3DS.%26aulast%3DGuarna%26aufirst%3DA.%26aulast%3DTrabocchi%26aufirst%3DA.%26atitle%3DRole%2520of%2520side-chain%2520bioisosteres%2520in%2520determining%2520the%2520binding%2520affinity%2520of%2520click%2520chemistry%2520derived%2520RGD%2520peptidomimetics%2520to%2520alpha%2528v%2529beta%25283%2529%2520integrin%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2014%26volume%3D2014%26spage%3D7595%26epage%3D7604%26doi%3D10.1002%2Fejoc.201403129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Momoi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Yoseph, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadler, H. L.</span><span> </span><span class="NLM_article-title">Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">205</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">â</span> <span class="NLM_lpage">425</span><span class="refDoi">Â DOI: 10.1042/bj2050419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1042%2Fbj2050419" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=1982&pages=419-425&author=T.+Momoiauthor=Y.+Ben-Yosephauthor=H.+L.+Nadler&title=Substrate-specificities+of+acid+and+alkaline+ceramidases+in+fibroblasts+from+patients+with+Farber+disease+and+controls&doi=10.1042%2Fbj2050419"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1042%2Fbj2050419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj2050419%26sid%3Dliteratum%253Aachs%26aulast%3DMomoi%26aufirst%3DT.%26aulast%3DBen-Yoseph%26aufirst%3DY.%26aulast%3DNadler%26aufirst%3DH.%2BL.%26atitle%3DSubstrate-specificities%2520of%2520acid%2520and%2520alkaline%2520ceramidases%2520in%2520fibroblasts%2520from%2520patients%2520with%2520Farber%2520disease%2520and%2520controls%26jtitle%3DBiochem.%2520J.%26date%3D1982%26volume%3D205%26spage%3D419%26epage%3D425%26doi%3D10.1042%2Fbj2050419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Palermo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campomanes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlisberger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Wagging the tail: essential role of substrate flexibility in FAAH catalysis</span> <span class="citation_source-journal">J. Chem. Theory Comput.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1202</span><span class="NLM_x">â</span> <span class="NLM_lpage">1213</span><span class="refDoi">Â DOI: 10.1021/ct300611q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct300611q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVCgtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=1202-1213&author=G.+Palermoauthor=P.+Campomanesauthor=M.+Neriauthor=D.+Piomelliauthor=A.+Cavalliauthor=U.+Rothlisbergerauthor=M.+De+Vivo&title=Wagging+the+tail%3A+essential+role+of+substrate+flexibility+in+FAAH+catalysis&doi=10.1021%2Fct300611q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Wagging the Tail: Essential Role of Substrate Flexibility in FAAH Catalysis</span></div><div class="casAuthors">Palermo, Giulia; Campomanes, Pablo; Neri, Marilisa; Piomelli, Daniele; Cavalli, Andrea; Rothlisberger, Ursula; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1202-1213</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The serine hydrolase, fatty acid amide hydrolase (FAAH), is responsible for the intracellular degrdn. of anandamide and other bioactive fatty acid ethanolamides involved in the regulation of pain, inflammation, and other pathophysiol. processes.  The catalytic site of FAAH is composed of multiple cavities with mixed hydrophobic and hydrophilic properties, the role of which remains incompletely understood.  Anandamide is thought to enter the active site through a "membrane-access" (MA) channel and position its flexible fatty acyl chain in a highly hydrophobic "acyl chain-binding" (AB) cavity to allow for hydrolysis to occur.  Using microsecond mol. dynamics (MD) simulations of FAAH embedded in a realistic membrane/water environment, we show now that anandamide may not lock itself into the AB cavity but may rather assume catalytically significant conformations required for hydrolysis by moving its flexible arachidonoyl tail between the MA and AB cavities.  This process is regulated by a phenylalanine residue (Phe432) located at the boundary between the two cavities, which may act as a "dynamic paddle." The results identify structural flexibility as a key determinant by which FAAH recognizes its primary lipid substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcJrmcv6YEzLVg90H21EOLACvtfcHk0liZtI3geITTkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVCgtg%253D%253D&md5=c9d8bec4b97b8318ae09383400624f66</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fct300611q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct300611q%26sid%3Dliteratum%253Aachs%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DCampomanes%26aufirst%3DP.%26aulast%3DNeri%26aufirst%3DM.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRothlisberger%26aufirst%3DU.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DWagging%2520the%2520tail%253A%2520essential%2520role%2520of%2520substrate%2520flexibility%2520in%2520FAAH%2520catalysis%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2013%26volume%3D9%26spage%3D1202%26epage%3D1213%26doi%3D10.1021%2Fct300611q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Riccardi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arencibia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armirotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Lid domain plasticity and lipid flexibility modulate enzyme specificity in human monoacylglycerol lipase</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">1862</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">451</span><span class="refDoi">Â DOI: 10.1016/j.bbalip.2017.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.bbalip.2017.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=28088576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1Kqsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2017&pages=441-451&author=L.+Riccardiauthor=J.+M.+Arencibiaauthor=L.+Bonoauthor=A.+Armirottiauthor=S.+Girottoauthor=M.+De+Vivo&title=Lid+domain+plasticity+and+lipid+flexibility+modulate+enzyme+specificity+in+human+monoacylglycerol+lipase&doi=10.1016%2Fj.bbalip.2017.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Lid domain plasticity and lipid flexibility modulate enzyme specificity in human monoacylglycerol lipase</span></div><div class="casAuthors">Riccardi, Laura; Arencibia, Jose M.; Bono, Luca; Armirotti, Andrea; Girotto, Stefania; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-451</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Human monoacylglycerol lipase (MAGL) is a membrane-interacting enzyme that generates pro-inflammatory signaling mols.  For this reason, MAGL inhibition is a promising strategy to treat pain, cancer, and neuroinflammatory diseases.  MAGL can hydrolyze monoacylglycerols bearing an acyl chain of different lengths and degrees of unsatn., cleaving primarily the endocannabinoid 2-arachidonoylglycerol.  Importantly, the enzymic binding site of MAGL is confined by a 75-amino-acid-long, flexible cap domain, named 'lid domain', which is structurally similar to that found in several other lipases.  However, it is unclear how lid domain plasticity affects catalysis in MAGL.  By integrating extensive mol. dynamics simulations and free-energy calcns. with mutagenesis and kinetic expts., we here define a lid-domain-mediated mechanism for substrate selection and binding in MAGL catalysis.  In particular, we clarify the key role of Phe159 and Ile179, two conserved residues within the lid domain, in regulating substrate specificity in MAGL.  We conclude by proposing that other structurally related lipases may share this lid-domain-mediated mechanism for substrate specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcSfOcMvzTNLVg90H21EOLACvtfcHk0lhvhFViovkCdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1Kqsro%253D&md5=0c3c69bcd19d783e7da65da6988d86dd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2017.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2017.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DRiccardi%26aufirst%3DL.%26aulast%3DArencibia%26aufirst%3DJ.%2BM.%26aulast%3DBono%26aufirst%3DL.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DLid%2520domain%2520plasticity%2520and%2520lipid%2520flexibility%2520modulate%2520enzyme%2520specificity%2520in%2520human%2520monoacylglycerol%2520lipase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2017%26volume%3D1862%26spage%3D441%26epage%3D451%26doi%3D10.1016%2Fj.bbalip.2017.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Palermo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branduardi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodoa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Covalent inhibitors of fatty acid amide hydrolase: A rationale for the activity of piperidine and piperazine aryl ureas</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6612</span><span class="NLM_x">â</span> <span class="NLM_lpage">6623</span><span class="refDoi">Â DOI: 10.1021/jm2004283</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2004283" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCgsb3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6612-6623&author=G.+Palermoauthor=D.+Branduardiauthor=M.+Masettiauthor=A.+Lodoaauthor=M.+Morauthor=D.+Piomelliauthor=A.+Cavalliauthor=M.+De+Vivo&title=Covalent+inhibitors+of+fatty+acid+amide+hydrolase%3A+A+rationale+for+the+activity+of+piperidine+and+piperazine+aryl+ureas&doi=10.1021%2Fjm2004283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Inhibitors of Fatty Acid Amide Hydrolase: A Rationale for the Activity of Piperidine and Piperazine Aryl Ureas</span></div><div class="casAuthors">Palermo, Giulia; Branduardi, Davide; Masetti, Matteo; Lodola, Alessio; Mor, Marco; Piomelli, Daniele; Cavalli, Andrea; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6612-6623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, covalent drugs have attracted great interest in the drug discovery community, with successful examples that have demonstrated their therapeutic effects.  Here, we focus on the covalent inhibition of the fatty acid amide hydrolase (FAAH), which is a promising strategy in the treatment of pain and inflammation.  Among the most recent and potent FAAH inhibitors (FAAHi), there are the cyclic piperidine and piperazine aryl ureas.  FAAH hydrolyzes efficiently the amide bond of these compds., forming a covalent enzyme-inhibitor adduct.  To rationalize this exptl. evidence, we performed an extensive computational anal. centered on piperidine-based PF750 (1) and piperazine-based JNJ1661010 (2), two potent lead compds. used to generate covalent inhibitors as clin. candidates.  We found that FAAH induces a distortion of the amide bond of the piperidine and piperazine aryl ureas.  Quantum mechanics/mol. mechanics ÎELUMO-HOMO energies indicate that the obsd. enzyme-induced distortion of the amide bond favors the formation of a covalent FAAH-inhibitor adduct.  These findings could help in the rational structure-based design of novel covalent FAAHi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXM0Vnrifb87Vg90H21EOLACvtfcHk0lhvhFViovkCdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCgsb3O&md5=3130e9ef929a52cc0900ad77b38a7453</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm2004283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2004283%26sid%3Dliteratum%253Aachs%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DBranduardi%26aufirst%3DD.%26aulast%3DMasetti%26aufirst%3DM.%26aulast%3DLodoa%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DCovalent%2520inhibitors%2520of%2520fatty%2520acid%2520amide%2520hydrolase%253A%2520A%2520rationale%2520for%2520the%2520activity%2520of%2520piperidine%2520and%2520piperazine%2520aryl%2520ureas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6612%26epage%3D6623%26doi%3D10.1021%2Fjm2004283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branduardi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capoferri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span> </span><span class="NLM_article-title">A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e32397</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0032397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1371%2Fjournal.pone.0032397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=22389698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ehsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e32397&author=A.+Lodolaauthor=D.+Branduardiauthor=M.+De+Vivoauthor=L.+Capoferriauthor=M.+Morauthor=D.+Piomelliauthor=A.+Cavalli&title=A+catalytic+mechanism+for+cysteine+N-terminal+nucleophile+hydrolases%2C+as+revealed+by+free+energy+simulations&doi=10.1371%2Fjournal.pone.0032397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations</span></div><div class="casAuthors">Lodola, Alessio; Branduardi, Davide; De Vivo, Marco; Capoferri, Luigi; Mor, Marco; Piomelli, Daniele; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e32397</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The N-terminal nucleophile (Ntn) hydrolases are a superfamily of enzymes specialized in the hydrolytic cleavage of amide bonds.  Even though several members of this family are emerging as innovative drug targets for cancer, inflammation, and pain, the processes through which they catalyze amide hydrolysis remains poorly understood.  In particular, the catalytic reactions of cysteine Ntn-hydrolases have never been investigated from a mechanistic point of view.  In the present study, we used free energy simulations in the quantum mechanics/mol. mechanics framework to det. the reaction mechanism of amide hydrolysis catalyzed by the prototypical cysteine Ntn-hydrolase, conjugated bile acid hydrolase (CBAH).  The computational analyses, which were confirmed in water and using different CBAH mutants, revealed the existence of a chair-like transition state, which might be one of the specific features of the catalytic cycle of Ntn-hydrolases.  Our results offer new insights on Ntn-mediated hydrolysis and suggest possible strategies for the creation of therapeutically useful inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9fegIlwKNS7Vg90H21EOLACvtfcHk0lhvhFViovkCdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ehsbg%253D&md5=a74ef4b0ae6afbf23907bf3ee4f0da6e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0032397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0032397%26sid%3Dliteratum%253Aachs%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DBranduardi%26aufirst%3DD.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DCapoferri%26aufirst%3DL.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DA%2520catalytic%2520mechanism%2520for%2520cysteine%2520N-terminal%2520nucleophile%2520hydrolases%252C%2520as%2520revealed%2520by%2520free%2520energy%2520simulations%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De32397%26doi%3D10.1371%2Fjournal.pone.0032397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Palermo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlisberger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Computational insights into function and inhibition of fatty acid amide hydrolase</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">â</span> <span class="NLM_lpage">26</span><span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.09.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1016%2Fj.ejmech.2014.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=25240419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOls7jJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2015&pages=15-26&author=G.+Palermoauthor=U.+Rothlisbergerauthor=A.+Cavalliauthor=M.+De+Vivo&title=Computational+insights+into+function+and+inhibition+of+fatty+acid+amide+hydrolase&doi=10.1016%2Fj.ejmech.2014.09.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Computational insights into function and inhibition of fatty acid amide hydrolase</span></div><div class="casAuthors">Palermo, Giulia; Rothlisberger, Ursula; Cavalli, Andrea; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-26</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The Fatty Acid Amide Hydrolase (FAAH) enzyme is a membrane-bound serine hydrolase responsible for the deactivating hydrolysis of a family of naturally occurring fatty acid amides.  FAAH is a crit. enzyme of the endocannabinoid system, being mainly responsible for regulating the level of its main cannabinoid substrate anandamide.  For this reason, pharmacol. inhibition of FAAH, which increases the level of endogenous anandamide, is a promising strategy to cure a variety of diseases including pain, inflammation, and cancer.Much structural, mutagenesis, and kinetic data on FAAH has been generated over the last couple of decades.  This has prompted several informative computational investigations to elucidate, at the at.-level, mechanistic details on catalysis and inhibition of this pharmaceutically relevant enzyme.  Here, we review how these computational studies - based on classical mol. dynamics, full quantum mechanics, and hybrid QM/MM methods - have clarified the binding and reactivity of some relevant substrates and inhibitors of FAAH.  We also discuss the exptl. implications of these computational insights, which have provided a thoughtful elucidation of the complex phys. and chem. steps of the enzymic mechanism of FAAH.  Finally, we discuss how computations have been helpful for building structure-activity relationships of potent FAAH inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-xquSauxYo7Vg90H21EOLACvtfcHk0lh5H8C8U1aamA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOls7jJ&md5=5dd76bb3eda21ebdfe66e956a46f7858</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DRothlisberger%26aufirst%3DU.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DComputational%2520insights%2520into%2520function%2520and%2520inhibition%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D91%26spage%3D15%26epage%3D26%26doi%3D10.1016%2Fj.ejmech.2014.09.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Pavlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carloni, P.</span><span> </span><span class="NLM_article-title">Carnosine and homocarnosine degradation mechanisms by the human carnosinase enzyme CN1: Insights from multiscale simulations</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2772</span><span class="NLM_x">â</span> <span class="NLM_lpage">2784</span><span class="refDoi">Â DOI: 10.1021/acs.biochem.5b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=2772-2784&author=M.+Pavlinauthor=G.+Rossettiauthor=M.+De+Vivoauthor=P.+Carloni&title=Carnosine+and+homocarnosine+degradation+mechanisms+by+the+human+carnosinase+enzyme+CN1%3A+Insights+from+multiscale+simulations&doi=10.1021%2Facs.biochem.5b01263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b01263%26sid%3Dliteratum%253Aachs%26aulast%3DPavlin%26aufirst%3DM.%26aulast%3DRossetti%26aufirst%3DG.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DCarloni%26aufirst%3DP.%26atitle%3DCarnosine%2520and%2520homocarnosine%2520degradation%2520mechanisms%2520by%2520the%2520human%2520carnosinase%2520enzyme%2520CN1%253A%2520Insights%2520from%2520multiscale%2520simulations%26jtitle%3DBiochemistry%26date%3D2016%26volume%3D55%26spage%3D2772%26epage%3D2784%26doi%3D10.1021%2Facs.biochem.5b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Palermo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campomanes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlisberger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Anandamide hydrolysis in FAAH reveals a dual strategy for efficient enzyme-assisted amide bond cleavage via nitrogen inversion</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">â</span> <span class="NLM_lpage">801</span><span class="refDoi">Â DOI: 10.1021/jp5052276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp5052276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFWjsr7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2015&pages=789-801&author=G.+Palermoauthor=P.+Campomanesauthor=A.+Cavalliauthor=U.+Rothlisbergerauthor=M.+De+Vivo&title=Anandamide+hydrolysis+in+FAAH+reveals+a+dual+strategy+for+efficient+enzyme-assisted+amide+bond+cleavage+via+nitrogen+inversion&doi=10.1021%2Fjp5052276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Anandamide Hydrolysis in FAAH Reveals a Dual Strategy for Efficient Enzyme-Assisted Amide Bond Cleavage via Nitrogen Inversion</span></div><div class="casAuthors">Palermo, Giulia; Campomanes, Pablo; Cavalli, Andrea; Rothlisberger, Ursula; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">789-801</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-5207</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we combined classical mol. dynamics (MD) and quantum mech./mol. mechanics (QM/MM) simulations to unravel the whole catalytic cycle of fatty acid amide hydrolase (FAAH) in complex with anandamide, the main neurotransmitters involved in the control of pain.  While microsecond MD simulations of FAAH in a realistic membrane/water environment provided a solid model for the reactant state of the enzymic complex, QM/MM simulations depict now a highly concerted two-step catalytic mechanism characterized by (1) acyl-enzyme formation after hydrolysis of the substrate amide bond and (2) deacylation reaction with restoration of the catalytic machinery.  We found that a crucial event for anandamide hydrolysis is the inversion of the reactive nitrogen of the scissile amide bond, which occurs during the acylation rate-limiting step.  We show that FAAH uses an exquisite catalytic strategy to induce amide bond distortion, reactive nitrogen inversion, and amide bond hydrolysis, promoting catalysis to completion.  This new strategy is likely to be of general applicability to other amidases/peptidases that show similar catalytic site architectures, providing crucial insights for de novo enzyme design or drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUuuanDLcJLVg90H21EOLACvtfcHk0lh5H8C8U1aamA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFWjsr7N&md5=b6c738e9eb18172771070f5d7e8974b4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjp5052276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp5052276%26sid%3Dliteratum%253Aachs%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DCampomanes%26aufirst%3DP.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRothlisberger%26aufirst%3DU.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DAnandamide%2520hydrolysis%2520in%2520FAAH%2520reveals%2520a%2520dual%2520strategy%2520for%2520efficient%2520enzyme-assisted%2520amide%2520bond%2520cleavage%2520via%2520nitrogen%2520inversion%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2015%26volume%3D119%26spage%3D789%26epage%3D801%26doi%3D10.1021%2Fjp5052276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Palermo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campomanes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armirotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlisberger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Keys to lipid selection in fatty acid amide hydrolase catalysis: Structural flexibility, gating residues and multiple binding pockets</span> <span class="citation_source-journal">PLoS Comput. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1004231</span><span class="refDoi">Â DOI: 10.1371/journal.pcbi.1004231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1371%2Fjournal.pcbi.1004231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=26111155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsV2htLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1004231&author=G.+Palermoauthor=I.+Bauerauthor=P.+Campomanesauthor=A.+Cavalliauthor=A.+Armirottiauthor=S.+Girottoauthor=U.+Rothlisbergerauthor=M.+De+Vivo&title=Keys+to+lipid+selection+in+fatty+acid+amide+hydrolase+catalysis%3A+Structural+flexibility%2C+gating+residues+and+multiple+binding+pockets&doi=10.1371%2Fjournal.pcbi.1004231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Keys to lipid selection in fatty acid amide hydrolase catalysis: structural flexibility, gating residues and multiple binding pockets</span></div><div class="casAuthors">Palermo, Giulia; Bauer, Inga; Campomanes, Pablo; Cavalli, Andrea; Armirotti, Andrea; Girotto, Stefania; Rothlisberger, Ursula; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1004231/1-e1004231/25</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The fatty acid amide hydrolase (FAAH) regulates the endocannabinoid system, cleaving primarily the lipid messenger anandamide.  FAAH has been well characterized over the years, and importantly, it represents a promising drug target to treat several diseases, including inflammatory-related diseases and cancer.  But its enzymic mechanism for lipid selection to specifically hydrolyze anandamide, rather than similar bioactive lipids, remains elusive.  Here, we clarify this mechanism in FAAH, examg. the role of the dynamic paddle, which is formed by the gating residues Phe432 and Trp531 at the boundary between two cavities that form the FAAH catalytic site (the "membrane-access" and the "acyl chain-binding" pockets).  We integrate microsecond-long MD simulations of wild type and double mutant model systems (Phe432Ala and Trp531Ala) of FAAH, embedded in a realistic membrane/water environment, with mutagenesis and kinetic expts.  We comparatively analyze three fatty acid substrates with different hydrolysis rates (anandamide > oleamide > palmitoylethanolamide).  Our findings identify FAAH's mechanism to selectively accommodate anandamide into a multi-pocket binding site, and to properly orient the substrate in pre-reactive conformations for efficient hydrolysis that is interceded by the dynamic paddle.  Our findings therefore endorse a structural framework for a lipid selection mechanism mediated by structural flexibility and gating residues between multiple binding cavities, as found in FAAH.  Based on the available structural data, this exquisite catalytic strategy for substrate specificity seems to be shared by other lipid-degrading enzymes with similar enzymic architecture.  The mechanistic insights for lipid selection might assist de novo enzyme design or drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjpXtbYx6P0LVg90H21EOLACvtfcHk0lh5H8C8U1aamA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsV2htLY%253D&md5=33224e5dcd45d20a14b6e3f60f7ca8e6</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1004231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1004231%26sid%3Dliteratum%253Aachs%26aulast%3DPalermo%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DCampomanes%26aufirst%3DP.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DRothlisberger%26aufirst%3DU.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DKeys%2520to%2520lipid%2520selection%2520in%2520fatty%2520acid%2520amide%2520hydrolase%2520catalysis%253A%2520Structural%2520flexibility%252C%2520gating%2520residues%2520and%2520multiple%2520binding%2520pockets%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3De1004231%26doi%3D10.1371%2Fjournal.pcbi.1004231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Favia, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habrant, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertozzi, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionisi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarozzo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vivo, M.</span><span> </span><span class="NLM_article-title">Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8807</span><span class="NLM_x">â</span> <span class="NLM_lpage">8826</span><span class="refDoi">Â DOI: 10.1021/jm3011146</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3011146" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOiu7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8807-8826&author=A.+D.+Faviaauthor=D.+Habrantauthor=R.+Scarpelliauthor=M.+Miglioreauthor=C.+Albaniauthor=S.+M.+Bertozziauthor=M.+Dionisiauthor=G.+Tarozzoauthor=D.+Piomelliauthor=A.+Cavalliauthor=M.+De+Vivo&title=Identification+and+characterization+of+carprofen+as+a+multitarget+fatty+acid+amide+hydrolase%2Fcyclooxygenase+inhibitor&doi=10.1021%2Fjm3011146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of Carprofen as a Multitarget Fatty Acid Amide Hydrolase/Cyclooxygenase Inhibitor</span></div><div class="casAuthors">Favia, Angelo D.; Habrant, Damien; Scarpelli, Rita; Migliore, Marco; Albani, Clara; Bertozzi, Sine Mandrup; Dionisi, Mauro; Tarozzo, Glauco; Piomelli, Daniele; Cavalli, Andrea; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8807-8826</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pain and inflammation are major therapeutic areas for drug discovery.  Current drugs for these pathologies have limited efficacy, however, and often cause a no. of unwanted side effects.  In the present study, we identify the nonsteroidal anti-inflammatory drug carprofen as a multitarget-directed ligand that simultaneously inhibits cyclooxygenase-1 (COX-1), COX-2, and fatty acid amide hydrolase (FAAH).  Addnl., we synthesized and tested several derivs. of carprofen, sharing this multitarget activity.  This may result in improved analgesic efficacy and reduced side effects (Naidu et al. J. Pharmacol. Exp. Ther.2009, 329, 48-56; Fowler, C. J.; et al. J. Enzyme Inhib. Med. Chem.2012, in press; Sasso et al. Pharmacol. Res.2012, 65, 553).  The new compds., e.g., I, are among the most potent multitarget FAAH/COX inhibitors reported so far in the literature and thus may represent promising starting points for the discovery of new analgesic and anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoPehzqVv8BLVg90H21EOLACvtfcHk0lhlPvoi4G-qFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOiu7%252FO&md5=8fe3710c1b067f671f8cee331959b7a0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm3011146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3011146%26sid%3Dliteratum%253Aachs%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DHabrant%26aufirst%3DD.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DMigliore%26aufirst%3DM.%26aulast%3DAlbani%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DS.%2BM.%26aulast%3DDionisi%26aufirst%3DM.%26aulast%3DTarozzo%26aufirst%3DG.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520carprofen%2520as%2520a%2520multitarget%2520fatty%2520acid%2520amide%2520hydrolase%252Fcyclooxygenase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8807%26epage%3D8826%26doi%3D10.1021%2Fjm3011146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Realini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palese, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzirani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pontis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Acid ceramidase in melanoma: Expression, localization, and effects of pharmacological inhibtion</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">291</span><span class="NLM_x">, </span> <span class="NLM_fpage">2422</span><span class="NLM_x">â</span> <span class="NLM_lpage">34</span><span class="refDoi">Â DOI: 10.1074/jbc.M115.666909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1074%2Fjbc.M115.666909" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=2422-34&author=N.+Realiniauthor=F.+Paleseauthor=D.+Pizziraniauthor=S.+Pontisauthor=A.+Basitauthor=A.+Bachauthor=A.+Ganesanauthor=D.+Piomelli&title=Acid+ceramidase+in+melanoma%3A+Expression%2C+localization%2C+and+effects+of+pharmacological+inhibtion&doi=10.1074%2Fjbc.M115.666909"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.666909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.666909%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DPalese%26aufirst%3DF.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DPontis%26aufirst%3DS.%26aulast%3DBasit%26aufirst%3DA.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DAcid%2520ceramidase%2520in%2520melanoma%253A%2520Expression%252C%2520localization%252C%2520and%2520effects%2520of%2520pharmacological%2520inhibtion%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D2422%26epage%3D34%26doi%3D10.1074%2Fjbc.M115.666909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Bedia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camacho, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abad, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabrias, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levade, T.</span><span> </span><span class="NLM_article-title">A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease</span> <span class="citation_source-journal">J. Lipid Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3542</span><span class="NLM_x">â</span> <span class="NLM_lpage">3547</span><span class="refDoi">Â DOI: 10.1194/jlr.D010033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1194%2Fjlr.D010033" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=3542-3547&author=C.+Bediaauthor=L.+Camachoauthor=J.+L.+Abadauthor=G.+Fabriasauthor=T.+Levade&title=A+simple+fluorogenic+method+for+determination+of+acid+ceramidase+activity+and+diagnosis+of+Farber+disease&doi=10.1194%2Fjlr.D010033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1194%2Fjlr.D010033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.D010033%26sid%3Dliteratum%253Aachs%26aulast%3DBedia%26aufirst%3DC.%26aulast%3DCamacho%26aufirst%3DL.%26aulast%3DAbad%26aufirst%3DJ.%2BL.%26aulast%3DFabrias%26aufirst%3DG.%26aulast%3DLevade%26aufirst%3DT.%26atitle%3DA%2520simple%2520fluorogenic%2520method%2520for%2520determination%2520of%2520acid%2520ceramidase%2520activity%2520and%2520diagnosis%2520of%2520Farber%2520disease%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2010%26volume%3D51%26spage%3D3542%26epage%3D3547%26doi%3D10.1194%2Fjlr.D010033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Bedia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levade, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabrias, G.</span><span> </span><span class="NLM_article-title">Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">â</span> <span class="NLM_lpage">648</span><span class="refDoi">Â DOI: 10.1002/cbic.200600533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;key=10.1002%2Fcbic.200600533" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=642-648&author=C.+Bediaauthor=J.+Casasauthor=V.+Garciaauthor=T.+Levadeauthor=G.+Fabrias&title=Synthesis+of+a+novel+ceramide+analogue+and+its+use+in+a+high-throughput+fluorogenic+assay+for+ceramidases&doi=10.1002%2Fcbic.200600533"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200600533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200600533%26sid%3Dliteratum%253Aachs%26aulast%3DBedia%26aufirst%3DC.%26aulast%3DCasas%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DV.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DFabrias%26aufirst%3DG.%26atitle%3DSynthesis%2520of%2520a%2520novel%2520ceramide%2520analogue%2520and%2520its%2520use%2520in%2520a%2520high-throughput%2520fluorogenic%2520assay%2520for%2520ceramidases%26jtitle%3DChemBioChem%26date%3D2007%26volume%3D8%26spage%3D642%26epage%3D648%26doi%3D10.1002%2Fcbic.200600533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-4"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i66"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00472">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_70285"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00472">10.1021/acs.jmedchem.7b00472</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">General procedures and spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and additional experimental data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_001.pdf">jm7b00472_si_001.pdf (2.21 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00472/suppl_file/jm7b00472_si_002.csv">jm7b00472_si_002.csv (23.49 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-13%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00472%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00472" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a2889fd392367","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
